<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Brief Bioinform</journal-id>
    <journal-id journal-id-type="iso-abbrev">Brief Bioinform</journal-id>
    <journal-id journal-id-type="publisher-id">bib</journal-id>
    <journal-title-group>
      <journal-title>Briefings in Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1467-5463</issn>
    <issn pub-type="epub">1477-4054</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10883642</article-id>
    <article-id pub-id-type="pmid">38385872</article-id>
    <article-id pub-id-type="doi">10.1093/bib/bbae008</article-id>
    <article-id pub-id-type="publisher-id">bbae008</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Problem Solving Protocol</subject>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ChemMORT: an automatic ADMET optimization platform using deep learning and multi-objective particle swarm optimization</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6823-1882</contrib-id>
        <name>
          <surname>Yi</surname>
          <given-names>Jia-Cai</given-names>
        </name>
        <!--yjc@nudt.edu.cn-->
        <aff><institution>School of Computer Science, National University of Defense Technology</institution>, <addr-line>Changsha 410073, Hunan</addr-line>, <country country="CN">PR China</country></aff>
        <aff><institution>Xiangya School of Pharmaceutical Sciences, Central South University</institution>, <addr-line>Changsha 410013, Hunan</addr-line>, <country country="CN">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Zi-Yi</given-names>
        </name>
        <!--502241508@qq.com-->
        <aff><institution>Xiangya School of Pharmaceutical Sciences, Central South University</institution>, <addr-line>Changsha 410013, Hunan</addr-line>, <country country="CN">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Zhao</surname>
          <given-names>Wen-Tao</given-names>
        </name>
        <!--wtzhao@nudt.edu.cn-->
        <aff><institution>School of Computer Science, National University of Defense Technology</institution>, <addr-line>Changsha 410073, Hunan</addr-line>, <country country="CN">PR China</country></aff>
        <xref rid="cor1" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Zhi-Jiang</given-names>
        </name>
        <!--1223821976@qq.com-->
        <aff><institution>Xiangya School of Pharmaceutical Sciences, Central South University</institution>, <addr-line>Changsha 410013, Hunan</addr-line>, <country country="CN">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7187-435X</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Xiao-Chen</given-names>
        </name>
        <!--zhangxiaochen@nudt.edu.cn-->
        <aff><institution>School of Computer Science, National University of Defense Technology</institution>, <addr-line>Changsha 410073, Hunan</addr-line>, <country country="CN">PR China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wu</surname>
          <given-names>Cheng-Kun</given-names>
        </name>
        <!--chengkun_wu@nudt.edu.cn-->
        <aff><institution>State Key Laboratory of High-Performance Computing</institution>, <addr-line>Changsha 410073, Hunan</addr-line>, <country country="CN">PR China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lu</surname>
          <given-names>Ai-Ping</given-names>
        </name>
        <!--lap64067611@126.com-->
        <aff><institution>Institute for Advancing Translational Medicine in Bone and Joint Diseases</institution>, School of Chinese Medicine, <institution>Hong Kong Baptist University</institution>, <addr-line>Hong Kong SAR</addr-line>, <country country="CN">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3604-3785</contrib-id>
        <name>
          <surname>Cao</surname>
          <given-names>Dong-Sheng</given-names>
        </name>
        <!--oriental-cds@163.com-->
        <aff><institution>Xiangya School of Pharmaceutical Sciences, Central South University</institution>, <addr-line>Changsha 410013, Hunan</addr-line>, <country country="CN">P. R. China</country></aff>
        <aff><institution>Institute for Advancing Translational Medicine in Bone and Joint Diseases</institution>, School of Chinese Medicine, <institution>Hong Kong Baptist University</institution>, <addr-line>Hong Kong SAR</addr-line>, <country country="CN">P. R. China</country></aff>
        <xref rid="cor1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="cor1">Corresponding authors. Dongsheng Cao, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410003, P.R. China. Tel.: +86-139-7488-0914; E-mail: <email>oriental-cds@163.com</email>; Wentao Zhao, School of Computer Science, National University of Defense Technology, Changsha, Hunan 410073, P.R. China. Tel.: +86-159-0731-1680; E-mail: <email>wtzhao@nudt.edu.cn</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>3</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-02-20">
      <day>20</day>
      <month>2</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>20</day>
      <month>2</month>
      <year>2024</year>
    </pub-date>
    <volume>25</volume>
    <issue>2</issue>
    <elocation-id>bbae008</elocation-id>
    <history>
      <date date-type="received">
        <day>24</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>17</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>2</day>
        <month>1</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Â© The Author(s) 2024. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="bbae008.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Drug discovery and development constitute a laborious and costly undertaking. The success of a drug hinges not only good efficacy but also acceptable absorption, distribution, metabolism, elimination, and toxicity (ADMET) properties. Overall, up to 50% of drug development failures have been contributed from undesirable ADMET profiles. As a multiple parameter objective, the optimization of the ADMET properties is extremely challenging owing to the vast chemical space and limited human expert knowledge. In this study, a freely available platform called Chemical Molecular Optimization, Representation and Translation (ChemMORT) is developed for the optimization of multiple ADMET endpoints without the loss of potency (<ext-link xlink:href="https://cadd.nscc-tj.cn/deploy/chemmort/" ext-link-type="uri">https://cadd.nscc-tj.cn/deploy/chemmort/</ext-link>). ChemMORT contains three modules: Simplified Molecular Input Line Entry System (SMILES) Encoder, Descriptor Decoder and Molecular Optimizer. The SMILES Encoder can generate the molecular representation with a 512-dimensional vector, and the Descriptor Decoder is able to translate the above representation to the corresponding molecular structure with high accuracy. Based on reversible molecular representation and particle swarm optimization strategy, the Molecular Optimizer can be used to effectively optimize undesirable ADMET properties without the loss of bioactivity, which essentially accomplishes the design of inverse QSAR. The constrained multi-objective optimization of the poly (ADP-ribose) polymerase-1 inhibitor is provided as the case to explore the utility of ChemMORT.</p>
    </abstract>
    <kwd-group>
      <kwd>ADMET evaluation</kwd>
      <kwd>lead optimization</kwd>
      <kwd>substructure modification</kwd>
      <kwd>deep learning</kwd>
      <kwd>inverse QSAR</kwd>
      <kwd>reversible molecular representation</kwd>
      <kwd>particle swarm optimization</kwd>
    </kwd-group>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Key Research and Development Program of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100012166</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2022YFA1004303</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Foundation of State Key Laboratory of HPCL</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2023-KJWHPCL-01</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Science Foundation for Indigenous Innovation of National University of Defense Technology</institution>
          </institution-wrap>
        </funding-source>
        <award-id>23-ZZCX-JDZ-08</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>22173118</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Excellent Youth Foundation of Hunan Province</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2021JJ10068</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Key scientific research projects in higher education institutions of Henan Province</institution>
          </institution-wrap>
        </funding-source>
        <award-id>24A520036</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>HKBU Strategic Development Fund project</institution>
          </institution-wrap>
        </funding-source>
        <award-id>SDF19-0402-P02</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec id="sec3">
    <title>INTRODUCTION</title>
    <p>The journey of discovering a new drug candidate and shepherding it through clinical trials and onto the market is time-consuming, fraught with difficulties, inordinately expensive, and prone to failure, which typically costs 15Â years and $12â15 million for successfully developing a clinical candidate [<xref rid="ref1" ref-type="bibr">1</xref>]. Since the key to improving pharmaceutical productivity is to boost the efficiency of discovering drug candidates entering clinical trials, several revolutionary technologies have been used for accelerating drug candidate development, such as combinatorial chemistry, X-ray crystallography, high-throughput screening (HTS) and virtual screening (VS) [<xref rid="ref2" ref-type="bibr">2â4</xref>]. However, despite the inventiveness and rapid advances witnessed in HTS and VS [<xref rid="ref5" ref-type="bibr">5â7</xref>], the attrition rate during the early drug candidate discovery is still as high as 75%, even for those experienced global pharmaceutical companies [<xref rid="ref8" ref-type="bibr">8</xref>, <xref rid="ref9" ref-type="bibr">9</xref>]. It is estimated that up to 50% of failures are contributed from the deficiency in absorption, distribution, metabolism, elimination, and toxicity (ADMET) properties, which reaffirms the importance of optimizing ADMET properties during drug discovery campaigns [<xref rid="ref10" ref-type="bibr">10</xref>]. The ADMET optimization could be viewed as an extremely challenging multi-parameter optimization task, which aims to improve multiple ADMET properties while avoid the reduction of biological potency [<xref rid="ref11" ref-type="bibr">11</xref>, <xref rid="ref12" ref-type="bibr">12</xref>].</p>
    <p>With large-scale investigations of deep learning (DL) in molecular representations [<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref14" ref-type="bibr">14</xref>], it is found that the chemical space learned by deep neural networks represents several advantages: smooth, continuous, unique and expressive, which could efficiently benefit molecular optimization [<xref rid="ref15" ref-type="bibr">15</xref>]. Recently, a method proposed by Gomez-Bombarelli <italic toggle="yes">etÂ al.</italic> [<xref rid="ref16" ref-type="bibr">16</xref>] further illustrates the above advantages through the application of variational autoencoder, with the additional feature of reversibility. This autoencoder comprises two neural networks: an encoder and a decoder. The encoder network transforms input Simplified Molecular Input Line Entry System (SMILES) strings into a lower-dimensional representation, commonly referred to as the latent space. Conversely, the decoder network maps the points from this latent space back to SMILES sequences. To achieve the encoding of higher-level molecular features rather than the syntactic concepts or repetitive patterns of the sequence, the reconstruction task is transformed into a translation task, by translating one molecular representation to another syntactically different one [<xref rid="ref17" ref-type="bibr">17</xref>, <xref rid="ref18" ref-type="bibr">18</xref>]. Several researches have shown that the models trained with enumerated SMILES sequences own more advantages in data augmentation and important molecular feature learning than those only trained with one variant (e.g. canonical SMILES) [<xref rid="ref17" ref-type="bibr">17</xref>, <xref rid="ref19" ref-type="bibr">19</xref>]. In addition, it has been observed that latent space vectors showed superior performance in molecular similarity analysis and Quantitative StructureâActivity Relationship (QSAR) modeling than autoencoder-derived vectors and the models built using the Extended Connectivity Fingerprints (ECFP4) fingerprints, suggesting that they have increased relevant to biological activities and physicochemical properties [<xref rid="ref17" ref-type="bibr">17</xref>]. Due to high reversibility and information enrichment, latent space vectors are highly recommended for inverse QSAR problems. For the navigation of the optimization tasks for multiple molecular properties, the application of latent space vectors needs to be combined with efficient optimization strategy and necessary structural constraint, thus effectively avoiding the drop of target potency [<xref rid="ref20" ref-type="bibr">20</xref>].</p>
    <p>Considering the importance of ADMET optimization in drug discovery, here, a freely available platform called Chemical Molecular Optimization, Representation and Translation (ChemMORT) is developed for the optimization of multiple ADMET endpoints (<ext-link xlink:href="https://cadd.nscc-tj.cn/deploy/chemmort/" ext-link-type="uri">https://cadd.nscc-tj.cn/deploy/chemmort/</ext-link>). ChemMORT contains three basic modules: SMILES Encoder, Descriptor Decoder and Molecular Optimizer, which provide the representation, translation and optimization functions, respectively. Based on the training of 17 million enumerated SMILES strings, SMILES Encoder can generate the 512-dimensional molecular representation, and Descriptor Decoder is able to translate the above representation to the corresponding molecular structure with high accuracy. Based on the reversible molecular representation and particle swarm optimization (PSO) strategy, Molecular Optimizer can effectively accomplish ADMET optimization tasks while preserving the potency of the optimized molecules through necessary similarity and substructure constraint. To evaluate the utility of ChemMORT, the constrained multi-objective optimization of the poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor was provided as the case. It is believed that through the rational application of ChemMORT, researchers can discover potent drug candidates with improved ADMET profiles.</p>
  </sec>
  <sec id="sec4">
    <title>MATERIALS AND METHODS</title>
    <sec id="sec5">
      <title>Neural translation model</title>
      <p>In this study, inspired by human language neural network translation models, a sequence-to-sequence (seq2seq) model was trained based on the SMILES notation for chemical space exploration. It turns enumerated SMILES notation into a fixed-length vector representation in the encoder and turns this fixed-length vector into the Canonical SMILES of the molecule in the decoder, where the fixed-length vector will be used as the connection between structure modification and property optimization [<xref rid="ref18" ref-type="bibr">18</xref>]. Generally, recurrent neural networks are used as the backend of the seq2seq model, which often bring the vanishing or exploding gradient problems. To avoid it, three stacked <italic toggle="yes">Gate Recurrent Unit</italic> (GRU) layers were used in both the encoder and decoder networks. In addition, a fully connected layer (<italic toggle="yes">information bottleneck</italic>) with 512Â units and hyperbolic tangent activation function is used as the final layer of the encoder to generate a 512-dimensional latent representation. Through information bottleneck, it can capture the most statistically salient features about molecular structures, which ensures the accuracy of translation and the efficiency for property prediction. The decoder takes the latent representation as an input and feeds it into a similar three stacked aforementioned GRU layers with 1024, 512 and 256Â units. The input of the decoder to each time step is the output of the preceding time step and the embedding of the ground truth. In the training phase, the output of the decoder transfers to the ground truth to calculate the cross-entropy loss and conduct the gradient update. In the prediction phase, the beam search algorithm [<xref rid="ref21" ref-type="bibr">21</xref>], a heuristic search algorithm that explores the best combination of words by expanding the most promising node in a limited set, is used in the model to iteratively predict each character until a complete sequence is generated. An internal database with 1.7 million accessible molecules was used to validate the reliability and generalization ability of the model. All the molecules were randomly divided into a training set (1.53 million molecules) and a test set (0.17 million molecules) with a ratio of 9:1. Every molecule was represented by 10 different enumerated SMILES strings for encoding. A previous study has already proved that training the encoder with enumerated SMILES strings and the decoder with Canonical SMILES is able to achieve a better balance between translation correction rate and chemical space breadth [<xref rid="ref17" ref-type="bibr">17</xref>].</p>
    </sec>
    <sec id="sec6">
      <title>ADMET prediction model</title>
      <p>In order to construct credible ADMET-related prediction models for molecular optimization, a large and high quality ADMET dataset containing basic information and experimental values were collected from the ChEMBL, EPA and DrugBank databases, and all the molecules in the dataset were prepared by molecular operating environment (MOE, version 2016) [<xref rid="ref22" ref-type="bibr">22â25</xref>]. Finally, around 30 000 entries, covering logD7.4, LogS, Caco-2, MDCK cells, Plasma protein binding rate (PPB), AMES toxicity, human ether-a-go-go-related gene (hERG) toxicity, hepotoxicity and median lethal dose (LD50), were obtained for ADMET evaluation [<xref rid="ref23" ref-type="bibr">23</xref>, <xref rid="ref24" ref-type="bibr">24</xref>, <xref rid="ref26" ref-type="bibr">26â29</xref>]. The source and information about the ADMET dataset are summarized in <xref rid="sup1" ref-type="supplementary-material">Table S1</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>. Based on the combination of the calculated 512-dimensional vectors and XGBoost algorithm, nine high-quality ADMET prediction models were constructed for the evaluation and guidance of molecular optimization. In addition, three calculated properties, including SlogP, quantitative estimate of drug-likeness (QED) score and synthetic accessibility (SA) score, were also included in ChemMORT for more comprehensive evaluation of molecular suitability [<xref rid="ref30" ref-type="bibr">30â32</xref>].</p>
    </sec>
    <sec id="sec7">
      <title>Scoring scheme</title>
      <p>To provide a comprehensive perspective of multi-parameter optimization task, the scoring scheme was applied for a qualitative evaluation of the desirability of the optimized molecule. Based on the recommended value range (<xref rid="sup1" ref-type="supplementary-material">Table S2</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>), the customized aim range and the actual property value for individual scores will be: 1 for the value in the optimal range, (0, 1) for the value out of the optimal range but in the recommended value range, and 0 for the value out of the recommended value range. Considering the different requirements in different optimization tasks, the individual scaled score components with customized weights will be combined according to the importance of different features in the whole task. The Final Score (eq <xref rid="deqn02" ref-type="disp-formula">2</xref>) will be presented as the weighted average score of all scaled scores, where a low value corresponds to undesirable optimization and a high value indicates an acceptable optimization. </p>
      <disp-formula id="deqn01">
        <label>(1)</label>
        <tex-math notation="LaTeX" id="DmEquation1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} F=\frac{\sum_{i=1}^j\left({S}_i\cdotp{W}_i\right)}{\sum_{i=1}^j{W}_i} \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <p>where <inline-formula><tex-math notation="LaTeX" id="ineq01">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$j$\end{document}</tex-math></inline-formula> is the number of the objective functions used for optimization, <inline-formula><tex-math notation="LaTeX" id="ineq02">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${S}_i$\end{document}</tex-math></inline-formula> represents the desirability of the objective function <inline-formula><tex-math notation="LaTeX" id="ineq03">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$i$\end{document}</tex-math></inline-formula> of the optimized molecule, and <inline-formula><tex-math notation="LaTeX" id="ineq04">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${W}_i$\end{document}</tex-math></inline-formula> corresponds to the priority of the objective function <inline-formula><tex-math notation="LaTeX" id="ineq05">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$i$\end{document}</tex-math></inline-formula> in this task.</p>
    </sec>
    <sec id="sec8">
      <title>Particle swarm optimization</title>
      <p>Based on the continuous presentation and scoring scheme, the PSO [<xref rid="ref33" ref-type="bibr">33</xref>], a stochastic optimization method that mimics swarm intelligence to find an optimal point in a search space, was applied to explore the optimized molecules with desirable properties [<xref rid="ref34" ref-type="bibr">34â37</xref>]. Inspired by social behavior of bird flocking or fish schooling, the PSO consists of individuals for space searching, which utilizes and communicates the information gained during their search. During this process, each particle in the swarm is defined by their position <inline-formula><tex-math notation="LaTeX" id="ineq06">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$x$\end{document}</tex-math></inline-formula> and velocity <inline-formula><tex-math notation="LaTeX" id="ineq07">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$v$\end{document}</tex-math></inline-formula>, where the scoring scheme <inline-formula><tex-math notation="LaTeX" id="ineq08">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$f$\end{document}</tex-math></inline-formula> is applied for the detection of the potential surface of the search space. The movement of the <italic toggle="yes">i-</italic>th particle at iteration step <italic toggle="yes">k</italic> is influenced by the historical best point of itself: </p>
      <disp-formula id="deqn02">
        <label>(2)</label>
        <tex-math notation="LaTeX" id="DmEquation2">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} {x}_i^{best}= argmaxf\left({x}_i^k\right) \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <p>as well as the overall historical best point of the swarm:</p>
      <disp-formula id="deqn03">
        <label>(3)</label>
        <tex-math notation="LaTeX" id="DmEquation3">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} {x}^{best}= argmaxf\left({x}_i^{best}\right) \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <p>After each iteration, each particle will update its velocity and position based on the collected information and its status:</p>
      <disp-formula id="deqn04">
        <label>(4)</label>
        <tex-math notation="LaTeX" id="DmEquation4">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} {v}_i^{k+1}=w{v}_i^k+{c}_1{r}_1\left({x}_i^{best}-{x}_i^k\right)+{c}_2{r}_2\left({x}^{best}-{x}_i^k\right) \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <disp-formula id="deqn05">
        <label>(5)</label>
        <tex-math notation="LaTeX" id="DmEquation5">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} {x}_i^{k+1}={x}_i^k+{v}_i^{k+1} \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <p>where <inline-formula><tex-math notation="LaTeX" id="ineq09">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${c}_1$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math notation="LaTeX" id="ineq10">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${c}_2$\end{document}</tex-math></inline-formula> are the constants that weight the contribution of the individual experience versus the swarm experience; <inline-formula><tex-math notation="LaTeX" id="ineq11">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${r}_1$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math notation="LaTeX" id="ineq12">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${r}_2$\end{document}</tex-math></inline-formula> are the random numbers drawn from independent uniform distributions between 0 and 1; the inertia weight <inline-formula><tex-math notation="LaTeX" id="ineq13">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$w$\end{document}</tex-math></inline-formula> is a constant that controls the momentum of the particle from the previous iteration. In this work, the position of the particle is initialized by the output of the encoder.</p>
    </sec>
    <sec id="sec9">
      <title>Webserver development</title>
      <p>ChemMORT was developed by using Python 3.7, Django 2.2, Tensorflow 1.14.0, SQLite 3, celery 4.4.7, RabbitMQ 3.6.10 and RDKit 2019.03.1. It was a Django task, which is deployed on a high-performance Nginx Web server of Ubuntu 18.04.4 LTS via the application of uWSGI. ChemMORT applied the MVT (model, view and template)design pattern, including three layers: model layer, view layer and template layer. The model layer interfaces to the SQLite3 database which was applied for model construction, upload file storing and property prediction. The view layer contains the main logic code, which was used for providing access to the prediction models, handling file upload and download, and manipulating multi-prediction tasks. The template layer was applied for the presentation of the front-end pages, including result visualization, page rendering, document integration, etc. The browser compatibility testing is shown in <xref rid="sup1" ref-type="supplementary-material">Table S6</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>.</p>
    </sec>
  </sec>
  <sec id="sec10">
    <title>RESULTS AND DISCUSSION</title>
    <sec id="sec11">
      <title>ChemMORT workflow</title>
      <p>The ChemMORT protocol is presented as a workflow in <xref rid="f1" ref-type="fig">Figure 1</xref>. As shown in <xref rid="f1" ref-type="fig">Figure 1</xref>, there are three main modules in ChemMORT: SMILES Encoder, Descriptor Decoder and Molecular Optimizer, which refer to the functions of descriptor calculation, molecular translation and ADMET optimization, respectively.</p>
      <fig position="float" id="f1">
        <label>Figure 1</label>
        <caption>
          <p>The workflow of ChemMORT.</p>
        </caption>
        <graphic xlink:href="bbae008f1" position="float"/>
      </fig>
      <p>SMILES Encoder: Three molecular input types are supported by the SMILES Encoder module: inputting SMILES strings, drawing molecules from the editor, and uploading file (*.sdf/*.csv/*.txt). After the molecular preparation process, the corresponding 512-dimension vectors will be calculated based on the well-trained encoder network. In the following page, the Summary and Result block will present the overview of the results and the detailed information about the SMILES strings, molecular graphs and 512-dimension vectors. The calculated descriptors and related SMILES strings can be saved as .csv file.</p>
      <p>Descriptor Decoder: In this function, users can upload a 512-dimensional vector (between â1 and 1), which latter will be back-engineered to the corresponding uniform canonical SMILES string through the application of decoder network. It should be noted that owing to the character-by-character nature of the SMILES representation and the fragility of its internal syntax, an arbitrary combination may lead to the output of invalid or failed molecules. After calculation, the summary and result block are provided for the overview of the translated SMILES information, where the results can also be downloaded as .csv file. Owing to the advantage of reversibility, the combination of SMILES Encoder and Descriptor Decoder possesses the ability to deal with the inverse design problem, which is the key point of lead optimization.</p>
      <p>Molecular Optimizer: Molecular optimization is a complex and multi-objective task, which needs to balance bioactivity, pharmacokinetic profile and therapeutic safety. To achieve this goal, the Molecular Optimizer module is provided with the integration of reversible molecular representation, credible QSAR models, necessary structural constraint and multi-objective PSO strategy, which follows the principle of inverse QSAR methodology. Firstly, users are required to input the job information and the SMILES string of the molecule that needs to be optimized. Twelve credible objective functions covering basic molecular properties, synesthetic accessibility, drug-likeness, absorption, distribution and toxicity were provided for property optimization. To retain the efficacy and novelty of initial optimized molecule, the <italic toggle="yes">Similarity Constrain</italic> and <italic toggle="yes">Substructure Constrain</italic> functions were applied for the definition of the starting point and the annotation of important active motif, respectively [<xref rid="ref38" ref-type="bibr">38</xref>]. The application of the <italic toggle="yes">Similarity Constrain</italic> function enables the setting of the distance limitation between the generated molecule and the reference molecule based on the ECFP4 fingerprint and Tanimoto similarity metric, while the application of the <italic toggle="yes">Substructure Constrain</italic> function highlights the importance of bioactivity motif. All the above functions are allowed to set the weights according to their importance, which later will be applied to the scaled score for optimization navigation and comprehensive evaluation. Owing to the different requirements for optimal molecules, users can adjust the iteration steps and the number of the top desirable compounds in each iteration step. After submission, the optimization job will be calculated in the background. Users can obtain the optimized result from the email or the access of Queue page with the input of job token. The final result includes the information about the starting molecule and optimized molecules, of which the latter one provides the detailed table about the SMILES, the structural graph, selected optimized property values and the final score. Based on the combination of user-defined property value range, specific function weights and the optimized property value, the final score is a comprehensive desirability index of the optimized molecules, and it can quantitatively indicate the desirability and quality of the optimized molecule in the specified optimization task.</p>
    </sec>
    <sec id="sec12">
      <title>Neural translation model training</title>
      <p>A multi-layer gate recurrent unit network, including input dropout, bottleneck layer and Gaussian noise term, was employed for training and application. The model was trained until convergence, using a batch size of 64, dropout ratio of 0.15 and embedding noise of 0.05. As shown in <xref rid="f2" ref-type="fig">Figure 2</xref>, the translation accuracy for the training set and test set first increased rapidly, but after a point, it became stable and almost unchanged. The final average single character accuracy values for both the training and test sets reached 99.8%, indicating the proportion of correctly predicted characters to the total predicted length. This achievement underscores the reliability and credibility of this seq2seq model. It also indicated that the important feature of the molecule has already been encoded in the latent space, resulting in a potentially powerful molecular descriptor for further ADMET prediction and optimization task.</p>
      <fig position="float" id="f2">
        <label>Figure 2</label>
        <caption>
          <p>The translation accuracy for the training set and test set during the 160Â k training steps.</p>
        </caption>
        <graphic xlink:href="bbae008f2" position="float"/>
      </fig>
    </sec>
    <sec id="sec13">
      <title>ADMET predictive model validation</title>
      <p>Based on the 512-dimensional descriptors calculated by the encoder network, 9 ADMET-related prediction models, including logD7.4, AMES, Caco-2, MDCK, PPB, LogS, hERG, hepatoxicity and LD50, were constructed with the XGBoost algorithm. All the datasets were divided into the training set and test set according to the chemical space distribution computed by the âDiverse training set splitâ module in ChemSAR, where 75% compounds were used as the training set and the remaining 25% as the test set [<xref rid="ref39" ref-type="bibr">39</xref>]. The prediction performance of the ADMET prediction models and related parameters are summarized in <xref rid="TB1" ref-type="table">Table 1</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S3</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>, respectively.</p>
      <table-wrap position="float" id="TB1">
        <label>Table 1</label>
        <caption>
          <p>The performance of ADMET prediction models in ChemMORT</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th colspan="11" align="left" rowspan="1">ADMET regression model performance</th>
            </tr>
            <tr>
              <th rowspan="2" align="left" colspan="1">Property</th>
              <th rowspan="2" align="left" colspan="1">Description</th>
              <th rowspan="2" align="left" colspan="1">Algorithm<sup>*</sup></th>
              <th colspan="3" align="left" rowspan="1">5-Fold CV</th>
              <th colspan="3" align="left" rowspan="1">Test set</th>
              <th colspan="2" align="left" rowspan="1">Data information</th>
            </tr>
            <tr>
              <th align="left" rowspan="1" colspan="1">RMSE</th>
              <th align="left" rowspan="1" colspan="1">MAE</th>
              <th align="left" rowspan="1" colspan="1">R<sup>2</sup></th>
              <th align="left" rowspan="1" colspan="1">RMSE</th>
              <th align="left" rowspan="1" colspan="1">MAE</th>
              <th align="left" rowspan="1" colspan="1">R<sup>2</sup></th>
              <th align="left" rowspan="1" colspan="1">Training set</th>
              <th align="left" rowspan="1" colspan="1">Test set</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">logD7.4</td>
              <td align="left" rowspan="1" colspan="1">Log of the octanol/water distribution coefficient at pHÂ 7.4.</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.562âÂ±â0.009</td>
              <td align="left" rowspan="1" colspan="1">0.428âÂ±â0.13</td>
              <td align="left" rowspan="1" colspan="1">0.834âÂ±â0.005</td>
              <td align="left" rowspan="1" colspan="1">0.555âÂ±â0.010</td>
              <td align="left" rowspan="1" colspan="1">0.426âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.840âÂ±â0.004</td>
              <td align="left" rowspan="1" colspan="1">773</td>
              <td align="left" rowspan="1" colspan="1">258</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">logS</td>
              <td align="left" rowspan="1" colspan="1">Log of Solubility</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.842âÂ±â0.084</td>
              <td align="left" rowspan="1" colspan="1">0.592âÂ±â0.056</td>
              <td align="left" rowspan="1" colspan="1">0.839âÂ±â0.029</td>
              <td align="left" rowspan="1" colspan="1">0.823âÂ±â0.026</td>
              <td align="left" rowspan="1" colspan="1">0.572âÂ±â0.009</td>
              <td align="left" rowspan="1" colspan="1">0.862âÂ±â0.011</td>
              <td align="left" rowspan="1" colspan="1">4116</td>
              <td align="left" rowspan="1" colspan="1">1104</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Caco-2</td>
              <td align="left" rowspan="1" colspan="1">Caco-2 Permeability</td>
              <td align="left" rowspan="1" colspan="1">XGBoost&amp; Data Augment</td>
              <td align="left" rowspan="1" colspan="1">0.328âÂ±â0.004</td>
              <td align="left" rowspan="1" colspan="1">0.245âÂ±â0.005</td>
              <td align="left" rowspan="1" colspan="1">0.728âÂ±â0.011</td>
              <td align="left" rowspan="1" colspan="1">0.332âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.244âÂ±â0.004</td>
              <td align="left" rowspan="1" colspan="1">0.718âÂ±â0.019</td>
              <td align="left" rowspan="1" colspan="1">886</td>
              <td align="left" rowspan="1" colspan="1">296</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">MDCK</td>
              <td align="left" rowspan="1" colspan="1">MDCK Permeability</td>
              <td align="left" rowspan="1" colspan="1">XGBoost&amp; Data Augment</td>
              <td align="left" rowspan="1" colspan="1">0.322âÂ±â0.034</td>
              <td align="left" rowspan="1" colspan="1">0.235âÂ±â0.021</td>
              <td align="left" rowspan="1" colspan="1">0.644âÂ±â0.057</td>
              <td align="left" rowspan="1" colspan="1">0.323âÂ±â0.022</td>
              <td align="left" rowspan="1" colspan="1">0.232âÂ±â0.011</td>
              <td align="left" rowspan="1" colspan="1">0.650âÂ±â0.041</td>
              <td align="left" rowspan="1" colspan="1">912</td>
              <td align="left" rowspan="1" colspan="1">228</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">PPB</td>
              <td align="left" rowspan="1" colspan="1">Plasma Protein Binding</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.154âÂ±â0.010</td>
              <td align="left" rowspan="1" colspan="1">0.106âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.691âÂ±â0.025</td>
              <td align="left" rowspan="1" colspan="1">0.152âÂ±â0.003</td>
              <td align="left" rowspan="1" colspan="1">0.104âÂ±â0.002</td>
              <td align="left" rowspan="1" colspan="1">0.691âÂ±â0.016</td>
              <td align="left" rowspan="1" colspan="1">1368</td>
              <td align="left" rowspan="1" colspan="1">454</td>
            </tr>
            <tr>
              <td align="left" colspan="11" rowspan="1">ADMET classification model performance</td>
            </tr>
            <tr>
              <td align="left" rowspan="2" colspan="1">Property</td>
              <td align="left" rowspan="2" colspan="1">Description</td>
              <td align="left" rowspan="2" colspan="1">Algorithm<sup>*</sup></td>
              <td align="left" colspan="3" rowspan="1">5-Fold CV</td>
              <td align="left" colspan="3" rowspan="1">Test set</td>
              <td align="left" colspan="2" rowspan="1">Data information</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Accuracy</td>
              <td align="left" rowspan="1" colspan="1">Sensitivity</td>
              <td align="left" rowspan="1" colspan="1">AUC</td>
              <td align="left" rowspan="1" colspan="1">Accuracy</td>
              <td align="left" rowspan="1" colspan="1">Sensitivity</td>
              <td align="left" rowspan="1" colspan="1">AUC</td>
              <td align="left" rowspan="1" colspan="1">Training set</td>
              <td align="left" rowspan="1" colspan="1">Test set</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">AMES</td>
              <td align="left" rowspan="1" colspan="1">The probability to be positive in Ames test.</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.810âÂ±â0.016</td>
              <td align="left" rowspan="1" colspan="1">0.838âÂ±â0.014</td>
              <td align="left" rowspan="1" colspan="1">0.889âÂ±â0.013</td>
              <td align="left" rowspan="1" colspan="1">0.813âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.835âÂ±â0.013</td>
              <td align="left" rowspan="1" colspan="1">0.888âÂ±â0.004</td>
              <td align="left" rowspan="1" colspan="1">7514</td>
              <td align="left" rowspan="1" colspan="1">1905</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">hERG</td>
              <td align="left" rowspan="1" colspan="1">The probability to be hERG Blocker</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.800âÂ±â0.036</td>
              <td align="left" rowspan="1" colspan="1">0.820âÂ±â0.068</td>
              <td align="left" rowspan="1" colspan="1">0.857âÂ±â0.053</td>
              <td align="left" rowspan="1" colspan="1">0.814âÂ±â0.026</td>
              <td align="left" rowspan="1" colspan="1">0.841âÂ±â0.042</td>
              <td align="left" rowspan="1" colspan="1">0.854âÂ±â0.032</td>
              <td align="left" rowspan="1" colspan="1">392</td>
              <td align="left" rowspan="1" colspan="1">263</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">hepatoxicity</td>
              <td align="left" rowspan="1" colspan="1">The probability of owning liver toxicity</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.700âÂ±â0.026</td>
              <td align="left" rowspan="1" colspan="1">0.701âÂ±â0.030</td>
              <td align="left" rowspan="1" colspan="1">0.764âÂ±â0.030</td>
              <td align="left" rowspan="1" colspan="1">0.729âÂ±â0.016</td>
              <td align="left" rowspan="1" colspan="1">0.732âÂ±â0.019</td>
              <td align="left" rowspan="1" colspan="1">0.794âÂ±â0.015</td>
              <td align="left" rowspan="1" colspan="1">2208</td>
              <td align="left" rowspan="1" colspan="1">502</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">LD<sub>50</sub></td>
              <td align="left" rowspan="1" colspan="1">LD50 of acute toxicity</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.741âÂ±â0.045</td>
              <td align="left" rowspan="1" colspan="1">0.742âÂ±â0.128</td>
              <td align="left" rowspan="1" colspan="1">0.833âÂ±â0.033</td>
              <td align="left" rowspan="1" colspan="1">0.765âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.764âÂ±â0.015</td>
              <td align="left" rowspan="1" colspan="1">0.848âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">5917</td>
              <td align="left" rowspan="1" colspan="1">1480</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">QED</td>
              <td align="left" rowspan="1" colspan="1">quantitative estimate of drug-likeness</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">SlogP</td>
              <td align="left" rowspan="1" colspan="1">Log of the octanol/water partition coefficient, based on an atomic contribution model</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>*Data Augment refers to the application of enumerated SMILES in model construction.</p>
        </table-wrap-foot>
      </table-wrap>
      <p>As shown in <xref rid="TB1" ref-type="table">Table 1</xref>, it can be observed that most models have high and stable performance in both the 5-fold cross validation and the test set prediction. For the regression models, the average values of RMSE and R2 are 0.442 and 0.747 for the 5-fold cross validation, respectively, and 0.437 and 0.752 for the test set, respectively. For the classification models, the average values of accuracy and AUC are 0.763 and 0.836 for the 5-fold cross validation, respectively, and 0.780 and 0.846 for the test set, respectively. Such results not only proved the credibility of the ADMET prediction models, but also indicated the effectiveness and utility of the latent representations calculated by ChemMORT. In addition, the combination of the encoding and decoding networks ensures the reversibility of the latent representations, which enables the ADMET prediction models to navigate molecular optimization.</p>
    </sec>
    <sec id="sec14">
      <title>Constrained multi-objective optimization</title>
      <p>PARP-1 is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of PARP-1 provide a new type of anticancer drugs that selectively kill cancer cells by targeting homologous recombination repair defects [<xref rid="ref40" ref-type="bibr">40</xref>, <xref rid="ref41" ref-type="bibr">41</xref>]. However, most PARP-1 inhibitors suffer from the deficiency of poor aqueous solubility, which has severely disrupted the applicability value [<xref rid="ref42" ref-type="bibr">42</xref>]. Therefore, the optimization of more hydrophilic but still potent PARP-1 inhibitors for cancer therapy is quite necessary.</p>
      <p>The approved drug Olaparib is selected as the initial molecule for further optimization, which is an efficient PARP-1 inhibitor possessing IC<sub>50</sub> of 0.9Â nmol but solubility of only 0.0601Â mg/mL (logS of â3.8). During this multi-parameter optimization task, the solubility, QED and SA of the molecule are selected as the aim properties. In addition, to ensure the potency of the PARP-1 inhibitor, the bioactivity motif and similarity constraint are also used (<xref rid="f3" ref-type="fig">Figure 3A</xref>). This optimization task is repeated 100 times and 50 iterations are conducted for the PSO optimization each time. The detailed information about the privilege function section and corresponding weight, the different properties over the course of the optimization, and the final representative optimized molecules are depicted in <xref rid="f3" ref-type="fig">Figure 3</xref>.</p>
      <fig position="float" id="f3">
        <label>Figure 3</label>
        <caption>
          <p>The information about the initial molecule, optimization process and representative optimized molecules. (A) The introduction of the initial molecule Olaparib and related optimization task set; (B) The averaged values of the final score, QED, LogS, SA and similarity during the 50-step optimization; (C) The docking score, final score and LogS value of Olaparib and 171 unique optimized molecules; (D) Five representative optimized molecules with their property information.</p>
        </caption>
        <graphic xlink:href="bbae008f3" position="float"/>
      </fig>
      <p>As shown in <xref rid="f3" ref-type="fig">Figure 3B</xref>, ChemMORT is consistently able to optimize the initial molecule with respect to the defined multi-parameter properties. Clearly, the LogS value and the final score first increased rapidly, but after a point, it became stable and almost unchanged. For QED and SA, according to the dense interval settings, they tend to fluctuate between 0.70 and 0.72, and between 2.5 and 2.7, respectively. For similarity, the tendency is totally converse, with a stable value of 0.40 for the later optimized molecules. It is not surprising since it is a process for molecular optimization. Besides, according to the constraint of bioactivity motif, the optimized molecule is not far from the initial molecule, indicating the importance of structural constraints. Finally, 171 unique optimized molecules with higher bioactivity and better water-solubility than the initial molecule are generated after 100 optimization cycles (<xref rid="sup1" ref-type="supplementary-material">Table S4</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>). As shown in <xref rid="f3" ref-type="fig">Figure 3C</xref>, the solubility and final desirable score of the optimized molecules are much higher than those of the initial molecule. One of the main reasons is the substitution of 1,2-dihydrophthalazine to a more polar function group, such as 1H-1,2,4-triazole, piperazine and imidazolidine with N,N-dimethylacetamide, thus strengthening the hydration of compounds and promoting the thermodynamic process of dissolution [<xref rid="ref43" ref-type="bibr">43</xref>]. Though the ability to optimize molecular pharmacokinetic properties often comes at the price of limited bioactivity to target, but with the application of molecular docking, it is found that most optimized molecules have rather high docking scores, which indicated preliminary guarantee of their potency (<xref rid="sup1" ref-type="supplementary-material">Table S4</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>). Such privileged results have a close relationship with the implementation of the constraints of the essential bioactivity motif and the similarity threshold to the initial molecule. Five representative optimized molecules with their property information are provided in <xref rid="f3" ref-type="fig">Figure 3D</xref>. All of them possess high structural similarity to Olaparib and other approved PARP1 drugs, which successfully replicated the ideation of medicinal chemists during lead optimization.</p>
      <p>We then investigated the detailed interactions between the optimized molecules and the PARP-1 target (PDB ID: 4L6S). The predicted binding modes of Olaparib and the optimized molecules are presented in <xref rid="f4" ref-type="fig">Figure 4</xref>. As shown in <xref rid="f4" ref-type="fig">Figure 4</xref>, most of the optimized molecules have several key interactions, such as the H-bonding networks with Gly863 and Ser904 and the Ï-Ï stacking with Tyr907, which are known as the key binding patterns between PARP-1 inhibitors and PARP-1.</p>
      <fig position="float" id="f4">
        <label>Figure 4</label>
        <caption>
          <p>The interactions between the generated active molecules with PARP1. Figures A-F correspond to the binding mode of Olaparib and the optimized molecules 1â~â5, respectively. The hydrogen-bonding, Ï-Ï stacking interactions and charged interactions are indicated by different colors.</p>
        </caption>
        <graphic xlink:href="bbae008f4" position="float"/>
      </fig>
      <p>To further ensure the utility and potency of these optimized molecules, molecular dynamics (MD) simulation was used to characterize the proteinâligand interactions of the optimized molecules [<xref rid="ref44" ref-type="bibr">44</xref>]. Specifically, the AMBER ff19SB force field [<xref rid="ref45" ref-type="bibr">45</xref>] and the General AMBER Force Field 2 [<xref rid="ref46" ref-type="bibr">46</xref>] were used to parameterize the system. The conformation of the proteinâligand complex was generated using Vina [<xref rid="ref47" ref-type="bibr">47</xref>]. Prior to the MD simulation, two-step minimizations, heating and equilibration were performed. The minimized system was heated to 298.15Â K and increased to atmospheric pressure. Then, 20Â ns production MD simulation was carried out for each complex in the ensemble with a time step of 2Â fs. The structural root-mean-square-deviations (RMSDs) of the backbone atoms (C, C<sub>a</sub> and N) of the protein relative to the initial structures were examined as a function of time (<xref rid="sup1" ref-type="supplementary-material">Figure S1</xref>). As can be seen in the plot, all the systems were stable during the 20-ns MD simulations. The RMSDs of PARP-1 in complex with five optimized molecules showed almost the same RMSDs with Olaparib. Additionally, we uniformly extracted 100 frames from the trajectory of the last 2 nanoseconds. Subsequently, we performed molecular mechanics generalized Born surface area (MM/GBSA) calculations and residue energy decomposition using AmberTools2023 [<xref rid="ref48" ref-type="bibr">48</xref>]. The predicted binding free energies listed in <xref rid="sup1" ref-type="supplementary-material">Table S5</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>, also indicate that the optimized molecule 3 (â56.772Â kcal/mol), 4 (â58.949Â kcal/mol) and 5 (â58.831Â kcal/mol) were almost at the same level of the binding affinity for Olaparib (â52.130Â kcal/mol). To further identify the key residues related to the binding process, the free energy contributions of the top 10 residues at the binding site were estimated. As shown in <xref rid="f5" ref-type="fig">Figure 5</xref>, Tyr896, Tyr907, Hie862 and Tyr907 are the most important residues for most optimized molecules, which is in high agreement with the residue contributions for PARP1 inhibitors (<xref rid="f5" ref-type="fig">Figure 5A</xref>). Such analysis indicated that the reasonable application of privileged motif and similarity constraint is necessary to maintain molecular bioactivity during lead optimization [<xref rid="ref49" ref-type="bibr">49</xref>]. Although this multi-parameter optimization task consists of many different and partially conflicting individual objectives, such as aqueous solubility, activity, SA and structural constraints, ChemMORT is consistently able to find some molecules in the vast chemical space that meets the desirable ranges for all of the defined ADMET objectives within the guarantee of target bioactivity.</p>
      <fig position="float" id="f5">
        <label>Figure 5</label>
        <caption>
          <p>The top 10 residues contributing to the binding free energies of the generated active molecules. Figures A-F correspond to the binding modes of Olaparib and the optimized molecules 1â~â5, respectively.</p>
        </caption>
        <graphic xlink:href="bbae008f5" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec15">
    <title>CONCLUSION</title>
    <p>The success of a drug is determined not only by good efficacy and specificity, but also the acceptable ADMET properties. However, the optimization of the lead molecules is a multiple parameter optimization problem, covering potency, selectivity, pharmacokinetics features and safety, which is extremely challenging owing to the vast and discrete drug-like chemical space and limited knowledge from experimental transformation. Therefore, to break through this bottleneck, ChemMORT is developed for the multiple ADMET property optimization of drug candidates through the application of NMT, credible ADMET prediction models and multi-objective PSO strategy. Three modules are included in ChemMORT: SMILES Encoder, Descriptor Decoder and Molecular Optimizer, which provide the representation, translation and optimization functions, respectively. The constrained multi-objective optimization of PARP-1 inhibitors has indicated the successful match of ChemMORT to chemist design, which has successfully optimized ADMET properties of the initial molecule with the preservation of target binding affinity. It is anticipated that the future is bright for ADMET property optimization of lead molecules with the rational application of ChemMORT.</p>
    <boxed-text id="box01" position="float">
      <sec id="sec28a">
        <title>Key Points</title>
        <list list-type="bullet">
          <list-item>
            <p>ChemMORT is a web-based integrated tool that learns molecular representations based on an encoder-decoder neural network architecture. It enhances network performance using SMILES enumeration and conducts multi-objective optimization of molecular properties through particle swarm optimization algorithms. ChemMORT can effectively optimize undesirable ADMET properties without compromising bioactivity, thereby achieving reverse QSAR design at its core.</p>
          </list-item>
          <list-item>
            <p>ChemMORT has been meticulously designed and optimized for its functional modules to enhance user experience. It supports batch upload and download functionalities. Users can define promising and desirable molecules based on their own criteria. The optimizer also provides substructure and similarity constraints, allowing users to freely adjust the importance of each property for highly customizable molecular optimization.</p>
          </list-item>
          <list-item>
            <p>The constrained multi-objective optimization of the PARP-1 inhibitor is provided as the case to explore the utility of ChemMORT.</p>
          </list-item>
        </list>
      </sec>
    </boxed-text>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>supplementary_materials_bbae008</label>
      <media xlink:href="supplementary_materials_bbae008.zip"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="bbae008-ack">
    <title>ACKNOWLEDGEMENTS</title>
    <p>This work was supported by National Key Research and Development Program of China (2022YFA1004303), Foundation of State Key Laboratory of HPCL (2023-KJWHPCL-01), Science Foundation for Indigenous Innovation of National University of Defense Technology under Grant (23-ZZCX-JDZ-08), National Science Foundation of China (22173118), Excellent Youth Foundation of Hunan Province (2021JJ10068), Key scientific research projects in higher education institutions of Henan Province (24A520036) and HKBU Strategic Development Fund project (SDF19-0402-P02). The study was approved by the university's review board.</p>
  </ack>
  <sec sec-type="data-availability" id="sec17">
    <title>DATA AVAILABILITY</title>
    <p>The project is available in the GitHub address (<ext-link xlink:href="https://github.com/antwiser/ChemMORT" ext-link-type="uri">https://github.com/antwiser/ChemMORT</ext-link>).</p>
  </sec>
  <sec id="sec18">
    <title>ABBREVIATIONS</title>
    <p>ADMET, absorption, distribution, metabolism, elimination, and toxicity; QSAR, quantitative structureâactivity relationship; DL, deep learning; SMILES, simplified molecular input line entry specification; HTS, high-throughput screening; VS, virtual screening; ECFP4, extended connectivity fingerprints; RNNs, recurrent neural networks; hERG, human ether-a-go-go-related gene; PPB, plasma protein binding rate; PSO, particle swarm optimization; PARP-1, Poly (ADP-ribose) polymerase-1; MD, molecular dynamics; RMSDs, root-mean-square-deviations;</p>
  </sec>
  <notes id="bio1">
    <title>Author Biographies</title>
    <p><bold>Jia-cai Yi</bold> is a graduate student in the School of Computer Science, National University of Defense Technology. His researches focus on artificial intelligence for drug discovery.</p>
    <sec id="sec18b">
      <p><bold>Zi-yi Yang</bold> is a graduate student at Xiangya School of Pharmaceutical Sciences, Central South University. Her researches focus on screening for frequent hit compounds.</p>
    </sec>
    <sec id="sec18c">
      <p><bold>Wen-Tao Zhao</bold> is currently a professor in the School of Computer Science, National University of Defense Technology, China. His research interests include network performance optimization, information processing, and machine learning.</p>
    </sec>
    <sec id="sec18d">
      <p><bold>Zhi-Jiang Yang</bold> is a graduate student at Xiangya School of Pharmaceutical Sciences, Central South University. His researches focus on the development of cheminformatics tools.</p>
    </sec>
    <sec id="sec18e">
      <p><bold>Xiao-Chen Zhang</bold> is a Ph.D. student in the School of Computer Science, National University of Defense Technology, China. His researches focus on the development of cheminformatics tools.</p>
    </sec>
    <sec id="sec18g">
      <p><bold>Cheng-Kun Wu</bold> is currently an associate professor research fellow student in Institute for Quantum Information &amp; State Key Laboratory of High Performance Computing, College of Computer Science and Technology, National University of Defense Technology. His researches focus on Systems Biology, High-Performance Computing, Pattern Recognition, Machine Learning, and Data Mining.</p>
    </sec>
    <sec id="sec18h">
      <p><bold>Ai-Ping Lu</bold> is a professor at the Hong Kong Baptist University and has long been engaged in basic and new drug discovery and development of Chinese medicine for the treatment of rheumatoid arthritis and oncology, as well as the research of aptamer-targeted delivery of innovative drugs.</p>
    </sec>
    <sec id="sec18i">
      <p><bold>Dong-Sheng Cao</bold> is currently an associate professor in the Xiangya School of Pharmaceutical Sciences, Central South University, China. His research interests can be found at the website of his group: <ext-link xlink:href="http://www.scbdd.com" ext-link-type="uri">http://www.scbdd.com</ext-link>.</p>
    </sec>
  </notes>
  <ref-list id="bib1">
    <title>References</title>
    <ref id="ref1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roses</surname><given-names>AD</given-names></string-name></person-group>. <article-title>Pharmacogenetics in drug discovery and development: a translational perspective</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2008</year>;<volume>7</volume>:<fpage>807</fpage>â<lpage>17</lpage>.<pub-id pub-id-type="pmid">18806753</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>BergstrÃ¶m</surname><given-names>F</given-names></string-name>, <string-name><surname>Lindmark</surname><given-names>B</given-names></string-name></person-group>. <article-title>Accelerated drug discovery by rapid candidate drug identification</article-title>. <source>Drug Discov Today</source> Â <year>2019</year>;<volume>24</volume>:<fpage>1237</fpage>â<lpage>41</lpage>.<pub-id pub-id-type="pmid">30946980</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burt</surname><given-names>T</given-names></string-name>, <string-name><surname>Young</surname><given-names>G</given-names></string-name>, <string-name><surname>Lee</surname><given-names>W</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Phase 0/microdosing approaches: time for mainstream application in drug development?</article-title> Â <source>Nat Rev Drug Discov</source> Â <year>2020</year>;<volume>19</volume>:<fpage>801</fpage>â<lpage>18</lpage>.<pub-id pub-id-type="pmid">32901140</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schneider</surname><given-names>P</given-names></string-name>, <string-name><surname>Walters</surname><given-names>WP</given-names></string-name>, <string-name><surname>Plowright</surname><given-names>AT</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Rethinking drug design in the artificial intelligence era</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2020</year>;<volume>19</volume>:<fpage>353</fpage>â<lpage>64</lpage>.<pub-id pub-id-type="pmid">31801986</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vamathevan</surname><given-names>J</given-names></string-name>, <string-name><surname>Clark</surname><given-names>D</given-names></string-name>, <string-name><surname>Czodrowski</surname><given-names>P</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Applications of machine learning in drug discovery and development</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2019</year>;<volume>18</volume>:<fpage>463</fpage>â<lpage>77</lpage>.<pub-id pub-id-type="pmid">30976107</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gloriam</surname><given-names>DE</given-names></string-name></person-group>. <article-title>Bigger is better in virtual drug screens</article-title>. <source>Nature</source> Â <year>2019</year>;<volume>566</volume>:<fpage>193</fpage>â<lpage>4</lpage>.</mixed-citation>
    </ref>
    <ref id="ref7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ekins</surname><given-names>S</given-names></string-name>, <string-name><surname>Puhl</surname><given-names>AC</given-names></string-name>, <string-name><surname>Zorn</surname><given-names>KM</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Exploiting machine learning for end-to-end drug discovery and development</article-title>. <source>Nat Mater</source> Â <year>2019</year>;<volume>18</volume>:<fpage>435</fpage>â<lpage>41</lpage>.<pub-id pub-id-type="pmid">31000803</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Waring</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Arrowsmith</surname><given-names>J</given-names></string-name>, <string-name><surname>Leach</surname><given-names>AR</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>An analysis of the attrition of drug candidates from four major pharmaceutical companies</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2015</year>;<volume>14</volume>:<fpage>475</fpage>â<lpage>86</lpage>.<pub-id pub-id-type="pmid">26091267</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kola</surname><given-names>I</given-names></string-name>, <string-name><surname>Landis</surname><given-names>J</given-names></string-name></person-group>. <article-title>Can the pharmaceutical industry reduce attrition rates?</article-title> Â <source>Nat Rev Drug Discov</source> Â <year>2004</year>;<volume>3</volume>:<fpage>711</fpage>â<lpage>6</lpage>.<pub-id pub-id-type="pmid">15286737</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sutherland</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Raymond</surname><given-names>JW</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>JL</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes</article-title>. <source>J Med Chem</source> Â <year>2012</year>;<volume>55</volume>:<fpage>6455</fpage>â<lpage>66</lpage>.<pub-id pub-id-type="pmid">22716080</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schneider</surname><given-names>G</given-names></string-name>, <string-name><surname>Clark</surname><given-names>DE</given-names></string-name></person-group>. <article-title>Automated de novo drug design: are we nearly there yet?</article-title> Â <source>Angew Chem Int Ed</source> Â <year>2019</year>;<volume>58</volume>:<fpage>10792</fpage>â<lpage>803</lpage>.</mixed-citation>
    </ref>
    <ref id="ref12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schneider</surname><given-names>G</given-names></string-name>, <string-name><surname>Fechner</surname><given-names>U</given-names></string-name></person-group>. <article-title>Computer-based de novo design of drug-like molecules</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2005</year>;<volume>4</volume>:<fpage>649</fpage>â<lpage>63</lpage>.<pub-id pub-id-type="pmid">16056391</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref13">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>XC</given-names></string-name>, <string-name><surname>Wu</surname><given-names>CK</given-names></string-name>, <string-name><surname>Yang</surname><given-names>ZJ</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>MG-BERT: leveraging unsupervised atomic representation learning for molecular property prediction</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>(<issue>6</issue>):bbab152. <pub-id pub-id-type="doi">10.1093/bib/bbab152</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref14">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>CK</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>XC</given-names></string-name>, <string-name><surname>Yang</surname><given-names>ZJ</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Learning to SMILES: BAN-based strategies to improve latent representation learning from molecules</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>(<issue>6</issue>):bbab327. <pub-id pub-id-type="doi">10.1093/bib/bbab327</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chuang</surname><given-names>KV</given-names></string-name>, <string-name><surname>Gunsalus</surname><given-names>LM</given-names></string-name>, <string-name><surname>Keiser</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>Learning molecular representations for medicinal chemistry: miniperspective</article-title>. <source>J Med Chem</source> Â <year>2020</year>;<volume>63</volume>:<fpage>8705</fpage>â<lpage>22</lpage>.<pub-id pub-id-type="pmid">32366098</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>GÃ³mez-Bombarelli</surname><given-names>R</given-names></string-name>, <string-name><surname>Wei</surname><given-names>JN</given-names></string-name>, <string-name><surname>Duvenaud</surname><given-names>D</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Automatic chemical design using a data-driven continuous representation of molecules</article-title>. <source>ACS Cent Sci</source> Â <year>2018</year>;<volume>4</volume>:<fpage>268</fpage>â<lpage>76</lpage>.<pub-id pub-id-type="pmid">29532027</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bjerrum</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Sattarov</surname><given-names>B</given-names></string-name></person-group>. <article-title>Improving chemical autoencoder latent space and molecular de novo generation diversity with heteroencoders</article-title>. <source>Biomolecules</source> Â <year>2018</year>;<volume>8</volume>:<fpage>131</fpage>.<pub-id pub-id-type="pmid">30380783</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Winter</surname><given-names>R</given-names></string-name>, <string-name><surname>Montanari</surname><given-names>F</given-names></string-name>, <string-name><surname>NoÃ©</surname><given-names>F</given-names></string-name>, <string-name><surname>Clevert</surname><given-names>DA</given-names></string-name></person-group>. <article-title>Learning continuous and data-driven molecular descriptors by translating equivalent chemical representations</article-title>. <source>Chem Sci</source> Â <year>2019</year>;<volume>10</volume>:<fpage>1692</fpage>â<lpage>701</lpage>.<pub-id pub-id-type="pmid">30842833</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>ArÃºs-Pous</surname><given-names>J</given-names></string-name>, <string-name><surname>Johansson</surname><given-names>SV</given-names></string-name>, <string-name><surname>Prykhodko</surname><given-names>O</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Randomized SMILES strings improve the quality of molecular generative models</article-title>. <source>J Chem</source> Â <year>2019</year>;<volume>11</volume>:<fpage>1</fpage>â<lpage>13</lpage>.</mixed-citation>
    </ref>
    <ref id="ref20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Winter</surname><given-names>R</given-names></string-name>, <string-name><surname>Montanari</surname><given-names>F</given-names></string-name>, <string-name><surname>Steffen</surname><given-names>A</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Efficient multi-objective molecular optimization in a continuous latent space</article-title>. <source>Chem Sci</source> Â <year>2019</year>;<volume>10</volume>:<fpage>8016</fpage>â<lpage>24</lpage>.<pub-id pub-id-type="pmid">31853357</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vijayakumar</surname><given-names>AK</given-names></string-name>, <string-name><surname>Cogswell</surname><given-names>M</given-names></string-name>, <string-name><surname>Selvaraju</surname><given-names>RR</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Diverse beam search: Decoding diverse solutions from neural sequence model</article-title>. <source>Proceedings of the AAAI Conference on Artificial Intelligence</source> Â <year>2016</year>;<volume>32</volume>(<issue>1</issue>). <pub-id pub-id-type="doi">10.1609/aaai.v32i1.12340</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiong</surname><given-names>G</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Yi</surname><given-names>J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties</article-title>. <source>Nucleic Acids Res</source> Â <year>2021</year>;<volume>49</volume>:<fpage>W5</fpage>â<lpage>14</lpage>.<pub-id pub-id-type="pmid">33893803</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dong</surname><given-names>J</given-names></string-name>, <string-name><surname>Wang</surname><given-names>N-N</given-names></string-name>, <string-name><surname>Yao</surname><given-names>Z-J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database</article-title>. <source>J Chem</source> Â <year>2018</year>;<volume>10</volume>:<fpage>1</fpage>â<lpage>11</lpage>.</mixed-citation>
    </ref>
    <ref id="ref24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gaulton</surname><given-names>A</given-names></string-name>, <string-name><surname>Hersey</surname><given-names>A</given-names></string-name>, <string-name><surname>Nowotka</surname><given-names>M</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>The ChEMBL database in 2017</article-title>. <source>Nucleic Acids Res</source> Â <year>2017</year>;<volume>45</volume>:<fpage>D945</fpage>â<lpage>54</lpage>.<pub-id pub-id-type="pmid">27899562</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>DS</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>YD</given-names></string-name>, <string-name><surname>Guo</surname><given-names>AC</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res</source> Â <year>2018</year>;<volume>46</volume>:<fpage>D1074</fpage>â<lpage>82</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Fu</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J-W</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Three-level hepatotoxicity prediction system based on adverse hepatic effects</article-title>. <source>Mol Pharm</source> Â <year>2018</year>;<volume>16</volume>:<fpage>393</fpage>â<lpage>408</lpage>.<pub-id pub-id-type="pmid">30475633</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname><given-names>L</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Systematic Modeling of log D 7.4 Based on Ensemble Machine Learning, Group Contribution, and Matched Molecular Pair Analysis</article-title>. <source>J Chem Inf Model</source> Â <year>2019</year>;<volume>60</volume>:<fpage>63</fpage>â<lpage>76</lpage>.</mixed-citation>
    </ref>
    <ref id="ref28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname><given-names>L</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>QSAR-assisted-MMPA to expand chemical transformation space for lead optimization</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>:<fpage>bbaa374</fpage>.<pub-id pub-id-type="pmid">33418563</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>N-N</given-names></string-name>, <string-name><surname>Deng</surname><given-names>Z-K</given-names></string-name>, <string-name><surname>Huang</surname><given-names>C</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ADME properties evaluation in drug discovery: Prediction of plasma protein binding using NSGA-II combining PLS and consensus modeling</article-title>. <source>Chemom Intel Lab Syst</source> Â <year>2017</year>;<volume>170</volume>:<fpage>84</fpage>â<lpage>95</lpage>.</mixed-citation>
    </ref>
    <ref id="ref30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ertl</surname><given-names>P</given-names></string-name>, <string-name><surname>Schuffenhauer</surname><given-names>A</given-names></string-name></person-group>. <article-title>Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions</article-title>. <source>J Chem</source> Â <year>2009</year>;<volume>1</volume>:<fpage>1</fpage>â<lpage>11</lpage>.</mixed-citation>
    </ref>
    <ref id="ref31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wildman</surname><given-names>SA</given-names></string-name>, <string-name><surname>Crippen</surname><given-names>GM</given-names></string-name></person-group>. <article-title>Prediction of physicochemical parameters by atomic contributions</article-title>. <source>J Chem Inf Comput Sci</source> Â <year>1999</year>;<volume>39</volume>:<fpage>868</fpage>â<lpage>73</lpage>.</mixed-citation>
    </ref>
    <ref id="ref32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bickerton</surname><given-names>GR</given-names></string-name>, <string-name><surname>Paolini</surname><given-names>GV</given-names></string-name>, <string-name><surname>Besnard</surname><given-names>J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Quantifying the chemical beauty of drugs</article-title>. <source>Nat Chem</source> Â <year>2012</year>;<volume>4</volume>:<fpage>90</fpage>â<lpage>8</lpage>.<pub-id pub-id-type="pmid">22270643</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref33">
      <label>33.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Kennedy</surname><given-names>J</given-names></string-name>, <string-name><surname>Eberhart</surname><given-names>R</given-names></string-name></person-group>. <part-title>Particle swarm optimization</part-title>. In: <source>Proceedings of ICNN'95-international conference on neural networks</source>, <year>1995</year>, <year>IEEE</year>, <fpage>1942</fpage>â<lpage>8</lpage>.</mixed-citation>
    </ref>
    <ref id="ref34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Z-Z</given-names></string-name>, <string-name><surname>Huang</surname><given-names>J-W</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cao</surname><given-names>DS</given-names></string-name></person-group>. <article-title>ECoFFeS: a software using evolutionary computation for feature selection in drug discovery</article-title>. <source>IEEE Access</source> Â <year>2018</year>;<volume>6</volume>:<fpage>20950</fpage>â<lpage>63</lpage>.</mixed-citation>
    </ref>
    <ref id="ref35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Huang</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>N</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Incorporating PLS model information into particle swarm optimization for descriptor selection in QSAR/QSPR</article-title>. <source>J Chemometr</source> Â <year>2015</year>;<volume>29</volume>:<fpage>627</fpage>â<lpage>36</lpage>.</mixed-citation>
    </ref>
    <ref id="ref36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cao</surname><given-names>D-S</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name><surname>Fan</surname><given-names>L</given-names></string-name>, <string-name><surname>Liang</surname><given-names>YZ</given-names></string-name></person-group>. <article-title>QSAR analysis of the effects of OATP1B1 transporter by structurally diverse natural products using a particle swarm optimization-combined multiple linear regression approach</article-title>. <source>Chemom Intel Lab Syst</source> Â <year>2014</year>;<volume>130</volume>:<fpage>84</fpage>â<lpage>90</lpage>.</mixed-citation>
    </ref>
    <ref id="ref37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yun</surname><given-names>Y-H</given-names></string-name>, <string-name><surname>Cao</surname><given-names>D-S</given-names></string-name>, <string-name><surname>Tan</surname><given-names>M-L</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>A simple idea on applying large regression coefficient to improve the genetic algorithm-PLS for variable selection in multivariate calibration</article-title>. <source>Chemom Intel Lab Syst</source> Â <year>2014</year>;<volume>130</volume>:<fpage>76</fpage>â<lpage>83</lpage>.</mixed-citation>
    </ref>
    <ref id="ref38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eckert</surname><given-names>H</given-names></string-name>, <string-name><surname>Bajorath</surname><given-names>J</given-names></string-name></person-group>. <article-title>Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches</article-title>. <source>Drug Discov Today</source> Â <year>2007</year>;<volume>12</volume>:<fpage>225</fpage>â<lpage>33</lpage>.<pub-id pub-id-type="pmid">17331887</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dong</surname><given-names>J</given-names></string-name>, <string-name><surname>Yao</surname><given-names>Z-J</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>M-F</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ChemSAR: an online pipelining platform for molecular SAR modeling</article-title>. <source>J Chem</source> Â <year>2017</year>;<volume>9</volume>:<fpage>1</fpage>â<lpage>13</lpage>.</mixed-citation>
    </ref>
    <ref id="ref40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X-G</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Z-Y</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>:<fpage>bbab135</fpage>.<pub-id pub-id-type="pmid">33940596</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y-Q</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P-Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y-T</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>An update on poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy</article-title>. <source>J Med Chem</source> Â <year>2016</year>;<volume>59</volume>:<fpage>9575</fpage>â<lpage>98</lpage>.<pub-id pub-id-type="pmid">27416328</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L-X</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>T</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>The ups and downs of Poly (ADP-ribose) Polymerase-1 inhibitors in cancer therapyâCurrent progress and future direction</article-title>. <source>Eur J Med Chem</source> Â <year>2020</year>;<volume>203</volume>:<elocation-id>112570</elocation-id>.<pub-id pub-id-type="pmid">32717529</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name><surname>Mathiowetz</surname><given-names>A</given-names></string-name>, <string-name><surname>Gao</surname><given-names>H</given-names></string-name></person-group>. <article-title>Deep understanding of structureâsolubility relationship for a diverse set of organic compounds using matched molecular pairs</article-title>. <source>Bioorg Med Chem</source> Â <year>2011</year>;<volume>19</volume>:<fpage>5763</fpage>â<lpage>70</lpage>.<pub-id pub-id-type="pmid">21906951</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Do</surname><given-names>P-C</given-names></string-name>, <string-name><surname>Lee</surname><given-names>EH</given-names></string-name>, <string-name><surname>Le</surname><given-names>L</given-names></string-name></person-group>. <article-title>Steered molecular dynamics simulation in rational drug design</article-title>. <source>J Chem Inf Model</source> Â <year>2018</year>;<volume>58</volume>:<fpage>1473</fpage>â<lpage>82</lpage>.<pub-id pub-id-type="pmid">29975531</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tian</surname><given-names>C</given-names></string-name>, <string-name><surname>Kasavajhala</surname><given-names>K</given-names></string-name>, <string-name><surname>Belfon</surname><given-names>KAA</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum Mechanics Energy Surfaces in Solution</article-title>. <source>J Chem Theory Comput</source> Â <year>2020</year>;<volume>16</volume>:<fpage>528</fpage>â<lpage>52</lpage>.<pub-id pub-id-type="pmid">31714766</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vassetti</surname><given-names>D</given-names></string-name>, <string-name><surname>Pagliai</surname><given-names>M</given-names></string-name>, <string-name><surname>Procacci</surname><given-names>P</given-names></string-name></person-group>. <article-title>Assessment of GAFF2 and OPLS-AA general force fields in combination with the water models TIP3P, SPCE, and OPC3 for the solvation free energy of druglike organic molecules</article-title>. <source>J Chem Theory Comput</source> Â <year>2019</year>;<volume>15</volume>:<fpage>1983</fpage>â<lpage>95</lpage>.<pub-id pub-id-type="pmid">30694667</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eberhardt</surname><given-names>J</given-names></string-name>, <string-name><surname>Santos-Martins</surname><given-names>D</given-names></string-name>, <string-name><surname>Tillack</surname><given-names>AF</given-names></string-name>, <string-name><surname>Forli</surname><given-names>S</given-names></string-name></person-group>. <article-title>AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings</article-title>. <source>J Chem Inf Model</source> Â <year>2021</year>;<volume>61</volume>:<fpage>3891</fpage>â<lpage>8</lpage>.<pub-id pub-id-type="pmid">34278794</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Case</surname><given-names>DA</given-names></string-name>, <string-name><surname>Aktulga</surname><given-names>HM</given-names></string-name>, <string-name><surname>Belfon</surname><given-names>K</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>AmberTools</article-title>. <source>J Chem Inf Model</source> Â <year>2023</year>;<volume>63</volume>:<fpage>6183</fpage>â<lpage>91</lpage>.<pub-id pub-id-type="pmid">37805934</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>Z-Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-J</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>PySmash: Python package and individual executable program for representative substructure generation and application</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>:<fpage>bbab017</fpage>.<pub-id pub-id-type="pmid">33709154</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Brief Bioinform</journal-id>
    <journal-id journal-id-type="iso-abbrev">Brief Bioinform</journal-id>
    <journal-id journal-id-type="publisher-id">bib</journal-id>
    <journal-title-group>
      <journal-title>Briefings in Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1467-5463</issn>
    <issn pub-type="epub">1477-4054</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10883642</article-id>
    <article-id pub-id-type="pmid">38385872</article-id>
    <article-id pub-id-type="doi">10.1093/bib/bbae008</article-id>
    <article-id pub-id-type="publisher-id">bbae008</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Problem Solving Protocol</subject>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ChemMORT: an automatic ADMET optimization platform using deep learning and multi-objective particle swarm optimization</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6823-1882</contrib-id>
        <name>
          <surname>Yi</surname>
          <given-names>Jia-Cai</given-names>
        </name>
        <!--yjc@nudt.edu.cn-->
        <aff><institution>School of Computer Science, National University of Defense Technology</institution>, <addr-line>Changsha 410073, Hunan</addr-line>, <country country="CN">PR China</country></aff>
        <aff><institution>Xiangya School of Pharmaceutical Sciences, Central South University</institution>, <addr-line>Changsha 410013, Hunan</addr-line>, <country country="CN">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Zi-Yi</given-names>
        </name>
        <!--502241508@qq.com-->
        <aff><institution>Xiangya School of Pharmaceutical Sciences, Central South University</institution>, <addr-line>Changsha 410013, Hunan</addr-line>, <country country="CN">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Zhao</surname>
          <given-names>Wen-Tao</given-names>
        </name>
        <!--wtzhao@nudt.edu.cn-->
        <aff><institution>School of Computer Science, National University of Defense Technology</institution>, <addr-line>Changsha 410073, Hunan</addr-line>, <country country="CN">PR China</country></aff>
        <xref rid="cor1" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Zhi-Jiang</given-names>
        </name>
        <!--1223821976@qq.com-->
        <aff><institution>Xiangya School of Pharmaceutical Sciences, Central South University</institution>, <addr-line>Changsha 410013, Hunan</addr-line>, <country country="CN">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7187-435X</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Xiao-Chen</given-names>
        </name>
        <!--zhangxiaochen@nudt.edu.cn-->
        <aff><institution>School of Computer Science, National University of Defense Technology</institution>, <addr-line>Changsha 410073, Hunan</addr-line>, <country country="CN">PR China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wu</surname>
          <given-names>Cheng-Kun</given-names>
        </name>
        <!--chengkun_wu@nudt.edu.cn-->
        <aff><institution>State Key Laboratory of High-Performance Computing</institution>, <addr-line>Changsha 410073, Hunan</addr-line>, <country country="CN">PR China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lu</surname>
          <given-names>Ai-Ping</given-names>
        </name>
        <!--lap64067611@126.com-->
        <aff><institution>Institute for Advancing Translational Medicine in Bone and Joint Diseases</institution>, School of Chinese Medicine, <institution>Hong Kong Baptist University</institution>, <addr-line>Hong Kong SAR</addr-line>, <country country="CN">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3604-3785</contrib-id>
        <name>
          <surname>Cao</surname>
          <given-names>Dong-Sheng</given-names>
        </name>
        <!--oriental-cds@163.com-->
        <aff><institution>Xiangya School of Pharmaceutical Sciences, Central South University</institution>, <addr-line>Changsha 410013, Hunan</addr-line>, <country country="CN">P. R. China</country></aff>
        <aff><institution>Institute for Advancing Translational Medicine in Bone and Joint Diseases</institution>, School of Chinese Medicine, <institution>Hong Kong Baptist University</institution>, <addr-line>Hong Kong SAR</addr-line>, <country country="CN">P. R. China</country></aff>
        <xref rid="cor1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="cor1">Corresponding authors. Dongsheng Cao, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410003, P.R. China. Tel.: +86-139-7488-0914; E-mail: <email>oriental-cds@163.com</email>; Wentao Zhao, School of Computer Science, National University of Defense Technology, Changsha, Hunan 410073, P.R. China. Tel.: +86-159-0731-1680; E-mail: <email>wtzhao@nudt.edu.cn</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>3</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-02-20">
      <day>20</day>
      <month>2</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>20</day>
      <month>2</month>
      <year>2024</year>
    </pub-date>
    <volume>25</volume>
    <issue>2</issue>
    <elocation-id>bbae008</elocation-id>
    <history>
      <date date-type="received">
        <day>24</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>17</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>2</day>
        <month>1</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Â© The Author(s) 2024. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="bbae008.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Drug discovery and development constitute a laborious and costly undertaking. The success of a drug hinges not only good efficacy but also acceptable absorption, distribution, metabolism, elimination, and toxicity (ADMET) properties. Overall, up to 50% of drug development failures have been contributed from undesirable ADMET profiles. As a multiple parameter objective, the optimization of the ADMET properties is extremely challenging owing to the vast chemical space and limited human expert knowledge. In this study, a freely available platform called Chemical Molecular Optimization, Representation and Translation (ChemMORT) is developed for the optimization of multiple ADMET endpoints without the loss of potency (<ext-link xlink:href="https://cadd.nscc-tj.cn/deploy/chemmort/" ext-link-type="uri">https://cadd.nscc-tj.cn/deploy/chemmort/</ext-link>). ChemMORT contains three modules: Simplified Molecular Input Line Entry System (SMILES) Encoder, Descriptor Decoder and Molecular Optimizer. The SMILES Encoder can generate the molecular representation with a 512-dimensional vector, and the Descriptor Decoder is able to translate the above representation to the corresponding molecular structure with high accuracy. Based on reversible molecular representation and particle swarm optimization strategy, the Molecular Optimizer can be used to effectively optimize undesirable ADMET properties without the loss of bioactivity, which essentially accomplishes the design of inverse QSAR. The constrained multi-objective optimization of the poly (ADP-ribose) polymerase-1 inhibitor is provided as the case to explore the utility of ChemMORT.</p>
    </abstract>
    <kwd-group>
      <kwd>ADMET evaluation</kwd>
      <kwd>lead optimization</kwd>
      <kwd>substructure modification</kwd>
      <kwd>deep learning</kwd>
      <kwd>inverse QSAR</kwd>
      <kwd>reversible molecular representation</kwd>
      <kwd>particle swarm optimization</kwd>
    </kwd-group>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Key Research and Development Program of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100012166</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2022YFA1004303</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Foundation of State Key Laboratory of HPCL</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2023-KJWHPCL-01</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Science Foundation for Indigenous Innovation of National University of Defense Technology</institution>
          </institution-wrap>
        </funding-source>
        <award-id>23-ZZCX-JDZ-08</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>22173118</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Excellent Youth Foundation of Hunan Province</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2021JJ10068</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Key scientific research projects in higher education institutions of Henan Province</institution>
          </institution-wrap>
        </funding-source>
        <award-id>24A520036</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>HKBU Strategic Development Fund project</institution>
          </institution-wrap>
        </funding-source>
        <award-id>SDF19-0402-P02</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec id="sec3">
    <title>INTRODUCTION</title>
    <p>The journey of discovering a new drug candidate and shepherding it through clinical trials and onto the market is time-consuming, fraught with difficulties, inordinately expensive, and prone to failure, which typically costs 15Â years and $12â15 million for successfully developing a clinical candidate [<xref rid="ref1" ref-type="bibr">1</xref>]. Since the key to improving pharmaceutical productivity is to boost the efficiency of discovering drug candidates entering clinical trials, several revolutionary technologies have been used for accelerating drug candidate development, such as combinatorial chemistry, X-ray crystallography, high-throughput screening (HTS) and virtual screening (VS) [<xref rid="ref2" ref-type="bibr">2â4</xref>]. However, despite the inventiveness and rapid advances witnessed in HTS and VS [<xref rid="ref5" ref-type="bibr">5â7</xref>], the attrition rate during the early drug candidate discovery is still as high as 75%, even for those experienced global pharmaceutical companies [<xref rid="ref8" ref-type="bibr">8</xref>, <xref rid="ref9" ref-type="bibr">9</xref>]. It is estimated that up to 50% of failures are contributed from the deficiency in absorption, distribution, metabolism, elimination, and toxicity (ADMET) properties, which reaffirms the importance of optimizing ADMET properties during drug discovery campaigns [<xref rid="ref10" ref-type="bibr">10</xref>]. The ADMET optimization could be viewed as an extremely challenging multi-parameter optimization task, which aims to improve multiple ADMET properties while avoid the reduction of biological potency [<xref rid="ref11" ref-type="bibr">11</xref>, <xref rid="ref12" ref-type="bibr">12</xref>].</p>
    <p>With large-scale investigations of deep learning (DL) in molecular representations [<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref14" ref-type="bibr">14</xref>], it is found that the chemical space learned by deep neural networks represents several advantages: smooth, continuous, unique and expressive, which could efficiently benefit molecular optimization [<xref rid="ref15" ref-type="bibr">15</xref>]. Recently, a method proposed by Gomez-Bombarelli <italic toggle="yes">etÂ al.</italic> [<xref rid="ref16" ref-type="bibr">16</xref>] further illustrates the above advantages through the application of variational autoencoder, with the additional feature of reversibility. This autoencoder comprises two neural networks: an encoder and a decoder. The encoder network transforms input Simplified Molecular Input Line Entry System (SMILES) strings into a lower-dimensional representation, commonly referred to as the latent space. Conversely, the decoder network maps the points from this latent space back to SMILES sequences. To achieve the encoding of higher-level molecular features rather than the syntactic concepts or repetitive patterns of the sequence, the reconstruction task is transformed into a translation task, by translating one molecular representation to another syntactically different one [<xref rid="ref17" ref-type="bibr">17</xref>, <xref rid="ref18" ref-type="bibr">18</xref>]. Several researches have shown that the models trained with enumerated SMILES sequences own more advantages in data augmentation and important molecular feature learning than those only trained with one variant (e.g. canonical SMILES) [<xref rid="ref17" ref-type="bibr">17</xref>, <xref rid="ref19" ref-type="bibr">19</xref>]. In addition, it has been observed that latent space vectors showed superior performance in molecular similarity analysis and Quantitative StructureâActivity Relationship (QSAR) modeling than autoencoder-derived vectors and the models built using the Extended Connectivity Fingerprints (ECFP4) fingerprints, suggesting that they have increased relevant to biological activities and physicochemical properties [<xref rid="ref17" ref-type="bibr">17</xref>]. Due to high reversibility and information enrichment, latent space vectors are highly recommended for inverse QSAR problems. For the navigation of the optimization tasks for multiple molecular properties, the application of latent space vectors needs to be combined with efficient optimization strategy and necessary structural constraint, thus effectively avoiding the drop of target potency [<xref rid="ref20" ref-type="bibr">20</xref>].</p>
    <p>Considering the importance of ADMET optimization in drug discovery, here, a freely available platform called Chemical Molecular Optimization, Representation and Translation (ChemMORT) is developed for the optimization of multiple ADMET endpoints (<ext-link xlink:href="https://cadd.nscc-tj.cn/deploy/chemmort/" ext-link-type="uri">https://cadd.nscc-tj.cn/deploy/chemmort/</ext-link>). ChemMORT contains three basic modules: SMILES Encoder, Descriptor Decoder and Molecular Optimizer, which provide the representation, translation and optimization functions, respectively. Based on the training of 17 million enumerated SMILES strings, SMILES Encoder can generate the 512-dimensional molecular representation, and Descriptor Decoder is able to translate the above representation to the corresponding molecular structure with high accuracy. Based on the reversible molecular representation and particle swarm optimization (PSO) strategy, Molecular Optimizer can effectively accomplish ADMET optimization tasks while preserving the potency of the optimized molecules through necessary similarity and substructure constraint. To evaluate the utility of ChemMORT, the constrained multi-objective optimization of the poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor was provided as the case. It is believed that through the rational application of ChemMORT, researchers can discover potent drug candidates with improved ADMET profiles.</p>
  </sec>
  <sec id="sec4">
    <title>MATERIALS AND METHODS</title>
    <sec id="sec5">
      <title>Neural translation model</title>
      <p>In this study, inspired by human language neural network translation models, a sequence-to-sequence (seq2seq) model was trained based on the SMILES notation for chemical space exploration. It turns enumerated SMILES notation into a fixed-length vector representation in the encoder and turns this fixed-length vector into the Canonical SMILES of the molecule in the decoder, where the fixed-length vector will be used as the connection between structure modification and property optimization [<xref rid="ref18" ref-type="bibr">18</xref>]. Generally, recurrent neural networks are used as the backend of the seq2seq model, which often bring the vanishing or exploding gradient problems. To avoid it, three stacked <italic toggle="yes">Gate Recurrent Unit</italic> (GRU) layers were used in both the encoder and decoder networks. In addition, a fully connected layer (<italic toggle="yes">information bottleneck</italic>) with 512Â units and hyperbolic tangent activation function is used as the final layer of the encoder to generate a 512-dimensional latent representation. Through information bottleneck, it can capture the most statistically salient features about molecular structures, which ensures the accuracy of translation and the efficiency for property prediction. The decoder takes the latent representation as an input and feeds it into a similar three stacked aforementioned GRU layers with 1024, 512 and 256Â units. The input of the decoder to each time step is the output of the preceding time step and the embedding of the ground truth. In the training phase, the output of the decoder transfers to the ground truth to calculate the cross-entropy loss and conduct the gradient update. In the prediction phase, the beam search algorithm [<xref rid="ref21" ref-type="bibr">21</xref>], a heuristic search algorithm that explores the best combination of words by expanding the most promising node in a limited set, is used in the model to iteratively predict each character until a complete sequence is generated. An internal database with 1.7 million accessible molecules was used to validate the reliability and generalization ability of the model. All the molecules were randomly divided into a training set (1.53 million molecules) and a test set (0.17 million molecules) with a ratio of 9:1. Every molecule was represented by 10 different enumerated SMILES strings for encoding. A previous study has already proved that training the encoder with enumerated SMILES strings and the decoder with Canonical SMILES is able to achieve a better balance between translation correction rate and chemical space breadth [<xref rid="ref17" ref-type="bibr">17</xref>].</p>
    </sec>
    <sec id="sec6">
      <title>ADMET prediction model</title>
      <p>In order to construct credible ADMET-related prediction models for molecular optimization, a large and high quality ADMET dataset containing basic information and experimental values were collected from the ChEMBL, EPA and DrugBank databases, and all the molecules in the dataset were prepared by molecular operating environment (MOE, version 2016) [<xref rid="ref22" ref-type="bibr">22â25</xref>]. Finally, around 30 000 entries, covering logD7.4, LogS, Caco-2, MDCK cells, Plasma protein binding rate (PPB), AMES toxicity, human ether-a-go-go-related gene (hERG) toxicity, hepotoxicity and median lethal dose (LD50), were obtained for ADMET evaluation [<xref rid="ref23" ref-type="bibr">23</xref>, <xref rid="ref24" ref-type="bibr">24</xref>, <xref rid="ref26" ref-type="bibr">26â29</xref>]. The source and information about the ADMET dataset are summarized in <xref rid="sup1" ref-type="supplementary-material">Table S1</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>. Based on the combination of the calculated 512-dimensional vectors and XGBoost algorithm, nine high-quality ADMET prediction models were constructed for the evaluation and guidance of molecular optimization. In addition, three calculated properties, including SlogP, quantitative estimate of drug-likeness (QED) score and synthetic accessibility (SA) score, were also included in ChemMORT for more comprehensive evaluation of molecular suitability [<xref rid="ref30" ref-type="bibr">30â32</xref>].</p>
    </sec>
    <sec id="sec7">
      <title>Scoring scheme</title>
      <p>To provide a comprehensive perspective of multi-parameter optimization task, the scoring scheme was applied for a qualitative evaluation of the desirability of the optimized molecule. Based on the recommended value range (<xref rid="sup1" ref-type="supplementary-material">Table S2</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>), the customized aim range and the actual property value for individual scores will be: 1 for the value in the optimal range, (0, 1) for the value out of the optimal range but in the recommended value range, and 0 for the value out of the recommended value range. Considering the different requirements in different optimization tasks, the individual scaled score components with customized weights will be combined according to the importance of different features in the whole task. The Final Score (eq <xref rid="deqn02" ref-type="disp-formula">2</xref>) will be presented as the weighted average score of all scaled scores, where a low value corresponds to undesirable optimization and a high value indicates an acceptable optimization. </p>
      <disp-formula id="deqn01">
        <label>(1)</label>
        <tex-math notation="LaTeX" id="DmEquation1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} F=\frac{\sum_{i=1}^j\left({S}_i\cdotp{W}_i\right)}{\sum_{i=1}^j{W}_i} \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <p>where <inline-formula><tex-math notation="LaTeX" id="ineq01">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$j$\end{document}</tex-math></inline-formula> is the number of the objective functions used for optimization, <inline-formula><tex-math notation="LaTeX" id="ineq02">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${S}_i$\end{document}</tex-math></inline-formula> represents the desirability of the objective function <inline-formula><tex-math notation="LaTeX" id="ineq03">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$i$\end{document}</tex-math></inline-formula> of the optimized molecule, and <inline-formula><tex-math notation="LaTeX" id="ineq04">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${W}_i$\end{document}</tex-math></inline-formula> corresponds to the priority of the objective function <inline-formula><tex-math notation="LaTeX" id="ineq05">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$i$\end{document}</tex-math></inline-formula> in this task.</p>
    </sec>
    <sec id="sec8">
      <title>Particle swarm optimization</title>
      <p>Based on the continuous presentation and scoring scheme, the PSO [<xref rid="ref33" ref-type="bibr">33</xref>], a stochastic optimization method that mimics swarm intelligence to find an optimal point in a search space, was applied to explore the optimized molecules with desirable properties [<xref rid="ref34" ref-type="bibr">34â37</xref>]. Inspired by social behavior of bird flocking or fish schooling, the PSO consists of individuals for space searching, which utilizes and communicates the information gained during their search. During this process, each particle in the swarm is defined by their position <inline-formula><tex-math notation="LaTeX" id="ineq06">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$x$\end{document}</tex-math></inline-formula> and velocity <inline-formula><tex-math notation="LaTeX" id="ineq07">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$v$\end{document}</tex-math></inline-formula>, where the scoring scheme <inline-formula><tex-math notation="LaTeX" id="ineq08">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$f$\end{document}</tex-math></inline-formula> is applied for the detection of the potential surface of the search space. The movement of the <italic toggle="yes">i-</italic>th particle at iteration step <italic toggle="yes">k</italic> is influenced by the historical best point of itself: </p>
      <disp-formula id="deqn02">
        <label>(2)</label>
        <tex-math notation="LaTeX" id="DmEquation2">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} {x}_i^{best}= argmaxf\left({x}_i^k\right) \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <p>as well as the overall historical best point of the swarm:</p>
      <disp-formula id="deqn03">
        <label>(3)</label>
        <tex-math notation="LaTeX" id="DmEquation3">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} {x}^{best}= argmaxf\left({x}_i^{best}\right) \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <p>After each iteration, each particle will update its velocity and position based on the collected information and its status:</p>
      <disp-formula id="deqn04">
        <label>(4)</label>
        <tex-math notation="LaTeX" id="DmEquation4">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} {v}_i^{k+1}=w{v}_i^k+{c}_1{r}_1\left({x}_i^{best}-{x}_i^k\right)+{c}_2{r}_2\left({x}^{best}-{x}_i^k\right) \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <disp-formula id="deqn05">
        <label>(5)</label>
        <tex-math notation="LaTeX" id="DmEquation5">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} {x}_i^{k+1}={x}_i^k+{v}_i^{k+1} \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <p>where <inline-formula><tex-math notation="LaTeX" id="ineq09">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${c}_1$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math notation="LaTeX" id="ineq10">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${c}_2$\end{document}</tex-math></inline-formula> are the constants that weight the contribution of the individual experience versus the swarm experience; <inline-formula><tex-math notation="LaTeX" id="ineq11">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${r}_1$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math notation="LaTeX" id="ineq12">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${r}_2$\end{document}</tex-math></inline-formula> are the random numbers drawn from independent uniform distributions between 0 and 1; the inertia weight <inline-formula><tex-math notation="LaTeX" id="ineq13">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$w$\end{document}</tex-math></inline-formula> is a constant that controls the momentum of the particle from the previous iteration. In this work, the position of the particle is initialized by the output of the encoder.</p>
    </sec>
    <sec id="sec9">
      <title>Webserver development</title>
      <p>ChemMORT was developed by using Python 3.7, Django 2.2, Tensorflow 1.14.0, SQLite 3, celery 4.4.7, RabbitMQ 3.6.10 and RDKit 2019.03.1. It was a Django task, which is deployed on a high-performance Nginx Web server of Ubuntu 18.04.4 LTS via the application of uWSGI. ChemMORT applied the MVT (model, view and template)design pattern, including three layers: model layer, view layer and template layer. The model layer interfaces to the SQLite3 database which was applied for model construction, upload file storing and property prediction. The view layer contains the main logic code, which was used for providing access to the prediction models, handling file upload and download, and manipulating multi-prediction tasks. The template layer was applied for the presentation of the front-end pages, including result visualization, page rendering, document integration, etc. The browser compatibility testing is shown in <xref rid="sup1" ref-type="supplementary-material">Table S6</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>.</p>
    </sec>
  </sec>
  <sec id="sec10">
    <title>RESULTS AND DISCUSSION</title>
    <sec id="sec11">
      <title>ChemMORT workflow</title>
      <p>The ChemMORT protocol is presented as a workflow in <xref rid="f1" ref-type="fig">Figure 1</xref>. As shown in <xref rid="f1" ref-type="fig">Figure 1</xref>, there are three main modules in ChemMORT: SMILES Encoder, Descriptor Decoder and Molecular Optimizer, which refer to the functions of descriptor calculation, molecular translation and ADMET optimization, respectively.</p>
      <fig position="float" id="f1">
        <label>Figure 1</label>
        <caption>
          <p>The workflow of ChemMORT.</p>
        </caption>
        <graphic xlink:href="bbae008f1" position="float"/>
      </fig>
      <p>SMILES Encoder: Three molecular input types are supported by the SMILES Encoder module: inputting SMILES strings, drawing molecules from the editor, and uploading file (*.sdf/*.csv/*.txt). After the molecular preparation process, the corresponding 512-dimension vectors will be calculated based on the well-trained encoder network. In the following page, the Summary and Result block will present the overview of the results and the detailed information about the SMILES strings, molecular graphs and 512-dimension vectors. The calculated descriptors and related SMILES strings can be saved as .csv file.</p>
      <p>Descriptor Decoder: In this function, users can upload a 512-dimensional vector (between â1 and 1), which latter will be back-engineered to the corresponding uniform canonical SMILES string through the application of decoder network. It should be noted that owing to the character-by-character nature of the SMILES representation and the fragility of its internal syntax, an arbitrary combination may lead to the output of invalid or failed molecules. After calculation, the summary and result block are provided for the overview of the translated SMILES information, where the results can also be downloaded as .csv file. Owing to the advantage of reversibility, the combination of SMILES Encoder and Descriptor Decoder possesses the ability to deal with the inverse design problem, which is the key point of lead optimization.</p>
      <p>Molecular Optimizer: Molecular optimization is a complex and multi-objective task, which needs to balance bioactivity, pharmacokinetic profile and therapeutic safety. To achieve this goal, the Molecular Optimizer module is provided with the integration of reversible molecular representation, credible QSAR models, necessary structural constraint and multi-objective PSO strategy, which follows the principle of inverse QSAR methodology. Firstly, users are required to input the job information and the SMILES string of the molecule that needs to be optimized. Twelve credible objective functions covering basic molecular properties, synesthetic accessibility, drug-likeness, absorption, distribution and toxicity were provided for property optimization. To retain the efficacy and novelty of initial optimized molecule, the <italic toggle="yes">Similarity Constrain</italic> and <italic toggle="yes">Substructure Constrain</italic> functions were applied for the definition of the starting point and the annotation of important active motif, respectively [<xref rid="ref38" ref-type="bibr">38</xref>]. The application of the <italic toggle="yes">Similarity Constrain</italic> function enables the setting of the distance limitation between the generated molecule and the reference molecule based on the ECFP4 fingerprint and Tanimoto similarity metric, while the application of the <italic toggle="yes">Substructure Constrain</italic> function highlights the importance of bioactivity motif. All the above functions are allowed to set the weights according to their importance, which later will be applied to the scaled score for optimization navigation and comprehensive evaluation. Owing to the different requirements for optimal molecules, users can adjust the iteration steps and the number of the top desirable compounds in each iteration step. After submission, the optimization job will be calculated in the background. Users can obtain the optimized result from the email or the access of Queue page with the input of job token. The final result includes the information about the starting molecule and optimized molecules, of which the latter one provides the detailed table about the SMILES, the structural graph, selected optimized property values and the final score. Based on the combination of user-defined property value range, specific function weights and the optimized property value, the final score is a comprehensive desirability index of the optimized molecules, and it can quantitatively indicate the desirability and quality of the optimized molecule in the specified optimization task.</p>
    </sec>
    <sec id="sec12">
      <title>Neural translation model training</title>
      <p>A multi-layer gate recurrent unit network, including input dropout, bottleneck layer and Gaussian noise term, was employed for training and application. The model was trained until convergence, using a batch size of 64, dropout ratio of 0.15 and embedding noise of 0.05. As shown in <xref rid="f2" ref-type="fig">Figure 2</xref>, the translation accuracy for the training set and test set first increased rapidly, but after a point, it became stable and almost unchanged. The final average single character accuracy values for both the training and test sets reached 99.8%, indicating the proportion of correctly predicted characters to the total predicted length. This achievement underscores the reliability and credibility of this seq2seq model. It also indicated that the important feature of the molecule has already been encoded in the latent space, resulting in a potentially powerful molecular descriptor for further ADMET prediction and optimization task.</p>
      <fig position="float" id="f2">
        <label>Figure 2</label>
        <caption>
          <p>The translation accuracy for the training set and test set during the 160Â k training steps.</p>
        </caption>
        <graphic xlink:href="bbae008f2" position="float"/>
      </fig>
    </sec>
    <sec id="sec13">
      <title>ADMET predictive model validation</title>
      <p>Based on the 512-dimensional descriptors calculated by the encoder network, 9 ADMET-related prediction models, including logD7.4, AMES, Caco-2, MDCK, PPB, LogS, hERG, hepatoxicity and LD50, were constructed with the XGBoost algorithm. All the datasets were divided into the training set and test set according to the chemical space distribution computed by the âDiverse training set splitâ module in ChemSAR, where 75% compounds were used as the training set and the remaining 25% as the test set [<xref rid="ref39" ref-type="bibr">39</xref>]. The prediction performance of the ADMET prediction models and related parameters are summarized in <xref rid="TB1" ref-type="table">Table 1</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S3</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>, respectively.</p>
      <table-wrap position="float" id="TB1">
        <label>Table 1</label>
        <caption>
          <p>The performance of ADMET prediction models in ChemMORT</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th colspan="11" align="left" rowspan="1">ADMET regression model performance</th>
            </tr>
            <tr>
              <th rowspan="2" align="left" colspan="1">Property</th>
              <th rowspan="2" align="left" colspan="1">Description</th>
              <th rowspan="2" align="left" colspan="1">Algorithm<sup>*</sup></th>
              <th colspan="3" align="left" rowspan="1">5-Fold CV</th>
              <th colspan="3" align="left" rowspan="1">Test set</th>
              <th colspan="2" align="left" rowspan="1">Data information</th>
            </tr>
            <tr>
              <th align="left" rowspan="1" colspan="1">RMSE</th>
              <th align="left" rowspan="1" colspan="1">MAE</th>
              <th align="left" rowspan="1" colspan="1">R<sup>2</sup></th>
              <th align="left" rowspan="1" colspan="1">RMSE</th>
              <th align="left" rowspan="1" colspan="1">MAE</th>
              <th align="left" rowspan="1" colspan="1">R<sup>2</sup></th>
              <th align="left" rowspan="1" colspan="1">Training set</th>
              <th align="left" rowspan="1" colspan="1">Test set</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">logD7.4</td>
              <td align="left" rowspan="1" colspan="1">Log of the octanol/water distribution coefficient at pHÂ 7.4.</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.562âÂ±â0.009</td>
              <td align="left" rowspan="1" colspan="1">0.428âÂ±â0.13</td>
              <td align="left" rowspan="1" colspan="1">0.834âÂ±â0.005</td>
              <td align="left" rowspan="1" colspan="1">0.555âÂ±â0.010</td>
              <td align="left" rowspan="1" colspan="1">0.426âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.840âÂ±â0.004</td>
              <td align="left" rowspan="1" colspan="1">773</td>
              <td align="left" rowspan="1" colspan="1">258</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">logS</td>
              <td align="left" rowspan="1" colspan="1">Log of Solubility</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.842âÂ±â0.084</td>
              <td align="left" rowspan="1" colspan="1">0.592âÂ±â0.056</td>
              <td align="left" rowspan="1" colspan="1">0.839âÂ±â0.029</td>
              <td align="left" rowspan="1" colspan="1">0.823âÂ±â0.026</td>
              <td align="left" rowspan="1" colspan="1">0.572âÂ±â0.009</td>
              <td align="left" rowspan="1" colspan="1">0.862âÂ±â0.011</td>
              <td align="left" rowspan="1" colspan="1">4116</td>
              <td align="left" rowspan="1" colspan="1">1104</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Caco-2</td>
              <td align="left" rowspan="1" colspan="1">Caco-2 Permeability</td>
              <td align="left" rowspan="1" colspan="1">XGBoost&amp; Data Augment</td>
              <td align="left" rowspan="1" colspan="1">0.328âÂ±â0.004</td>
              <td align="left" rowspan="1" colspan="1">0.245âÂ±â0.005</td>
              <td align="left" rowspan="1" colspan="1">0.728âÂ±â0.011</td>
              <td align="left" rowspan="1" colspan="1">0.332âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.244âÂ±â0.004</td>
              <td align="left" rowspan="1" colspan="1">0.718âÂ±â0.019</td>
              <td align="left" rowspan="1" colspan="1">886</td>
              <td align="left" rowspan="1" colspan="1">296</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">MDCK</td>
              <td align="left" rowspan="1" colspan="1">MDCK Permeability</td>
              <td align="left" rowspan="1" colspan="1">XGBoost&amp; Data Augment</td>
              <td align="left" rowspan="1" colspan="1">0.322âÂ±â0.034</td>
              <td align="left" rowspan="1" colspan="1">0.235âÂ±â0.021</td>
              <td align="left" rowspan="1" colspan="1">0.644âÂ±â0.057</td>
              <td align="left" rowspan="1" colspan="1">0.323âÂ±â0.022</td>
              <td align="left" rowspan="1" colspan="1">0.232âÂ±â0.011</td>
              <td align="left" rowspan="1" colspan="1">0.650âÂ±â0.041</td>
              <td align="left" rowspan="1" colspan="1">912</td>
              <td align="left" rowspan="1" colspan="1">228</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">PPB</td>
              <td align="left" rowspan="1" colspan="1">Plasma Protein Binding</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.154âÂ±â0.010</td>
              <td align="left" rowspan="1" colspan="1">0.106âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.691âÂ±â0.025</td>
              <td align="left" rowspan="1" colspan="1">0.152âÂ±â0.003</td>
              <td align="left" rowspan="1" colspan="1">0.104âÂ±â0.002</td>
              <td align="left" rowspan="1" colspan="1">0.691âÂ±â0.016</td>
              <td align="left" rowspan="1" colspan="1">1368</td>
              <td align="left" rowspan="1" colspan="1">454</td>
            </tr>
            <tr>
              <td align="left" colspan="11" rowspan="1">ADMET classification model performance</td>
            </tr>
            <tr>
              <td align="left" rowspan="2" colspan="1">Property</td>
              <td align="left" rowspan="2" colspan="1">Description</td>
              <td align="left" rowspan="2" colspan="1">Algorithm<sup>*</sup></td>
              <td align="left" colspan="3" rowspan="1">5-Fold CV</td>
              <td align="left" colspan="3" rowspan="1">Test set</td>
              <td align="left" colspan="2" rowspan="1">Data information</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Accuracy</td>
              <td align="left" rowspan="1" colspan="1">Sensitivity</td>
              <td align="left" rowspan="1" colspan="1">AUC</td>
              <td align="left" rowspan="1" colspan="1">Accuracy</td>
              <td align="left" rowspan="1" colspan="1">Sensitivity</td>
              <td align="left" rowspan="1" colspan="1">AUC</td>
              <td align="left" rowspan="1" colspan="1">Training set</td>
              <td align="left" rowspan="1" colspan="1">Test set</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">AMES</td>
              <td align="left" rowspan="1" colspan="1">The probability to be positive in Ames test.</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.810âÂ±â0.016</td>
              <td align="left" rowspan="1" colspan="1">0.838âÂ±â0.014</td>
              <td align="left" rowspan="1" colspan="1">0.889âÂ±â0.013</td>
              <td align="left" rowspan="1" colspan="1">0.813âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.835âÂ±â0.013</td>
              <td align="left" rowspan="1" colspan="1">0.888âÂ±â0.004</td>
              <td align="left" rowspan="1" colspan="1">7514</td>
              <td align="left" rowspan="1" colspan="1">1905</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">hERG</td>
              <td align="left" rowspan="1" colspan="1">The probability to be hERG Blocker</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.800âÂ±â0.036</td>
              <td align="left" rowspan="1" colspan="1">0.820âÂ±â0.068</td>
              <td align="left" rowspan="1" colspan="1">0.857âÂ±â0.053</td>
              <td align="left" rowspan="1" colspan="1">0.814âÂ±â0.026</td>
              <td align="left" rowspan="1" colspan="1">0.841âÂ±â0.042</td>
              <td align="left" rowspan="1" colspan="1">0.854âÂ±â0.032</td>
              <td align="left" rowspan="1" colspan="1">392</td>
              <td align="left" rowspan="1" colspan="1">263</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">hepatoxicity</td>
              <td align="left" rowspan="1" colspan="1">The probability of owning liver toxicity</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.700âÂ±â0.026</td>
              <td align="left" rowspan="1" colspan="1">0.701âÂ±â0.030</td>
              <td align="left" rowspan="1" colspan="1">0.764âÂ±â0.030</td>
              <td align="left" rowspan="1" colspan="1">0.729âÂ±â0.016</td>
              <td align="left" rowspan="1" colspan="1">0.732âÂ±â0.019</td>
              <td align="left" rowspan="1" colspan="1">0.794âÂ±â0.015</td>
              <td align="left" rowspan="1" colspan="1">2208</td>
              <td align="left" rowspan="1" colspan="1">502</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">LD<sub>50</sub></td>
              <td align="left" rowspan="1" colspan="1">LD50 of acute toxicity</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.741âÂ±â0.045</td>
              <td align="left" rowspan="1" colspan="1">0.742âÂ±â0.128</td>
              <td align="left" rowspan="1" colspan="1">0.833âÂ±â0.033</td>
              <td align="left" rowspan="1" colspan="1">0.765âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.764âÂ±â0.015</td>
              <td align="left" rowspan="1" colspan="1">0.848âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">5917</td>
              <td align="left" rowspan="1" colspan="1">1480</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">QED</td>
              <td align="left" rowspan="1" colspan="1">quantitative estimate of drug-likeness</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">SlogP</td>
              <td align="left" rowspan="1" colspan="1">Log of the octanol/water partition coefficient, based on an atomic contribution model</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>*Data Augment refers to the application of enumerated SMILES in model construction.</p>
        </table-wrap-foot>
      </table-wrap>
      <p>As shown in <xref rid="TB1" ref-type="table">Table 1</xref>, it can be observed that most models have high and stable performance in both the 5-fold cross validation and the test set prediction. For the regression models, the average values of RMSE and R2 are 0.442 and 0.747 for the 5-fold cross validation, respectively, and 0.437 and 0.752 for the test set, respectively. For the classification models, the average values of accuracy and AUC are 0.763 and 0.836 for the 5-fold cross validation, respectively, and 0.780 and 0.846 for the test set, respectively. Such results not only proved the credibility of the ADMET prediction models, but also indicated the effectiveness and utility of the latent representations calculated by ChemMORT. In addition, the combination of the encoding and decoding networks ensures the reversibility of the latent representations, which enables the ADMET prediction models to navigate molecular optimization.</p>
    </sec>
    <sec id="sec14">
      <title>Constrained multi-objective optimization</title>
      <p>PARP-1 is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of PARP-1 provide a new type of anticancer drugs that selectively kill cancer cells by targeting homologous recombination repair defects [<xref rid="ref40" ref-type="bibr">40</xref>, <xref rid="ref41" ref-type="bibr">41</xref>]. However, most PARP-1 inhibitors suffer from the deficiency of poor aqueous solubility, which has severely disrupted the applicability value [<xref rid="ref42" ref-type="bibr">42</xref>]. Therefore, the optimization of more hydrophilic but still potent PARP-1 inhibitors for cancer therapy is quite necessary.</p>
      <p>The approved drug Olaparib is selected as the initial molecule for further optimization, which is an efficient PARP-1 inhibitor possessing IC<sub>50</sub> of 0.9Â nmol but solubility of only 0.0601Â mg/mL (logS of â3.8). During this multi-parameter optimization task, the solubility, QED and SA of the molecule are selected as the aim properties. In addition, to ensure the potency of the PARP-1 inhibitor, the bioactivity motif and similarity constraint are also used (<xref rid="f3" ref-type="fig">Figure 3A</xref>). This optimization task is repeated 100 times and 50 iterations are conducted for the PSO optimization each time. The detailed information about the privilege function section and corresponding weight, the different properties over the course of the optimization, and the final representative optimized molecules are depicted in <xref rid="f3" ref-type="fig">Figure 3</xref>.</p>
      <fig position="float" id="f3">
        <label>Figure 3</label>
        <caption>
          <p>The information about the initial molecule, optimization process and representative optimized molecules. (A) The introduction of the initial molecule Olaparib and related optimization task set; (B) The averaged values of the final score, QED, LogS, SA and similarity during the 50-step optimization; (C) The docking score, final score and LogS value of Olaparib and 171 unique optimized molecules; (D) Five representative optimized molecules with their property information.</p>
        </caption>
        <graphic xlink:href="bbae008f3" position="float"/>
      </fig>
      <p>As shown in <xref rid="f3" ref-type="fig">Figure 3B</xref>, ChemMORT is consistently able to optimize the initial molecule with respect to the defined multi-parameter properties. Clearly, the LogS value and the final score first increased rapidly, but after a point, it became stable and almost unchanged. For QED and SA, according to the dense interval settings, they tend to fluctuate between 0.70 and 0.72, and between 2.5 and 2.7, respectively. For similarity, the tendency is totally converse, with a stable value of 0.40 for the later optimized molecules. It is not surprising since it is a process for molecular optimization. Besides, according to the constraint of bioactivity motif, the optimized molecule is not far from the initial molecule, indicating the importance of structural constraints. Finally, 171 unique optimized molecules with higher bioactivity and better water-solubility than the initial molecule are generated after 100 optimization cycles (<xref rid="sup1" ref-type="supplementary-material">Table S4</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>). As shown in <xref rid="f3" ref-type="fig">Figure 3C</xref>, the solubility and final desirable score of the optimized molecules are much higher than those of the initial molecule. One of the main reasons is the substitution of 1,2-dihydrophthalazine to a more polar function group, such as 1H-1,2,4-triazole, piperazine and imidazolidine with N,N-dimethylacetamide, thus strengthening the hydration of compounds and promoting the thermodynamic process of dissolution [<xref rid="ref43" ref-type="bibr">43</xref>]. Though the ability to optimize molecular pharmacokinetic properties often comes at the price of limited bioactivity to target, but with the application of molecular docking, it is found that most optimized molecules have rather high docking scores, which indicated preliminary guarantee of their potency (<xref rid="sup1" ref-type="supplementary-material">Table S4</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>). Such privileged results have a close relationship with the implementation of the constraints of the essential bioactivity motif and the similarity threshold to the initial molecule. Five representative optimized molecules with their property information are provided in <xref rid="f3" ref-type="fig">Figure 3D</xref>. All of them possess high structural similarity to Olaparib and other approved PARP1 drugs, which successfully replicated the ideation of medicinal chemists during lead optimization.</p>
      <p>We then investigated the detailed interactions between the optimized molecules and the PARP-1 target (PDB ID: 4L6S). The predicted binding modes of Olaparib and the optimized molecules are presented in <xref rid="f4" ref-type="fig">Figure 4</xref>. As shown in <xref rid="f4" ref-type="fig">Figure 4</xref>, most of the optimized molecules have several key interactions, such as the H-bonding networks with Gly863 and Ser904 and the Ï-Ï stacking with Tyr907, which are known as the key binding patterns between PARP-1 inhibitors and PARP-1.</p>
      <fig position="float" id="f4">
        <label>Figure 4</label>
        <caption>
          <p>The interactions between the generated active molecules with PARP1. Figures A-F correspond to the binding mode of Olaparib and the optimized molecules 1â~â5, respectively. The hydrogen-bonding, Ï-Ï stacking interactions and charged interactions are indicated by different colors.</p>
        </caption>
        <graphic xlink:href="bbae008f4" position="float"/>
      </fig>
      <p>To further ensure the utility and potency of these optimized molecules, molecular dynamics (MD) simulation was used to characterize the proteinâligand interactions of the optimized molecules [<xref rid="ref44" ref-type="bibr">44</xref>]. Specifically, the AMBER ff19SB force field [<xref rid="ref45" ref-type="bibr">45</xref>] and the General AMBER Force Field 2 [<xref rid="ref46" ref-type="bibr">46</xref>] were used to parameterize the system. The conformation of the proteinâligand complex was generated using Vina [<xref rid="ref47" ref-type="bibr">47</xref>]. Prior to the MD simulation, two-step minimizations, heating and equilibration were performed. The minimized system was heated to 298.15Â K and increased to atmospheric pressure. Then, 20Â ns production MD simulation was carried out for each complex in the ensemble with a time step of 2Â fs. The structural root-mean-square-deviations (RMSDs) of the backbone atoms (C, C<sub>a</sub> and N) of the protein relative to the initial structures were examined as a function of time (<xref rid="sup1" ref-type="supplementary-material">Figure S1</xref>). As can be seen in the plot, all the systems were stable during the 20-ns MD simulations. The RMSDs of PARP-1 in complex with five optimized molecules showed almost the same RMSDs with Olaparib. Additionally, we uniformly extracted 100 frames from the trajectory of the last 2 nanoseconds. Subsequently, we performed molecular mechanics generalized Born surface area (MM/GBSA) calculations and residue energy decomposition using AmberTools2023 [<xref rid="ref48" ref-type="bibr">48</xref>]. The predicted binding free energies listed in <xref rid="sup1" ref-type="supplementary-material">Table S5</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>, also indicate that the optimized molecule 3 (â56.772Â kcal/mol), 4 (â58.949Â kcal/mol) and 5 (â58.831Â kcal/mol) were almost at the same level of the binding affinity for Olaparib (â52.130Â kcal/mol). To further identify the key residues related to the binding process, the free energy contributions of the top 10 residues at the binding site were estimated. As shown in <xref rid="f5" ref-type="fig">Figure 5</xref>, Tyr896, Tyr907, Hie862 and Tyr907 are the most important residues for most optimized molecules, which is in high agreement with the residue contributions for PARP1 inhibitors (<xref rid="f5" ref-type="fig">Figure 5A</xref>). Such analysis indicated that the reasonable application of privileged motif and similarity constraint is necessary to maintain molecular bioactivity during lead optimization [<xref rid="ref49" ref-type="bibr">49</xref>]. Although this multi-parameter optimization task consists of many different and partially conflicting individual objectives, such as aqueous solubility, activity, SA and structural constraints, ChemMORT is consistently able to find some molecules in the vast chemical space that meets the desirable ranges for all of the defined ADMET objectives within the guarantee of target bioactivity.</p>
      <fig position="float" id="f5">
        <label>Figure 5</label>
        <caption>
          <p>The top 10 residues contributing to the binding free energies of the generated active molecules. Figures A-F correspond to the binding modes of Olaparib and the optimized molecules 1â~â5, respectively.</p>
        </caption>
        <graphic xlink:href="bbae008f5" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec15">
    <title>CONCLUSION</title>
    <p>The success of a drug is determined not only by good efficacy and specificity, but also the acceptable ADMET properties. However, the optimization of the lead molecules is a multiple parameter optimization problem, covering potency, selectivity, pharmacokinetics features and safety, which is extremely challenging owing to the vast and discrete drug-like chemical space and limited knowledge from experimental transformation. Therefore, to break through this bottleneck, ChemMORT is developed for the multiple ADMET property optimization of drug candidates through the application of NMT, credible ADMET prediction models and multi-objective PSO strategy. Three modules are included in ChemMORT: SMILES Encoder, Descriptor Decoder and Molecular Optimizer, which provide the representation, translation and optimization functions, respectively. The constrained multi-objective optimization of PARP-1 inhibitors has indicated the successful match of ChemMORT to chemist design, which has successfully optimized ADMET properties of the initial molecule with the preservation of target binding affinity. It is anticipated that the future is bright for ADMET property optimization of lead molecules with the rational application of ChemMORT.</p>
    <boxed-text id="box01" position="float">
      <sec id="sec28a">
        <title>Key Points</title>
        <list list-type="bullet">
          <list-item>
            <p>ChemMORT is a web-based integrated tool that learns molecular representations based on an encoder-decoder neural network architecture. It enhances network performance using SMILES enumeration and conducts multi-objective optimization of molecular properties through particle swarm optimization algorithms. ChemMORT can effectively optimize undesirable ADMET properties without compromising bioactivity, thereby achieving reverse QSAR design at its core.</p>
          </list-item>
          <list-item>
            <p>ChemMORT has been meticulously designed and optimized for its functional modules to enhance user experience. It supports batch upload and download functionalities. Users can define promising and desirable molecules based on their own criteria. The optimizer also provides substructure and similarity constraints, allowing users to freely adjust the importance of each property for highly customizable molecular optimization.</p>
          </list-item>
          <list-item>
            <p>The constrained multi-objective optimization of the PARP-1 inhibitor is provided as the case to explore the utility of ChemMORT.</p>
          </list-item>
        </list>
      </sec>
    </boxed-text>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>supplementary_materials_bbae008</label>
      <media xlink:href="supplementary_materials_bbae008.zip"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="bbae008-ack">
    <title>ACKNOWLEDGEMENTS</title>
    <p>This work was supported by National Key Research and Development Program of China (2022YFA1004303), Foundation of State Key Laboratory of HPCL (2023-KJWHPCL-01), Science Foundation for Indigenous Innovation of National University of Defense Technology under Grant (23-ZZCX-JDZ-08), National Science Foundation of China (22173118), Excellent Youth Foundation of Hunan Province (2021JJ10068), Key scientific research projects in higher education institutions of Henan Province (24A520036) and HKBU Strategic Development Fund project (SDF19-0402-P02). The study was approved by the university's review board.</p>
  </ack>
  <sec sec-type="data-availability" id="sec17">
    <title>DATA AVAILABILITY</title>
    <p>The project is available in the GitHub address (<ext-link xlink:href="https://github.com/antwiser/ChemMORT" ext-link-type="uri">https://github.com/antwiser/ChemMORT</ext-link>).</p>
  </sec>
  <sec id="sec18">
    <title>ABBREVIATIONS</title>
    <p>ADMET, absorption, distribution, metabolism, elimination, and toxicity; QSAR, quantitative structureâactivity relationship; DL, deep learning; SMILES, simplified molecular input line entry specification; HTS, high-throughput screening; VS, virtual screening; ECFP4, extended connectivity fingerprints; RNNs, recurrent neural networks; hERG, human ether-a-go-go-related gene; PPB, plasma protein binding rate; PSO, particle swarm optimization; PARP-1, Poly (ADP-ribose) polymerase-1; MD, molecular dynamics; RMSDs, root-mean-square-deviations;</p>
  </sec>
  <notes id="bio1">
    <title>Author Biographies</title>
    <p><bold>Jia-cai Yi</bold> is a graduate student in the School of Computer Science, National University of Defense Technology. His researches focus on artificial intelligence for drug discovery.</p>
    <sec id="sec18b">
      <p><bold>Zi-yi Yang</bold> is a graduate student at Xiangya School of Pharmaceutical Sciences, Central South University. Her researches focus on screening for frequent hit compounds.</p>
    </sec>
    <sec id="sec18c">
      <p><bold>Wen-Tao Zhao</bold> is currently a professor in the School of Computer Science, National University of Defense Technology, China. His research interests include network performance optimization, information processing, and machine learning.</p>
    </sec>
    <sec id="sec18d">
      <p><bold>Zhi-Jiang Yang</bold> is a graduate student at Xiangya School of Pharmaceutical Sciences, Central South University. His researches focus on the development of cheminformatics tools.</p>
    </sec>
    <sec id="sec18e">
      <p><bold>Xiao-Chen Zhang</bold> is a Ph.D. student in the School of Computer Science, National University of Defense Technology, China. His researches focus on the development of cheminformatics tools.</p>
    </sec>
    <sec id="sec18g">
      <p><bold>Cheng-Kun Wu</bold> is currently an associate professor research fellow student in Institute for Quantum Information &amp; State Key Laboratory of High Performance Computing, College of Computer Science and Technology, National University of Defense Technology. His researches focus on Systems Biology, High-Performance Computing, Pattern Recognition, Machine Learning, and Data Mining.</p>
    </sec>
    <sec id="sec18h">
      <p><bold>Ai-Ping Lu</bold> is a professor at the Hong Kong Baptist University and has long been engaged in basic and new drug discovery and development of Chinese medicine for the treatment of rheumatoid arthritis and oncology, as well as the research of aptamer-targeted delivery of innovative drugs.</p>
    </sec>
    <sec id="sec18i">
      <p><bold>Dong-Sheng Cao</bold> is currently an associate professor in the Xiangya School of Pharmaceutical Sciences, Central South University, China. His research interests can be found at the website of his group: <ext-link xlink:href="http://www.scbdd.com" ext-link-type="uri">http://www.scbdd.com</ext-link>.</p>
    </sec>
  </notes>
  <ref-list id="bib1">
    <title>References</title>
    <ref id="ref1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roses</surname><given-names>AD</given-names></string-name></person-group>. <article-title>Pharmacogenetics in drug discovery and development: a translational perspective</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2008</year>;<volume>7</volume>:<fpage>807</fpage>â<lpage>17</lpage>.<pub-id pub-id-type="pmid">18806753</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>BergstrÃ¶m</surname><given-names>F</given-names></string-name>, <string-name><surname>Lindmark</surname><given-names>B</given-names></string-name></person-group>. <article-title>Accelerated drug discovery by rapid candidate drug identification</article-title>. <source>Drug Discov Today</source> Â <year>2019</year>;<volume>24</volume>:<fpage>1237</fpage>â<lpage>41</lpage>.<pub-id pub-id-type="pmid">30946980</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burt</surname><given-names>T</given-names></string-name>, <string-name><surname>Young</surname><given-names>G</given-names></string-name>, <string-name><surname>Lee</surname><given-names>W</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Phase 0/microdosing approaches: time for mainstream application in drug development?</article-title> Â <source>Nat Rev Drug Discov</source> Â <year>2020</year>;<volume>19</volume>:<fpage>801</fpage>â<lpage>18</lpage>.<pub-id pub-id-type="pmid">32901140</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schneider</surname><given-names>P</given-names></string-name>, <string-name><surname>Walters</surname><given-names>WP</given-names></string-name>, <string-name><surname>Plowright</surname><given-names>AT</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Rethinking drug design in the artificial intelligence era</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2020</year>;<volume>19</volume>:<fpage>353</fpage>â<lpage>64</lpage>.<pub-id pub-id-type="pmid">31801986</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vamathevan</surname><given-names>J</given-names></string-name>, <string-name><surname>Clark</surname><given-names>D</given-names></string-name>, <string-name><surname>Czodrowski</surname><given-names>P</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Applications of machine learning in drug discovery and development</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2019</year>;<volume>18</volume>:<fpage>463</fpage>â<lpage>77</lpage>.<pub-id pub-id-type="pmid">30976107</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gloriam</surname><given-names>DE</given-names></string-name></person-group>. <article-title>Bigger is better in virtual drug screens</article-title>. <source>Nature</source> Â <year>2019</year>;<volume>566</volume>:<fpage>193</fpage>â<lpage>4</lpage>.</mixed-citation>
    </ref>
    <ref id="ref7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ekins</surname><given-names>S</given-names></string-name>, <string-name><surname>Puhl</surname><given-names>AC</given-names></string-name>, <string-name><surname>Zorn</surname><given-names>KM</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Exploiting machine learning for end-to-end drug discovery and development</article-title>. <source>Nat Mater</source> Â <year>2019</year>;<volume>18</volume>:<fpage>435</fpage>â<lpage>41</lpage>.<pub-id pub-id-type="pmid">31000803</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Waring</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Arrowsmith</surname><given-names>J</given-names></string-name>, <string-name><surname>Leach</surname><given-names>AR</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>An analysis of the attrition of drug candidates from four major pharmaceutical companies</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2015</year>;<volume>14</volume>:<fpage>475</fpage>â<lpage>86</lpage>.<pub-id pub-id-type="pmid">26091267</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kola</surname><given-names>I</given-names></string-name>, <string-name><surname>Landis</surname><given-names>J</given-names></string-name></person-group>. <article-title>Can the pharmaceutical industry reduce attrition rates?</article-title> Â <source>Nat Rev Drug Discov</source> Â <year>2004</year>;<volume>3</volume>:<fpage>711</fpage>â<lpage>6</lpage>.<pub-id pub-id-type="pmid">15286737</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sutherland</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Raymond</surname><given-names>JW</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>JL</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes</article-title>. <source>J Med Chem</source> Â <year>2012</year>;<volume>55</volume>:<fpage>6455</fpage>â<lpage>66</lpage>.<pub-id pub-id-type="pmid">22716080</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schneider</surname><given-names>G</given-names></string-name>, <string-name><surname>Clark</surname><given-names>DE</given-names></string-name></person-group>. <article-title>Automated de novo drug design: are we nearly there yet?</article-title> Â <source>Angew Chem Int Ed</source> Â <year>2019</year>;<volume>58</volume>:<fpage>10792</fpage>â<lpage>803</lpage>.</mixed-citation>
    </ref>
    <ref id="ref12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schneider</surname><given-names>G</given-names></string-name>, <string-name><surname>Fechner</surname><given-names>U</given-names></string-name></person-group>. <article-title>Computer-based de novo design of drug-like molecules</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2005</year>;<volume>4</volume>:<fpage>649</fpage>â<lpage>63</lpage>.<pub-id pub-id-type="pmid">16056391</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref13">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>XC</given-names></string-name>, <string-name><surname>Wu</surname><given-names>CK</given-names></string-name>, <string-name><surname>Yang</surname><given-names>ZJ</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>MG-BERT: leveraging unsupervised atomic representation learning for molecular property prediction</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>(<issue>6</issue>):bbab152. <pub-id pub-id-type="doi">10.1093/bib/bbab152</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref14">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>CK</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>XC</given-names></string-name>, <string-name><surname>Yang</surname><given-names>ZJ</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Learning to SMILES: BAN-based strategies to improve latent representation learning from molecules</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>(<issue>6</issue>):bbab327. <pub-id pub-id-type="doi">10.1093/bib/bbab327</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chuang</surname><given-names>KV</given-names></string-name>, <string-name><surname>Gunsalus</surname><given-names>LM</given-names></string-name>, <string-name><surname>Keiser</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>Learning molecular representations for medicinal chemistry: miniperspective</article-title>. <source>J Med Chem</source> Â <year>2020</year>;<volume>63</volume>:<fpage>8705</fpage>â<lpage>22</lpage>.<pub-id pub-id-type="pmid">32366098</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>GÃ³mez-Bombarelli</surname><given-names>R</given-names></string-name>, <string-name><surname>Wei</surname><given-names>JN</given-names></string-name>, <string-name><surname>Duvenaud</surname><given-names>D</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Automatic chemical design using a data-driven continuous representation of molecules</article-title>. <source>ACS Cent Sci</source> Â <year>2018</year>;<volume>4</volume>:<fpage>268</fpage>â<lpage>76</lpage>.<pub-id pub-id-type="pmid">29532027</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bjerrum</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Sattarov</surname><given-names>B</given-names></string-name></person-group>. <article-title>Improving chemical autoencoder latent space and molecular de novo generation diversity with heteroencoders</article-title>. <source>Biomolecules</source> Â <year>2018</year>;<volume>8</volume>:<fpage>131</fpage>.<pub-id pub-id-type="pmid">30380783</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Winter</surname><given-names>R</given-names></string-name>, <string-name><surname>Montanari</surname><given-names>F</given-names></string-name>, <string-name><surname>NoÃ©</surname><given-names>F</given-names></string-name>, <string-name><surname>Clevert</surname><given-names>DA</given-names></string-name></person-group>. <article-title>Learning continuous and data-driven molecular descriptors by translating equivalent chemical representations</article-title>. <source>Chem Sci</source> Â <year>2019</year>;<volume>10</volume>:<fpage>1692</fpage>â<lpage>701</lpage>.<pub-id pub-id-type="pmid">30842833</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>ArÃºs-Pous</surname><given-names>J</given-names></string-name>, <string-name><surname>Johansson</surname><given-names>SV</given-names></string-name>, <string-name><surname>Prykhodko</surname><given-names>O</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Randomized SMILES strings improve the quality of molecular generative models</article-title>. <source>J Chem</source> Â <year>2019</year>;<volume>11</volume>:<fpage>1</fpage>â<lpage>13</lpage>.</mixed-citation>
    </ref>
    <ref id="ref20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Winter</surname><given-names>R</given-names></string-name>, <string-name><surname>Montanari</surname><given-names>F</given-names></string-name>, <string-name><surname>Steffen</surname><given-names>A</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Efficient multi-objective molecular optimization in a continuous latent space</article-title>. <source>Chem Sci</source> Â <year>2019</year>;<volume>10</volume>:<fpage>8016</fpage>â<lpage>24</lpage>.<pub-id pub-id-type="pmid">31853357</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vijayakumar</surname><given-names>AK</given-names></string-name>, <string-name><surname>Cogswell</surname><given-names>M</given-names></string-name>, <string-name><surname>Selvaraju</surname><given-names>RR</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Diverse beam search: Decoding diverse solutions from neural sequence model</article-title>. <source>Proceedings of the AAAI Conference on Artificial Intelligence</source> Â <year>2016</year>;<volume>32</volume>(<issue>1</issue>). <pub-id pub-id-type="doi">10.1609/aaai.v32i1.12340</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiong</surname><given-names>G</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Yi</surname><given-names>J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties</article-title>. <source>Nucleic Acids Res</source> Â <year>2021</year>;<volume>49</volume>:<fpage>W5</fpage>â<lpage>14</lpage>.<pub-id pub-id-type="pmid">33893803</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dong</surname><given-names>J</given-names></string-name>, <string-name><surname>Wang</surname><given-names>N-N</given-names></string-name>, <string-name><surname>Yao</surname><given-names>Z-J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database</article-title>. <source>J Chem</source> Â <year>2018</year>;<volume>10</volume>:<fpage>1</fpage>â<lpage>11</lpage>.</mixed-citation>
    </ref>
    <ref id="ref24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gaulton</surname><given-names>A</given-names></string-name>, <string-name><surname>Hersey</surname><given-names>A</given-names></string-name>, <string-name><surname>Nowotka</surname><given-names>M</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>The ChEMBL database in 2017</article-title>. <source>Nucleic Acids Res</source> Â <year>2017</year>;<volume>45</volume>:<fpage>D945</fpage>â<lpage>54</lpage>.<pub-id pub-id-type="pmid">27899562</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>DS</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>YD</given-names></string-name>, <string-name><surname>Guo</surname><given-names>AC</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res</source> Â <year>2018</year>;<volume>46</volume>:<fpage>D1074</fpage>â<lpage>82</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Fu</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J-W</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Three-level hepatotoxicity prediction system based on adverse hepatic effects</article-title>. <source>Mol Pharm</source> Â <year>2018</year>;<volume>16</volume>:<fpage>393</fpage>â<lpage>408</lpage>.<pub-id pub-id-type="pmid">30475633</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname><given-names>L</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Systematic Modeling of log D 7.4 Based on Ensemble Machine Learning, Group Contribution, and Matched Molecular Pair Analysis</article-title>. <source>J Chem Inf Model</source> Â <year>2019</year>;<volume>60</volume>:<fpage>63</fpage>â<lpage>76</lpage>.</mixed-citation>
    </ref>
    <ref id="ref28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname><given-names>L</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>QSAR-assisted-MMPA to expand chemical transformation space for lead optimization</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>:<fpage>bbaa374</fpage>.<pub-id pub-id-type="pmid">33418563</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>N-N</given-names></string-name>, <string-name><surname>Deng</surname><given-names>Z-K</given-names></string-name>, <string-name><surname>Huang</surname><given-names>C</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ADME properties evaluation in drug discovery: Prediction of plasma protein binding using NSGA-II combining PLS and consensus modeling</article-title>. <source>Chemom Intel Lab Syst</source> Â <year>2017</year>;<volume>170</volume>:<fpage>84</fpage>â<lpage>95</lpage>.</mixed-citation>
    </ref>
    <ref id="ref30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ertl</surname><given-names>P</given-names></string-name>, <string-name><surname>Schuffenhauer</surname><given-names>A</given-names></string-name></person-group>. <article-title>Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions</article-title>. <source>J Chem</source> Â <year>2009</year>;<volume>1</volume>:<fpage>1</fpage>â<lpage>11</lpage>.</mixed-citation>
    </ref>
    <ref id="ref31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wildman</surname><given-names>SA</given-names></string-name>, <string-name><surname>Crippen</surname><given-names>GM</given-names></string-name></person-group>. <article-title>Prediction of physicochemical parameters by atomic contributions</article-title>. <source>J Chem Inf Comput Sci</source> Â <year>1999</year>;<volume>39</volume>:<fpage>868</fpage>â<lpage>73</lpage>.</mixed-citation>
    </ref>
    <ref id="ref32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bickerton</surname><given-names>GR</given-names></string-name>, <string-name><surname>Paolini</surname><given-names>GV</given-names></string-name>, <string-name><surname>Besnard</surname><given-names>J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Quantifying the chemical beauty of drugs</article-title>. <source>Nat Chem</source> Â <year>2012</year>;<volume>4</volume>:<fpage>90</fpage>â<lpage>8</lpage>.<pub-id pub-id-type="pmid">22270643</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref33">
      <label>33.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Kennedy</surname><given-names>J</given-names></string-name>, <string-name><surname>Eberhart</surname><given-names>R</given-names></string-name></person-group>. <part-title>Particle swarm optimization</part-title>. In: <source>Proceedings of ICNN'95-international conference on neural networks</source>, <year>1995</year>, <year>IEEE</year>, <fpage>1942</fpage>â<lpage>8</lpage>.</mixed-citation>
    </ref>
    <ref id="ref34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Z-Z</given-names></string-name>, <string-name><surname>Huang</surname><given-names>J-W</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cao</surname><given-names>DS</given-names></string-name></person-group>. <article-title>ECoFFeS: a software using evolutionary computation for feature selection in drug discovery</article-title>. <source>IEEE Access</source> Â <year>2018</year>;<volume>6</volume>:<fpage>20950</fpage>â<lpage>63</lpage>.</mixed-citation>
    </ref>
    <ref id="ref35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Huang</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>N</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Incorporating PLS model information into particle swarm optimization for descriptor selection in QSAR/QSPR</article-title>. <source>J Chemometr</source> Â <year>2015</year>;<volume>29</volume>:<fpage>627</fpage>â<lpage>36</lpage>.</mixed-citation>
    </ref>
    <ref id="ref36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cao</surname><given-names>D-S</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name><surname>Fan</surname><given-names>L</given-names></string-name>, <string-name><surname>Liang</surname><given-names>YZ</given-names></string-name></person-group>. <article-title>QSAR analysis of the effects of OATP1B1 transporter by structurally diverse natural products using a particle swarm optimization-combined multiple linear regression approach</article-title>. <source>Chemom Intel Lab Syst</source> Â <year>2014</year>;<volume>130</volume>:<fpage>84</fpage>â<lpage>90</lpage>.</mixed-citation>
    </ref>
    <ref id="ref37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yun</surname><given-names>Y-H</given-names></string-name>, <string-name><surname>Cao</surname><given-names>D-S</given-names></string-name>, <string-name><surname>Tan</surname><given-names>M-L</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>A simple idea on applying large regression coefficient to improve the genetic algorithm-PLS for variable selection in multivariate calibration</article-title>. <source>Chemom Intel Lab Syst</source> Â <year>2014</year>;<volume>130</volume>:<fpage>76</fpage>â<lpage>83</lpage>.</mixed-citation>
    </ref>
    <ref id="ref38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eckert</surname><given-names>H</given-names></string-name>, <string-name><surname>Bajorath</surname><given-names>J</given-names></string-name></person-group>. <article-title>Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches</article-title>. <source>Drug Discov Today</source> Â <year>2007</year>;<volume>12</volume>:<fpage>225</fpage>â<lpage>33</lpage>.<pub-id pub-id-type="pmid">17331887</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dong</surname><given-names>J</given-names></string-name>, <string-name><surname>Yao</surname><given-names>Z-J</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>M-F</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ChemSAR: an online pipelining platform for molecular SAR modeling</article-title>. <source>J Chem</source> Â <year>2017</year>;<volume>9</volume>:<fpage>1</fpage>â<lpage>13</lpage>.</mixed-citation>
    </ref>
    <ref id="ref40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X-G</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Z-Y</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>:<fpage>bbab135</fpage>.<pub-id pub-id-type="pmid">33940596</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y-Q</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P-Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y-T</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>An update on poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy</article-title>. <source>J Med Chem</source> Â <year>2016</year>;<volume>59</volume>:<fpage>9575</fpage>â<lpage>98</lpage>.<pub-id pub-id-type="pmid">27416328</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L-X</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>T</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>The ups and downs of Poly (ADP-ribose) Polymerase-1 inhibitors in cancer therapyâCurrent progress and future direction</article-title>. <source>Eur J Med Chem</source> Â <year>2020</year>;<volume>203</volume>:<elocation-id>112570</elocation-id>.<pub-id pub-id-type="pmid">32717529</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name><surname>Mathiowetz</surname><given-names>A</given-names></string-name>, <string-name><surname>Gao</surname><given-names>H</given-names></string-name></person-group>. <article-title>Deep understanding of structureâsolubility relationship for a diverse set of organic compounds using matched molecular pairs</article-title>. <source>Bioorg Med Chem</source> Â <year>2011</year>;<volume>19</volume>:<fpage>5763</fpage>â<lpage>70</lpage>.<pub-id pub-id-type="pmid">21906951</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Do</surname><given-names>P-C</given-names></string-name>, <string-name><surname>Lee</surname><given-names>EH</given-names></string-name>, <string-name><surname>Le</surname><given-names>L</given-names></string-name></person-group>. <article-title>Steered molecular dynamics simulation in rational drug design</article-title>. <source>J Chem Inf Model</source> Â <year>2018</year>;<volume>58</volume>:<fpage>1473</fpage>â<lpage>82</lpage>.<pub-id pub-id-type="pmid">29975531</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tian</surname><given-names>C</given-names></string-name>, <string-name><surname>Kasavajhala</surname><given-names>K</given-names></string-name>, <string-name><surname>Belfon</surname><given-names>KAA</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum Mechanics Energy Surfaces in Solution</article-title>. <source>J Chem Theory Comput</source> Â <year>2020</year>;<volume>16</volume>:<fpage>528</fpage>â<lpage>52</lpage>.<pub-id pub-id-type="pmid">31714766</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vassetti</surname><given-names>D</given-names></string-name>, <string-name><surname>Pagliai</surname><given-names>M</given-names></string-name>, <string-name><surname>Procacci</surname><given-names>P</given-names></string-name></person-group>. <article-title>Assessment of GAFF2 and OPLS-AA general force fields in combination with the water models TIP3P, SPCE, and OPC3 for the solvation free energy of druglike organic molecules</article-title>. <source>J Chem Theory Comput</source> Â <year>2019</year>;<volume>15</volume>:<fpage>1983</fpage>â<lpage>95</lpage>.<pub-id pub-id-type="pmid">30694667</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eberhardt</surname><given-names>J</given-names></string-name>, <string-name><surname>Santos-Martins</surname><given-names>D</given-names></string-name>, <string-name><surname>Tillack</surname><given-names>AF</given-names></string-name>, <string-name><surname>Forli</surname><given-names>S</given-names></string-name></person-group>. <article-title>AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings</article-title>. <source>J Chem Inf Model</source> Â <year>2021</year>;<volume>61</volume>:<fpage>3891</fpage>â<lpage>8</lpage>.<pub-id pub-id-type="pmid">34278794</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Case</surname><given-names>DA</given-names></string-name>, <string-name><surname>Aktulga</surname><given-names>HM</given-names></string-name>, <string-name><surname>Belfon</surname><given-names>K</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>AmberTools</article-title>. <source>J Chem Inf Model</source> Â <year>2023</year>;<volume>63</volume>:<fpage>6183</fpage>â<lpage>91</lpage>.<pub-id pub-id-type="pmid">37805934</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>Z-Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-J</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>PySmash: Python package and individual executable program for representative substructure generation and application</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>:<fpage>bbab017</fpage>.<pub-id pub-id-type="pmid">33709154</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Brief Bioinform</journal-id>
    <journal-id journal-id-type="iso-abbrev">Brief Bioinform</journal-id>
    <journal-id journal-id-type="publisher-id">bib</journal-id>
    <journal-title-group>
      <journal-title>Briefings in Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1467-5463</issn>
    <issn pub-type="epub">1477-4054</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10883642</article-id>
    <article-id pub-id-type="pmid">38385872</article-id>
    <article-id pub-id-type="doi">10.1093/bib/bbae008</article-id>
    <article-id pub-id-type="publisher-id">bbae008</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Problem Solving Protocol</subject>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ChemMORT: an automatic ADMET optimization platform using deep learning and multi-objective particle swarm optimization</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6823-1882</contrib-id>
        <name>
          <surname>Yi</surname>
          <given-names>Jia-Cai</given-names>
        </name>
        <!--yjc@nudt.edu.cn-->
        <aff><institution>School of Computer Science, National University of Defense Technology</institution>, <addr-line>Changsha 410073, Hunan</addr-line>, <country country="CN">PR China</country></aff>
        <aff><institution>Xiangya School of Pharmaceutical Sciences, Central South University</institution>, <addr-line>Changsha 410013, Hunan</addr-line>, <country country="CN">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Zi-Yi</given-names>
        </name>
        <!--502241508@qq.com-->
        <aff><institution>Xiangya School of Pharmaceutical Sciences, Central South University</institution>, <addr-line>Changsha 410013, Hunan</addr-line>, <country country="CN">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Zhao</surname>
          <given-names>Wen-Tao</given-names>
        </name>
        <!--wtzhao@nudt.edu.cn-->
        <aff><institution>School of Computer Science, National University of Defense Technology</institution>, <addr-line>Changsha 410073, Hunan</addr-line>, <country country="CN">PR China</country></aff>
        <xref rid="cor1" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Zhi-Jiang</given-names>
        </name>
        <!--1223821976@qq.com-->
        <aff><institution>Xiangya School of Pharmaceutical Sciences, Central South University</institution>, <addr-line>Changsha 410013, Hunan</addr-line>, <country country="CN">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7187-435X</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Xiao-Chen</given-names>
        </name>
        <!--zhangxiaochen@nudt.edu.cn-->
        <aff><institution>School of Computer Science, National University of Defense Technology</institution>, <addr-line>Changsha 410073, Hunan</addr-line>, <country country="CN">PR China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wu</surname>
          <given-names>Cheng-Kun</given-names>
        </name>
        <!--chengkun_wu@nudt.edu.cn-->
        <aff><institution>State Key Laboratory of High-Performance Computing</institution>, <addr-line>Changsha 410073, Hunan</addr-line>, <country country="CN">PR China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lu</surname>
          <given-names>Ai-Ping</given-names>
        </name>
        <!--lap64067611@126.com-->
        <aff><institution>Institute for Advancing Translational Medicine in Bone and Joint Diseases</institution>, School of Chinese Medicine, <institution>Hong Kong Baptist University</institution>, <addr-line>Hong Kong SAR</addr-line>, <country country="CN">P. R. China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3604-3785</contrib-id>
        <name>
          <surname>Cao</surname>
          <given-names>Dong-Sheng</given-names>
        </name>
        <!--oriental-cds@163.com-->
        <aff><institution>Xiangya School of Pharmaceutical Sciences, Central South University</institution>, <addr-line>Changsha 410013, Hunan</addr-line>, <country country="CN">P. R. China</country></aff>
        <aff><institution>Institute for Advancing Translational Medicine in Bone and Joint Diseases</institution>, School of Chinese Medicine, <institution>Hong Kong Baptist University</institution>, <addr-line>Hong Kong SAR</addr-line>, <country country="CN">P. R. China</country></aff>
        <xref rid="cor1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="cor1">Corresponding authors. Dongsheng Cao, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410003, P.R. China. Tel.: +86-139-7488-0914; E-mail: <email>oriental-cds@163.com</email>; Wentao Zhao, School of Computer Science, National University of Defense Technology, Changsha, Hunan 410073, P.R. China. Tel.: +86-159-0731-1680; E-mail: <email>wtzhao@nudt.edu.cn</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>3</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-02-20">
      <day>20</day>
      <month>2</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>20</day>
      <month>2</month>
      <year>2024</year>
    </pub-date>
    <volume>25</volume>
    <issue>2</issue>
    <elocation-id>bbae008</elocation-id>
    <history>
      <date date-type="received">
        <day>24</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>17</day>
        <month>12</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>2</day>
        <month>1</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Â© The Author(s) 2024. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="bbae008.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Drug discovery and development constitute a laborious and costly undertaking. The success of a drug hinges not only good efficacy but also acceptable absorption, distribution, metabolism, elimination, and toxicity (ADMET) properties. Overall, up to 50% of drug development failures have been contributed from undesirable ADMET profiles. As a multiple parameter objective, the optimization of the ADMET properties is extremely challenging owing to the vast chemical space and limited human expert knowledge. In this study, a freely available platform called Chemical Molecular Optimization, Representation and Translation (ChemMORT) is developed for the optimization of multiple ADMET endpoints without the loss of potency (<ext-link xlink:href="https://cadd.nscc-tj.cn/deploy/chemmort/" ext-link-type="uri">https://cadd.nscc-tj.cn/deploy/chemmort/</ext-link>). ChemMORT contains three modules: Simplified Molecular Input Line Entry System (SMILES) Encoder, Descriptor Decoder and Molecular Optimizer. The SMILES Encoder can generate the molecular representation with a 512-dimensional vector, and the Descriptor Decoder is able to translate the above representation to the corresponding molecular structure with high accuracy. Based on reversible molecular representation and particle swarm optimization strategy, the Molecular Optimizer can be used to effectively optimize undesirable ADMET properties without the loss of bioactivity, which essentially accomplishes the design of inverse QSAR. The constrained multi-objective optimization of the poly (ADP-ribose) polymerase-1 inhibitor is provided as the case to explore the utility of ChemMORT.</p>
    </abstract>
    <kwd-group>
      <kwd>ADMET evaluation</kwd>
      <kwd>lead optimization</kwd>
      <kwd>substructure modification</kwd>
      <kwd>deep learning</kwd>
      <kwd>inverse QSAR</kwd>
      <kwd>reversible molecular representation</kwd>
      <kwd>particle swarm optimization</kwd>
    </kwd-group>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Key Research and Development Program of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100012166</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2022YFA1004303</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Foundation of State Key Laboratory of HPCL</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2023-KJWHPCL-01</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Science Foundation for Indigenous Innovation of National University of Defense Technology</institution>
          </institution-wrap>
        </funding-source>
        <award-id>23-ZZCX-JDZ-08</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>22173118</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Excellent Youth Foundation of Hunan Province</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2021JJ10068</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Key scientific research projects in higher education institutions of Henan Province</institution>
          </institution-wrap>
        </funding-source>
        <award-id>24A520036</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>HKBU Strategic Development Fund project</institution>
          </institution-wrap>
        </funding-source>
        <award-id>SDF19-0402-P02</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="10"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec id="sec3">
    <title>INTRODUCTION</title>
    <p>The journey of discovering a new drug candidate and shepherding it through clinical trials and onto the market is time-consuming, fraught with difficulties, inordinately expensive, and prone to failure, which typically costs 15Â years and $12â15 million for successfully developing a clinical candidate [<xref rid="ref1" ref-type="bibr">1</xref>]. Since the key to improving pharmaceutical productivity is to boost the efficiency of discovering drug candidates entering clinical trials, several revolutionary technologies have been used for accelerating drug candidate development, such as combinatorial chemistry, X-ray crystallography, high-throughput screening (HTS) and virtual screening (VS) [<xref rid="ref2" ref-type="bibr">2â4</xref>]. However, despite the inventiveness and rapid advances witnessed in HTS and VS [<xref rid="ref5" ref-type="bibr">5â7</xref>], the attrition rate during the early drug candidate discovery is still as high as 75%, even for those experienced global pharmaceutical companies [<xref rid="ref8" ref-type="bibr">8</xref>, <xref rid="ref9" ref-type="bibr">9</xref>]. It is estimated that up to 50% of failures are contributed from the deficiency in absorption, distribution, metabolism, elimination, and toxicity (ADMET) properties, which reaffirms the importance of optimizing ADMET properties during drug discovery campaigns [<xref rid="ref10" ref-type="bibr">10</xref>]. The ADMET optimization could be viewed as an extremely challenging multi-parameter optimization task, which aims to improve multiple ADMET properties while avoid the reduction of biological potency [<xref rid="ref11" ref-type="bibr">11</xref>, <xref rid="ref12" ref-type="bibr">12</xref>].</p>
    <p>With large-scale investigations of deep learning (DL) in molecular representations [<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref14" ref-type="bibr">14</xref>], it is found that the chemical space learned by deep neural networks represents several advantages: smooth, continuous, unique and expressive, which could efficiently benefit molecular optimization [<xref rid="ref15" ref-type="bibr">15</xref>]. Recently, a method proposed by Gomez-Bombarelli <italic toggle="yes">etÂ al.</italic> [<xref rid="ref16" ref-type="bibr">16</xref>] further illustrates the above advantages through the application of variational autoencoder, with the additional feature of reversibility. This autoencoder comprises two neural networks: an encoder and a decoder. The encoder network transforms input Simplified Molecular Input Line Entry System (SMILES) strings into a lower-dimensional representation, commonly referred to as the latent space. Conversely, the decoder network maps the points from this latent space back to SMILES sequences. To achieve the encoding of higher-level molecular features rather than the syntactic concepts or repetitive patterns of the sequence, the reconstruction task is transformed into a translation task, by translating one molecular representation to another syntactically different one [<xref rid="ref17" ref-type="bibr">17</xref>, <xref rid="ref18" ref-type="bibr">18</xref>]. Several researches have shown that the models trained with enumerated SMILES sequences own more advantages in data augmentation and important molecular feature learning than those only trained with one variant (e.g. canonical SMILES) [<xref rid="ref17" ref-type="bibr">17</xref>, <xref rid="ref19" ref-type="bibr">19</xref>]. In addition, it has been observed that latent space vectors showed superior performance in molecular similarity analysis and Quantitative StructureâActivity Relationship (QSAR) modeling than autoencoder-derived vectors and the models built using the Extended Connectivity Fingerprints (ECFP4) fingerprints, suggesting that they have increased relevant to biological activities and physicochemical properties [<xref rid="ref17" ref-type="bibr">17</xref>]. Due to high reversibility and information enrichment, latent space vectors are highly recommended for inverse QSAR problems. For the navigation of the optimization tasks for multiple molecular properties, the application of latent space vectors needs to be combined with efficient optimization strategy and necessary structural constraint, thus effectively avoiding the drop of target potency [<xref rid="ref20" ref-type="bibr">20</xref>].</p>
    <p>Considering the importance of ADMET optimization in drug discovery, here, a freely available platform called Chemical Molecular Optimization, Representation and Translation (ChemMORT) is developed for the optimization of multiple ADMET endpoints (<ext-link xlink:href="https://cadd.nscc-tj.cn/deploy/chemmort/" ext-link-type="uri">https://cadd.nscc-tj.cn/deploy/chemmort/</ext-link>). ChemMORT contains three basic modules: SMILES Encoder, Descriptor Decoder and Molecular Optimizer, which provide the representation, translation and optimization functions, respectively. Based on the training of 17 million enumerated SMILES strings, SMILES Encoder can generate the 512-dimensional molecular representation, and Descriptor Decoder is able to translate the above representation to the corresponding molecular structure with high accuracy. Based on the reversible molecular representation and particle swarm optimization (PSO) strategy, Molecular Optimizer can effectively accomplish ADMET optimization tasks while preserving the potency of the optimized molecules through necessary similarity and substructure constraint. To evaluate the utility of ChemMORT, the constrained multi-objective optimization of the poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor was provided as the case. It is believed that through the rational application of ChemMORT, researchers can discover potent drug candidates with improved ADMET profiles.</p>
  </sec>
  <sec id="sec4">
    <title>MATERIALS AND METHODS</title>
    <sec id="sec5">
      <title>Neural translation model</title>
      <p>In this study, inspired by human language neural network translation models, a sequence-to-sequence (seq2seq) model was trained based on the SMILES notation for chemical space exploration. It turns enumerated SMILES notation into a fixed-length vector representation in the encoder and turns this fixed-length vector into the Canonical SMILES of the molecule in the decoder, where the fixed-length vector will be used as the connection between structure modification and property optimization [<xref rid="ref18" ref-type="bibr">18</xref>]. Generally, recurrent neural networks are used as the backend of the seq2seq model, which often bring the vanishing or exploding gradient problems. To avoid it, three stacked <italic toggle="yes">Gate Recurrent Unit</italic> (GRU) layers were used in both the encoder and decoder networks. In addition, a fully connected layer (<italic toggle="yes">information bottleneck</italic>) with 512Â units and hyperbolic tangent activation function is used as the final layer of the encoder to generate a 512-dimensional latent representation. Through information bottleneck, it can capture the most statistically salient features about molecular structures, which ensures the accuracy of translation and the efficiency for property prediction. The decoder takes the latent representation as an input and feeds it into a similar three stacked aforementioned GRU layers with 1024, 512 and 256Â units. The input of the decoder to each time step is the output of the preceding time step and the embedding of the ground truth. In the training phase, the output of the decoder transfers to the ground truth to calculate the cross-entropy loss and conduct the gradient update. In the prediction phase, the beam search algorithm [<xref rid="ref21" ref-type="bibr">21</xref>], a heuristic search algorithm that explores the best combination of words by expanding the most promising node in a limited set, is used in the model to iteratively predict each character until a complete sequence is generated. An internal database with 1.7 million accessible molecules was used to validate the reliability and generalization ability of the model. All the molecules were randomly divided into a training set (1.53 million molecules) and a test set (0.17 million molecules) with a ratio of 9:1. Every molecule was represented by 10 different enumerated SMILES strings for encoding. A previous study has already proved that training the encoder with enumerated SMILES strings and the decoder with Canonical SMILES is able to achieve a better balance between translation correction rate and chemical space breadth [<xref rid="ref17" ref-type="bibr">17</xref>].</p>
    </sec>
    <sec id="sec6">
      <title>ADMET prediction model</title>
      <p>In order to construct credible ADMET-related prediction models for molecular optimization, a large and high quality ADMET dataset containing basic information and experimental values were collected from the ChEMBL, EPA and DrugBank databases, and all the molecules in the dataset were prepared by molecular operating environment (MOE, version 2016) [<xref rid="ref22" ref-type="bibr">22â25</xref>]. Finally, around 30 000 entries, covering logD7.4, LogS, Caco-2, MDCK cells, Plasma protein binding rate (PPB), AMES toxicity, human ether-a-go-go-related gene (hERG) toxicity, hepotoxicity and median lethal dose (LD50), were obtained for ADMET evaluation [<xref rid="ref23" ref-type="bibr">23</xref>, <xref rid="ref24" ref-type="bibr">24</xref>, <xref rid="ref26" ref-type="bibr">26â29</xref>]. The source and information about the ADMET dataset are summarized in <xref rid="sup1" ref-type="supplementary-material">Table S1</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>. Based on the combination of the calculated 512-dimensional vectors and XGBoost algorithm, nine high-quality ADMET prediction models were constructed for the evaluation and guidance of molecular optimization. In addition, three calculated properties, including SlogP, quantitative estimate of drug-likeness (QED) score and synthetic accessibility (SA) score, were also included in ChemMORT for more comprehensive evaluation of molecular suitability [<xref rid="ref30" ref-type="bibr">30â32</xref>].</p>
    </sec>
    <sec id="sec7">
      <title>Scoring scheme</title>
      <p>To provide a comprehensive perspective of multi-parameter optimization task, the scoring scheme was applied for a qualitative evaluation of the desirability of the optimized molecule. Based on the recommended value range (<xref rid="sup1" ref-type="supplementary-material">Table S2</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>), the customized aim range and the actual property value for individual scores will be: 1 for the value in the optimal range, (0, 1) for the value out of the optimal range but in the recommended value range, and 0 for the value out of the recommended value range. Considering the different requirements in different optimization tasks, the individual scaled score components with customized weights will be combined according to the importance of different features in the whole task. The Final Score (eq <xref rid="deqn02" ref-type="disp-formula">2</xref>) will be presented as the weighted average score of all scaled scores, where a low value corresponds to undesirable optimization and a high value indicates an acceptable optimization. </p>
      <disp-formula id="deqn01">
        <label>(1)</label>
        <tex-math notation="LaTeX" id="DmEquation1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} F=\frac{\sum_{i=1}^j\left({S}_i\cdotp{W}_i\right)}{\sum_{i=1}^j{W}_i} \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <p>where <inline-formula><tex-math notation="LaTeX" id="ineq01">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$j$\end{document}</tex-math></inline-formula> is the number of the objective functions used for optimization, <inline-formula><tex-math notation="LaTeX" id="ineq02">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${S}_i$\end{document}</tex-math></inline-formula> represents the desirability of the objective function <inline-formula><tex-math notation="LaTeX" id="ineq03">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$i$\end{document}</tex-math></inline-formula> of the optimized molecule, and <inline-formula><tex-math notation="LaTeX" id="ineq04">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${W}_i$\end{document}</tex-math></inline-formula> corresponds to the priority of the objective function <inline-formula><tex-math notation="LaTeX" id="ineq05">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$i$\end{document}</tex-math></inline-formula> in this task.</p>
    </sec>
    <sec id="sec8">
      <title>Particle swarm optimization</title>
      <p>Based on the continuous presentation and scoring scheme, the PSO [<xref rid="ref33" ref-type="bibr">33</xref>], a stochastic optimization method that mimics swarm intelligence to find an optimal point in a search space, was applied to explore the optimized molecules with desirable properties [<xref rid="ref34" ref-type="bibr">34â37</xref>]. Inspired by social behavior of bird flocking or fish schooling, the PSO consists of individuals for space searching, which utilizes and communicates the information gained during their search. During this process, each particle in the swarm is defined by their position <inline-formula><tex-math notation="LaTeX" id="ineq06">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$x$\end{document}</tex-math></inline-formula> and velocity <inline-formula><tex-math notation="LaTeX" id="ineq07">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$v$\end{document}</tex-math></inline-formula>, where the scoring scheme <inline-formula><tex-math notation="LaTeX" id="ineq08">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$f$\end{document}</tex-math></inline-formula> is applied for the detection of the potential surface of the search space. The movement of the <italic toggle="yes">i-</italic>th particle at iteration step <italic toggle="yes">k</italic> is influenced by the historical best point of itself: </p>
      <disp-formula id="deqn02">
        <label>(2)</label>
        <tex-math notation="LaTeX" id="DmEquation2">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} {x}_i^{best}= argmaxf\left({x}_i^k\right) \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <p>as well as the overall historical best point of the swarm:</p>
      <disp-formula id="deqn03">
        <label>(3)</label>
        <tex-math notation="LaTeX" id="DmEquation3">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} {x}^{best}= argmaxf\left({x}_i^{best}\right) \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <p>After each iteration, each particle will update its velocity and position based on the collected information and its status:</p>
      <disp-formula id="deqn04">
        <label>(4)</label>
        <tex-math notation="LaTeX" id="DmEquation4">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} {v}_i^{k+1}=w{v}_i^k+{c}_1{r}_1\left({x}_i^{best}-{x}_i^k\right)+{c}_2{r}_2\left({x}^{best}-{x}_i^k\right) \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <disp-formula id="deqn05">
        <label>(5)</label>
        <tex-math notation="LaTeX" id="DmEquation5">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{equation*} {x}_i^{k+1}={x}_i^k+{v}_i^{k+1} \end{equation*}\end{document}</tex-math>
      </disp-formula>
      <p>where <inline-formula><tex-math notation="LaTeX" id="ineq09">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${c}_1$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math notation="LaTeX" id="ineq10">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${c}_2$\end{document}</tex-math></inline-formula> are the constants that weight the contribution of the individual experience versus the swarm experience; <inline-formula><tex-math notation="LaTeX" id="ineq11">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${r}_1$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math notation="LaTeX" id="ineq12">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
${r}_2$\end{document}</tex-math></inline-formula> are the random numbers drawn from independent uniform distributions between 0 and 1; the inertia weight <inline-formula><tex-math notation="LaTeX" id="ineq13">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$w$\end{document}</tex-math></inline-formula> is a constant that controls the momentum of the particle from the previous iteration. In this work, the position of the particle is initialized by the output of the encoder.</p>
    </sec>
    <sec id="sec9">
      <title>Webserver development</title>
      <p>ChemMORT was developed by using Python 3.7, Django 2.2, Tensorflow 1.14.0, SQLite 3, celery 4.4.7, RabbitMQ 3.6.10 and RDKit 2019.03.1. It was a Django task, which is deployed on a high-performance Nginx Web server of Ubuntu 18.04.4 LTS via the application of uWSGI. ChemMORT applied the MVT (model, view and template)design pattern, including three layers: model layer, view layer and template layer. The model layer interfaces to the SQLite3 database which was applied for model construction, upload file storing and property prediction. The view layer contains the main logic code, which was used for providing access to the prediction models, handling file upload and download, and manipulating multi-prediction tasks. The template layer was applied for the presentation of the front-end pages, including result visualization, page rendering, document integration, etc. The browser compatibility testing is shown in <xref rid="sup1" ref-type="supplementary-material">Table S6</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>.</p>
    </sec>
  </sec>
  <sec id="sec10">
    <title>RESULTS AND DISCUSSION</title>
    <sec id="sec11">
      <title>ChemMORT workflow</title>
      <p>The ChemMORT protocol is presented as a workflow in <xref rid="f1" ref-type="fig">Figure 1</xref>. As shown in <xref rid="f1" ref-type="fig">Figure 1</xref>, there are three main modules in ChemMORT: SMILES Encoder, Descriptor Decoder and Molecular Optimizer, which refer to the functions of descriptor calculation, molecular translation and ADMET optimization, respectively.</p>
      <fig position="float" id="f1">
        <label>Figure 1</label>
        <caption>
          <p>The workflow of ChemMORT.</p>
        </caption>
        <graphic xlink:href="bbae008f1" position="float"/>
      </fig>
      <p>SMILES Encoder: Three molecular input types are supported by the SMILES Encoder module: inputting SMILES strings, drawing molecules from the editor, and uploading file (*.sdf/*.csv/*.txt). After the molecular preparation process, the corresponding 512-dimension vectors will be calculated based on the well-trained encoder network. In the following page, the Summary and Result block will present the overview of the results and the detailed information about the SMILES strings, molecular graphs and 512-dimension vectors. The calculated descriptors and related SMILES strings can be saved as .csv file.</p>
      <p>Descriptor Decoder: In this function, users can upload a 512-dimensional vector (between â1 and 1), which latter will be back-engineered to the corresponding uniform canonical SMILES string through the application of decoder network. It should be noted that owing to the character-by-character nature of the SMILES representation and the fragility of its internal syntax, an arbitrary combination may lead to the output of invalid or failed molecules. After calculation, the summary and result block are provided for the overview of the translated SMILES information, where the results can also be downloaded as .csv file. Owing to the advantage of reversibility, the combination of SMILES Encoder and Descriptor Decoder possesses the ability to deal with the inverse design problem, which is the key point of lead optimization.</p>
      <p>Molecular Optimizer: Molecular optimization is a complex and multi-objective task, which needs to balance bioactivity, pharmacokinetic profile and therapeutic safety. To achieve this goal, the Molecular Optimizer module is provided with the integration of reversible molecular representation, credible QSAR models, necessary structural constraint and multi-objective PSO strategy, which follows the principle of inverse QSAR methodology. Firstly, users are required to input the job information and the SMILES string of the molecule that needs to be optimized. Twelve credible objective functions covering basic molecular properties, synesthetic accessibility, drug-likeness, absorption, distribution and toxicity were provided for property optimization. To retain the efficacy and novelty of initial optimized molecule, the <italic toggle="yes">Similarity Constrain</italic> and <italic toggle="yes">Substructure Constrain</italic> functions were applied for the definition of the starting point and the annotation of important active motif, respectively [<xref rid="ref38" ref-type="bibr">38</xref>]. The application of the <italic toggle="yes">Similarity Constrain</italic> function enables the setting of the distance limitation between the generated molecule and the reference molecule based on the ECFP4 fingerprint and Tanimoto similarity metric, while the application of the <italic toggle="yes">Substructure Constrain</italic> function highlights the importance of bioactivity motif. All the above functions are allowed to set the weights according to their importance, which later will be applied to the scaled score for optimization navigation and comprehensive evaluation. Owing to the different requirements for optimal molecules, users can adjust the iteration steps and the number of the top desirable compounds in each iteration step. After submission, the optimization job will be calculated in the background. Users can obtain the optimized result from the email or the access of Queue page with the input of job token. The final result includes the information about the starting molecule and optimized molecules, of which the latter one provides the detailed table about the SMILES, the structural graph, selected optimized property values and the final score. Based on the combination of user-defined property value range, specific function weights and the optimized property value, the final score is a comprehensive desirability index of the optimized molecules, and it can quantitatively indicate the desirability and quality of the optimized molecule in the specified optimization task.</p>
    </sec>
    <sec id="sec12">
      <title>Neural translation model training</title>
      <p>A multi-layer gate recurrent unit network, including input dropout, bottleneck layer and Gaussian noise term, was employed for training and application. The model was trained until convergence, using a batch size of 64, dropout ratio of 0.15 and embedding noise of 0.05. As shown in <xref rid="f2" ref-type="fig">Figure 2</xref>, the translation accuracy for the training set and test set first increased rapidly, but after a point, it became stable and almost unchanged. The final average single character accuracy values for both the training and test sets reached 99.8%, indicating the proportion of correctly predicted characters to the total predicted length. This achievement underscores the reliability and credibility of this seq2seq model. It also indicated that the important feature of the molecule has already been encoded in the latent space, resulting in a potentially powerful molecular descriptor for further ADMET prediction and optimization task.</p>
      <fig position="float" id="f2">
        <label>Figure 2</label>
        <caption>
          <p>The translation accuracy for the training set and test set during the 160Â k training steps.</p>
        </caption>
        <graphic xlink:href="bbae008f2" position="float"/>
      </fig>
    </sec>
    <sec id="sec13">
      <title>ADMET predictive model validation</title>
      <p>Based on the 512-dimensional descriptors calculated by the encoder network, 9 ADMET-related prediction models, including logD7.4, AMES, Caco-2, MDCK, PPB, LogS, hERG, hepatoxicity and LD50, were constructed with the XGBoost algorithm. All the datasets were divided into the training set and test set according to the chemical space distribution computed by the âDiverse training set splitâ module in ChemSAR, where 75% compounds were used as the training set and the remaining 25% as the test set [<xref rid="ref39" ref-type="bibr">39</xref>]. The prediction performance of the ADMET prediction models and related parameters are summarized in <xref rid="TB1" ref-type="table">Table 1</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S3</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>, respectively.</p>
      <table-wrap position="float" id="TB1">
        <label>Table 1</label>
        <caption>
          <p>The performance of ADMET prediction models in ChemMORT</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th colspan="11" align="left" rowspan="1">ADMET regression model performance</th>
            </tr>
            <tr>
              <th rowspan="2" align="left" colspan="1">Property</th>
              <th rowspan="2" align="left" colspan="1">Description</th>
              <th rowspan="2" align="left" colspan="1">Algorithm<sup>*</sup></th>
              <th colspan="3" align="left" rowspan="1">5-Fold CV</th>
              <th colspan="3" align="left" rowspan="1">Test set</th>
              <th colspan="2" align="left" rowspan="1">Data information</th>
            </tr>
            <tr>
              <th align="left" rowspan="1" colspan="1">RMSE</th>
              <th align="left" rowspan="1" colspan="1">MAE</th>
              <th align="left" rowspan="1" colspan="1">R<sup>2</sup></th>
              <th align="left" rowspan="1" colspan="1">RMSE</th>
              <th align="left" rowspan="1" colspan="1">MAE</th>
              <th align="left" rowspan="1" colspan="1">R<sup>2</sup></th>
              <th align="left" rowspan="1" colspan="1">Training set</th>
              <th align="left" rowspan="1" colspan="1">Test set</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">logD7.4</td>
              <td align="left" rowspan="1" colspan="1">Log of the octanol/water distribution coefficient at pHÂ 7.4.</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.562âÂ±â0.009</td>
              <td align="left" rowspan="1" colspan="1">0.428âÂ±â0.13</td>
              <td align="left" rowspan="1" colspan="1">0.834âÂ±â0.005</td>
              <td align="left" rowspan="1" colspan="1">0.555âÂ±â0.010</td>
              <td align="left" rowspan="1" colspan="1">0.426âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.840âÂ±â0.004</td>
              <td align="left" rowspan="1" colspan="1">773</td>
              <td align="left" rowspan="1" colspan="1">258</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">logS</td>
              <td align="left" rowspan="1" colspan="1">Log of Solubility</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.842âÂ±â0.084</td>
              <td align="left" rowspan="1" colspan="1">0.592âÂ±â0.056</td>
              <td align="left" rowspan="1" colspan="1">0.839âÂ±â0.029</td>
              <td align="left" rowspan="1" colspan="1">0.823âÂ±â0.026</td>
              <td align="left" rowspan="1" colspan="1">0.572âÂ±â0.009</td>
              <td align="left" rowspan="1" colspan="1">0.862âÂ±â0.011</td>
              <td align="left" rowspan="1" colspan="1">4116</td>
              <td align="left" rowspan="1" colspan="1">1104</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Caco-2</td>
              <td align="left" rowspan="1" colspan="1">Caco-2 Permeability</td>
              <td align="left" rowspan="1" colspan="1">XGBoost&amp; Data Augment</td>
              <td align="left" rowspan="1" colspan="1">0.328âÂ±â0.004</td>
              <td align="left" rowspan="1" colspan="1">0.245âÂ±â0.005</td>
              <td align="left" rowspan="1" colspan="1">0.728âÂ±â0.011</td>
              <td align="left" rowspan="1" colspan="1">0.332âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.244âÂ±â0.004</td>
              <td align="left" rowspan="1" colspan="1">0.718âÂ±â0.019</td>
              <td align="left" rowspan="1" colspan="1">886</td>
              <td align="left" rowspan="1" colspan="1">296</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">MDCK</td>
              <td align="left" rowspan="1" colspan="1">MDCK Permeability</td>
              <td align="left" rowspan="1" colspan="1">XGBoost&amp; Data Augment</td>
              <td align="left" rowspan="1" colspan="1">0.322âÂ±â0.034</td>
              <td align="left" rowspan="1" colspan="1">0.235âÂ±â0.021</td>
              <td align="left" rowspan="1" colspan="1">0.644âÂ±â0.057</td>
              <td align="left" rowspan="1" colspan="1">0.323âÂ±â0.022</td>
              <td align="left" rowspan="1" colspan="1">0.232âÂ±â0.011</td>
              <td align="left" rowspan="1" colspan="1">0.650âÂ±â0.041</td>
              <td align="left" rowspan="1" colspan="1">912</td>
              <td align="left" rowspan="1" colspan="1">228</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">PPB</td>
              <td align="left" rowspan="1" colspan="1">Plasma Protein Binding</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.154âÂ±â0.010</td>
              <td align="left" rowspan="1" colspan="1">0.106âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.691âÂ±â0.025</td>
              <td align="left" rowspan="1" colspan="1">0.152âÂ±â0.003</td>
              <td align="left" rowspan="1" colspan="1">0.104âÂ±â0.002</td>
              <td align="left" rowspan="1" colspan="1">0.691âÂ±â0.016</td>
              <td align="left" rowspan="1" colspan="1">1368</td>
              <td align="left" rowspan="1" colspan="1">454</td>
            </tr>
            <tr>
              <td align="left" colspan="11" rowspan="1">ADMET classification model performance</td>
            </tr>
            <tr>
              <td align="left" rowspan="2" colspan="1">Property</td>
              <td align="left" rowspan="2" colspan="1">Description</td>
              <td align="left" rowspan="2" colspan="1">Algorithm<sup>*</sup></td>
              <td align="left" colspan="3" rowspan="1">5-Fold CV</td>
              <td align="left" colspan="3" rowspan="1">Test set</td>
              <td align="left" colspan="2" rowspan="1">Data information</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Accuracy</td>
              <td align="left" rowspan="1" colspan="1">Sensitivity</td>
              <td align="left" rowspan="1" colspan="1">AUC</td>
              <td align="left" rowspan="1" colspan="1">Accuracy</td>
              <td align="left" rowspan="1" colspan="1">Sensitivity</td>
              <td align="left" rowspan="1" colspan="1">AUC</td>
              <td align="left" rowspan="1" colspan="1">Training set</td>
              <td align="left" rowspan="1" colspan="1">Test set</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">AMES</td>
              <td align="left" rowspan="1" colspan="1">The probability to be positive in Ames test.</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.810âÂ±â0.016</td>
              <td align="left" rowspan="1" colspan="1">0.838âÂ±â0.014</td>
              <td align="left" rowspan="1" colspan="1">0.889âÂ±â0.013</td>
              <td align="left" rowspan="1" colspan="1">0.813âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.835âÂ±â0.013</td>
              <td align="left" rowspan="1" colspan="1">0.888âÂ±â0.004</td>
              <td align="left" rowspan="1" colspan="1">7514</td>
              <td align="left" rowspan="1" colspan="1">1905</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">hERG</td>
              <td align="left" rowspan="1" colspan="1">The probability to be hERG Blocker</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.800âÂ±â0.036</td>
              <td align="left" rowspan="1" colspan="1">0.820âÂ±â0.068</td>
              <td align="left" rowspan="1" colspan="1">0.857âÂ±â0.053</td>
              <td align="left" rowspan="1" colspan="1">0.814âÂ±â0.026</td>
              <td align="left" rowspan="1" colspan="1">0.841âÂ±â0.042</td>
              <td align="left" rowspan="1" colspan="1">0.854âÂ±â0.032</td>
              <td align="left" rowspan="1" colspan="1">392</td>
              <td align="left" rowspan="1" colspan="1">263</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">hepatoxicity</td>
              <td align="left" rowspan="1" colspan="1">The probability of owning liver toxicity</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.700âÂ±â0.026</td>
              <td align="left" rowspan="1" colspan="1">0.701âÂ±â0.030</td>
              <td align="left" rowspan="1" colspan="1">0.764âÂ±â0.030</td>
              <td align="left" rowspan="1" colspan="1">0.729âÂ±â0.016</td>
              <td align="left" rowspan="1" colspan="1">0.732âÂ±â0.019</td>
              <td align="left" rowspan="1" colspan="1">0.794âÂ±â0.015</td>
              <td align="left" rowspan="1" colspan="1">2208</td>
              <td align="left" rowspan="1" colspan="1">502</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">LD<sub>50</sub></td>
              <td align="left" rowspan="1" colspan="1">LD50 of acute toxicity</td>
              <td align="left" rowspan="1" colspan="1">XGBoost</td>
              <td align="left" rowspan="1" colspan="1">0.741âÂ±â0.045</td>
              <td align="left" rowspan="1" colspan="1">0.742âÂ±â0.128</td>
              <td align="left" rowspan="1" colspan="1">0.833âÂ±â0.033</td>
              <td align="left" rowspan="1" colspan="1">0.765âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">0.764âÂ±â0.015</td>
              <td align="left" rowspan="1" colspan="1">0.848âÂ±â0.007</td>
              <td align="left" rowspan="1" colspan="1">5917</td>
              <td align="left" rowspan="1" colspan="1">1480</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">QED</td>
              <td align="left" rowspan="1" colspan="1">quantitative estimate of drug-likeness</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">SlogP</td>
              <td align="left" rowspan="1" colspan="1">Log of the octanol/water partition coefficient, based on an atomic contribution model</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
              <td align="left" rowspan="1" colspan="1">n/a</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>*Data Augment refers to the application of enumerated SMILES in model construction.</p>
        </table-wrap-foot>
      </table-wrap>
      <p>As shown in <xref rid="TB1" ref-type="table">Table 1</xref>, it can be observed that most models have high and stable performance in both the 5-fold cross validation and the test set prediction. For the regression models, the average values of RMSE and R2 are 0.442 and 0.747 for the 5-fold cross validation, respectively, and 0.437 and 0.752 for the test set, respectively. For the classification models, the average values of accuracy and AUC are 0.763 and 0.836 for the 5-fold cross validation, respectively, and 0.780 and 0.846 for the test set, respectively. Such results not only proved the credibility of the ADMET prediction models, but also indicated the effectiveness and utility of the latent representations calculated by ChemMORT. In addition, the combination of the encoding and decoding networks ensures the reversibility of the latent representations, which enables the ADMET prediction models to navigate molecular optimization.</p>
    </sec>
    <sec id="sec14">
      <title>Constrained multi-objective optimization</title>
      <p>PARP-1 is a critical DNA repair enzyme in the base excision repair pathway. Inhibitors of PARP-1 provide a new type of anticancer drugs that selectively kill cancer cells by targeting homologous recombination repair defects [<xref rid="ref40" ref-type="bibr">40</xref>, <xref rid="ref41" ref-type="bibr">41</xref>]. However, most PARP-1 inhibitors suffer from the deficiency of poor aqueous solubility, which has severely disrupted the applicability value [<xref rid="ref42" ref-type="bibr">42</xref>]. Therefore, the optimization of more hydrophilic but still potent PARP-1 inhibitors for cancer therapy is quite necessary.</p>
      <p>The approved drug Olaparib is selected as the initial molecule for further optimization, which is an efficient PARP-1 inhibitor possessing IC<sub>50</sub> of 0.9Â nmol but solubility of only 0.0601Â mg/mL (logS of â3.8). During this multi-parameter optimization task, the solubility, QED and SA of the molecule are selected as the aim properties. In addition, to ensure the potency of the PARP-1 inhibitor, the bioactivity motif and similarity constraint are also used (<xref rid="f3" ref-type="fig">Figure 3A</xref>). This optimization task is repeated 100 times and 50 iterations are conducted for the PSO optimization each time. The detailed information about the privilege function section and corresponding weight, the different properties over the course of the optimization, and the final representative optimized molecules are depicted in <xref rid="f3" ref-type="fig">Figure 3</xref>.</p>
      <fig position="float" id="f3">
        <label>Figure 3</label>
        <caption>
          <p>The information about the initial molecule, optimization process and representative optimized molecules. (A) The introduction of the initial molecule Olaparib and related optimization task set; (B) The averaged values of the final score, QED, LogS, SA and similarity during the 50-step optimization; (C) The docking score, final score and LogS value of Olaparib and 171 unique optimized molecules; (D) Five representative optimized molecules with their property information.</p>
        </caption>
        <graphic xlink:href="bbae008f3" position="float"/>
      </fig>
      <p>As shown in <xref rid="f3" ref-type="fig">Figure 3B</xref>, ChemMORT is consistently able to optimize the initial molecule with respect to the defined multi-parameter properties. Clearly, the LogS value and the final score first increased rapidly, but after a point, it became stable and almost unchanged. For QED and SA, according to the dense interval settings, they tend to fluctuate between 0.70 and 0.72, and between 2.5 and 2.7, respectively. For similarity, the tendency is totally converse, with a stable value of 0.40 for the later optimized molecules. It is not surprising since it is a process for molecular optimization. Besides, according to the constraint of bioactivity motif, the optimized molecule is not far from the initial molecule, indicating the importance of structural constraints. Finally, 171 unique optimized molecules with higher bioactivity and better water-solubility than the initial molecule are generated after 100 optimization cycles (<xref rid="sup1" ref-type="supplementary-material">Table S4</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>). As shown in <xref rid="f3" ref-type="fig">Figure 3C</xref>, the solubility and final desirable score of the optimized molecules are much higher than those of the initial molecule. One of the main reasons is the substitution of 1,2-dihydrophthalazine to a more polar function group, such as 1H-1,2,4-triazole, piperazine and imidazolidine with N,N-dimethylacetamide, thus strengthening the hydration of compounds and promoting the thermodynamic process of dissolution [<xref rid="ref43" ref-type="bibr">43</xref>]. Though the ability to optimize molecular pharmacokinetic properties often comes at the price of limited bioactivity to target, but with the application of molecular docking, it is found that most optimized molecules have rather high docking scores, which indicated preliminary guarantee of their potency (<xref rid="sup1" ref-type="supplementary-material">Table S4</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>). Such privileged results have a close relationship with the implementation of the constraints of the essential bioactivity motif and the similarity threshold to the initial molecule. Five representative optimized molecules with their property information are provided in <xref rid="f3" ref-type="fig">Figure 3D</xref>. All of them possess high structural similarity to Olaparib and other approved PARP1 drugs, which successfully replicated the ideation of medicinal chemists during lead optimization.</p>
      <p>We then investigated the detailed interactions between the optimized molecules and the PARP-1 target (PDB ID: 4L6S). The predicted binding modes of Olaparib and the optimized molecules are presented in <xref rid="f4" ref-type="fig">Figure 4</xref>. As shown in <xref rid="f4" ref-type="fig">Figure 4</xref>, most of the optimized molecules have several key interactions, such as the H-bonding networks with Gly863 and Ser904 and the Ï-Ï stacking with Tyr907, which are known as the key binding patterns between PARP-1 inhibitors and PARP-1.</p>
      <fig position="float" id="f4">
        <label>Figure 4</label>
        <caption>
          <p>The interactions between the generated active molecules with PARP1. Figures A-F correspond to the binding mode of Olaparib and the optimized molecules 1â~â5, respectively. The hydrogen-bonding, Ï-Ï stacking interactions and charged interactions are indicated by different colors.</p>
        </caption>
        <graphic xlink:href="bbae008f4" position="float"/>
      </fig>
      <p>To further ensure the utility and potency of these optimized molecules, molecular dynamics (MD) simulation was used to characterize the proteinâligand interactions of the optimized molecules [<xref rid="ref44" ref-type="bibr">44</xref>]. Specifically, the AMBER ff19SB force field [<xref rid="ref45" ref-type="bibr">45</xref>] and the General AMBER Force Field 2 [<xref rid="ref46" ref-type="bibr">46</xref>] were used to parameterize the system. The conformation of the proteinâligand complex was generated using Vina [<xref rid="ref47" ref-type="bibr">47</xref>]. Prior to the MD simulation, two-step minimizations, heating and equilibration were performed. The minimized system was heated to 298.15Â K and increased to atmospheric pressure. Then, 20Â ns production MD simulation was carried out for each complex in the ensemble with a time step of 2Â fs. The structural root-mean-square-deviations (RMSDs) of the backbone atoms (C, C<sub>a</sub> and N) of the protein relative to the initial structures were examined as a function of time (<xref rid="sup1" ref-type="supplementary-material">Figure S1</xref>). As can be seen in the plot, all the systems were stable during the 20-ns MD simulations. The RMSDs of PARP-1 in complex with five optimized molecules showed almost the same RMSDs with Olaparib. Additionally, we uniformly extracted 100 frames from the trajectory of the last 2 nanoseconds. Subsequently, we performed molecular mechanics generalized Born surface area (MM/GBSA) calculations and residue energy decomposition using AmberTools2023 [<xref rid="ref48" ref-type="bibr">48</xref>]. The predicted binding free energies listed in <xref rid="sup1" ref-type="supplementary-material">Table S5</xref>, see Supplementary Data available online at <ext-link xlink:href="http://bib.oxfordjournals.org/" ext-link-type="uri">http://bib.oxfordjournals.org/</ext-link>, also indicate that the optimized molecule 3 (â56.772Â kcal/mol), 4 (â58.949Â kcal/mol) and 5 (â58.831Â kcal/mol) were almost at the same level of the binding affinity for Olaparib (â52.130Â kcal/mol). To further identify the key residues related to the binding process, the free energy contributions of the top 10 residues at the binding site were estimated. As shown in <xref rid="f5" ref-type="fig">Figure 5</xref>, Tyr896, Tyr907, Hie862 and Tyr907 are the most important residues for most optimized molecules, which is in high agreement with the residue contributions for PARP1 inhibitors (<xref rid="f5" ref-type="fig">Figure 5A</xref>). Such analysis indicated that the reasonable application of privileged motif and similarity constraint is necessary to maintain molecular bioactivity during lead optimization [<xref rid="ref49" ref-type="bibr">49</xref>]. Although this multi-parameter optimization task consists of many different and partially conflicting individual objectives, such as aqueous solubility, activity, SA and structural constraints, ChemMORT is consistently able to find some molecules in the vast chemical space that meets the desirable ranges for all of the defined ADMET objectives within the guarantee of target bioactivity.</p>
      <fig position="float" id="f5">
        <label>Figure 5</label>
        <caption>
          <p>The top 10 residues contributing to the binding free energies of the generated active molecules. Figures A-F correspond to the binding modes of Olaparib and the optimized molecules 1â~â5, respectively.</p>
        </caption>
        <graphic xlink:href="bbae008f5" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec15">
    <title>CONCLUSION</title>
    <p>The success of a drug is determined not only by good efficacy and specificity, but also the acceptable ADMET properties. However, the optimization of the lead molecules is a multiple parameter optimization problem, covering potency, selectivity, pharmacokinetics features and safety, which is extremely challenging owing to the vast and discrete drug-like chemical space and limited knowledge from experimental transformation. Therefore, to break through this bottleneck, ChemMORT is developed for the multiple ADMET property optimization of drug candidates through the application of NMT, credible ADMET prediction models and multi-objective PSO strategy. Three modules are included in ChemMORT: SMILES Encoder, Descriptor Decoder and Molecular Optimizer, which provide the representation, translation and optimization functions, respectively. The constrained multi-objective optimization of PARP-1 inhibitors has indicated the successful match of ChemMORT to chemist design, which has successfully optimized ADMET properties of the initial molecule with the preservation of target binding affinity. It is anticipated that the future is bright for ADMET property optimization of lead molecules with the rational application of ChemMORT.</p>
    <boxed-text id="box01" position="float">
      <sec id="sec28a">
        <title>Key Points</title>
        <list list-type="bullet">
          <list-item>
            <p>ChemMORT is a web-based integrated tool that learns molecular representations based on an encoder-decoder neural network architecture. It enhances network performance using SMILES enumeration and conducts multi-objective optimization of molecular properties through particle swarm optimization algorithms. ChemMORT can effectively optimize undesirable ADMET properties without compromising bioactivity, thereby achieving reverse QSAR design at its core.</p>
          </list-item>
          <list-item>
            <p>ChemMORT has been meticulously designed and optimized for its functional modules to enhance user experience. It supports batch upload and download functionalities. Users can define promising and desirable molecules based on their own criteria. The optimizer also provides substructure and similarity constraints, allowing users to freely adjust the importance of each property for highly customizable molecular optimization.</p>
          </list-item>
          <list-item>
            <p>The constrained multi-objective optimization of the PARP-1 inhibitor is provided as the case to explore the utility of ChemMORT.</p>
          </list-item>
        </list>
      </sec>
    </boxed-text>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>supplementary_materials_bbae008</label>
      <media xlink:href="supplementary_materials_bbae008.zip"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="bbae008-ack">
    <title>ACKNOWLEDGEMENTS</title>
    <p>This work was supported by National Key Research and Development Program of China (2022YFA1004303), Foundation of State Key Laboratory of HPCL (2023-KJWHPCL-01), Science Foundation for Indigenous Innovation of National University of Defense Technology under Grant (23-ZZCX-JDZ-08), National Science Foundation of China (22173118), Excellent Youth Foundation of Hunan Province (2021JJ10068), Key scientific research projects in higher education institutions of Henan Province (24A520036) and HKBU Strategic Development Fund project (SDF19-0402-P02). The study was approved by the university's review board.</p>
  </ack>
  <sec sec-type="data-availability" id="sec17">
    <title>DATA AVAILABILITY</title>
    <p>The project is available in the GitHub address (<ext-link xlink:href="https://github.com/antwiser/ChemMORT" ext-link-type="uri">https://github.com/antwiser/ChemMORT</ext-link>).</p>
  </sec>
  <sec id="sec18">
    <title>ABBREVIATIONS</title>
    <p>ADMET, absorption, distribution, metabolism, elimination, and toxicity; QSAR, quantitative structureâactivity relationship; DL, deep learning; SMILES, simplified molecular input line entry specification; HTS, high-throughput screening; VS, virtual screening; ECFP4, extended connectivity fingerprints; RNNs, recurrent neural networks; hERG, human ether-a-go-go-related gene; PPB, plasma protein binding rate; PSO, particle swarm optimization; PARP-1, Poly (ADP-ribose) polymerase-1; MD, molecular dynamics; RMSDs, root-mean-square-deviations;</p>
  </sec>
  <notes id="bio1">
    <title>Author Biographies</title>
    <p><bold>Jia-cai Yi</bold> is a graduate student in the School of Computer Science, National University of Defense Technology. His researches focus on artificial intelligence for drug discovery.</p>
    <sec id="sec18b">
      <p><bold>Zi-yi Yang</bold> is a graduate student at Xiangya School of Pharmaceutical Sciences, Central South University. Her researches focus on screening for frequent hit compounds.</p>
    </sec>
    <sec id="sec18c">
      <p><bold>Wen-Tao Zhao</bold> is currently a professor in the School of Computer Science, National University of Defense Technology, China. His research interests include network performance optimization, information processing, and machine learning.</p>
    </sec>
    <sec id="sec18d">
      <p><bold>Zhi-Jiang Yang</bold> is a graduate student at Xiangya School of Pharmaceutical Sciences, Central South University. His researches focus on the development of cheminformatics tools.</p>
    </sec>
    <sec id="sec18e">
      <p><bold>Xiao-Chen Zhang</bold> is a Ph.D. student in the School of Computer Science, National University of Defense Technology, China. His researches focus on the development of cheminformatics tools.</p>
    </sec>
    <sec id="sec18g">
      <p><bold>Cheng-Kun Wu</bold> is currently an associate professor research fellow student in Institute for Quantum Information &amp; State Key Laboratory of High Performance Computing, College of Computer Science and Technology, National University of Defense Technology. His researches focus on Systems Biology, High-Performance Computing, Pattern Recognition, Machine Learning, and Data Mining.</p>
    </sec>
    <sec id="sec18h">
      <p><bold>Ai-Ping Lu</bold> is a professor at the Hong Kong Baptist University and has long been engaged in basic and new drug discovery and development of Chinese medicine for the treatment of rheumatoid arthritis and oncology, as well as the research of aptamer-targeted delivery of innovative drugs.</p>
    </sec>
    <sec id="sec18i">
      <p><bold>Dong-Sheng Cao</bold> is currently an associate professor in the Xiangya School of Pharmaceutical Sciences, Central South University, China. His research interests can be found at the website of his group: <ext-link xlink:href="http://www.scbdd.com" ext-link-type="uri">http://www.scbdd.com</ext-link>.</p>
    </sec>
  </notes>
  <ref-list id="bib1">
    <title>References</title>
    <ref id="ref1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roses</surname><given-names>AD</given-names></string-name></person-group>. <article-title>Pharmacogenetics in drug discovery and development: a translational perspective</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2008</year>;<volume>7</volume>:<fpage>807</fpage>â<lpage>17</lpage>.<pub-id pub-id-type="pmid">18806753</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>BergstrÃ¶m</surname><given-names>F</given-names></string-name>, <string-name><surname>Lindmark</surname><given-names>B</given-names></string-name></person-group>. <article-title>Accelerated drug discovery by rapid candidate drug identification</article-title>. <source>Drug Discov Today</source> Â <year>2019</year>;<volume>24</volume>:<fpage>1237</fpage>â<lpage>41</lpage>.<pub-id pub-id-type="pmid">30946980</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burt</surname><given-names>T</given-names></string-name>, <string-name><surname>Young</surname><given-names>G</given-names></string-name>, <string-name><surname>Lee</surname><given-names>W</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Phase 0/microdosing approaches: time for mainstream application in drug development?</article-title> Â <source>Nat Rev Drug Discov</source> Â <year>2020</year>;<volume>19</volume>:<fpage>801</fpage>â<lpage>18</lpage>.<pub-id pub-id-type="pmid">32901140</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schneider</surname><given-names>P</given-names></string-name>, <string-name><surname>Walters</surname><given-names>WP</given-names></string-name>, <string-name><surname>Plowright</surname><given-names>AT</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Rethinking drug design in the artificial intelligence era</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2020</year>;<volume>19</volume>:<fpage>353</fpage>â<lpage>64</lpage>.<pub-id pub-id-type="pmid">31801986</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vamathevan</surname><given-names>J</given-names></string-name>, <string-name><surname>Clark</surname><given-names>D</given-names></string-name>, <string-name><surname>Czodrowski</surname><given-names>P</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Applications of machine learning in drug discovery and development</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2019</year>;<volume>18</volume>:<fpage>463</fpage>â<lpage>77</lpage>.<pub-id pub-id-type="pmid">30976107</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gloriam</surname><given-names>DE</given-names></string-name></person-group>. <article-title>Bigger is better in virtual drug screens</article-title>. <source>Nature</source> Â <year>2019</year>;<volume>566</volume>:<fpage>193</fpage>â<lpage>4</lpage>.</mixed-citation>
    </ref>
    <ref id="ref7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ekins</surname><given-names>S</given-names></string-name>, <string-name><surname>Puhl</surname><given-names>AC</given-names></string-name>, <string-name><surname>Zorn</surname><given-names>KM</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Exploiting machine learning for end-to-end drug discovery and development</article-title>. <source>Nat Mater</source> Â <year>2019</year>;<volume>18</volume>:<fpage>435</fpage>â<lpage>41</lpage>.<pub-id pub-id-type="pmid">31000803</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Waring</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Arrowsmith</surname><given-names>J</given-names></string-name>, <string-name><surname>Leach</surname><given-names>AR</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>An analysis of the attrition of drug candidates from four major pharmaceutical companies</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2015</year>;<volume>14</volume>:<fpage>475</fpage>â<lpage>86</lpage>.<pub-id pub-id-type="pmid">26091267</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kola</surname><given-names>I</given-names></string-name>, <string-name><surname>Landis</surname><given-names>J</given-names></string-name></person-group>. <article-title>Can the pharmaceutical industry reduce attrition rates?</article-title> Â <source>Nat Rev Drug Discov</source> Â <year>2004</year>;<volume>3</volume>:<fpage>711</fpage>â<lpage>6</lpage>.<pub-id pub-id-type="pmid">15286737</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sutherland</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Raymond</surname><given-names>JW</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>JL</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes</article-title>. <source>J Med Chem</source> Â <year>2012</year>;<volume>55</volume>:<fpage>6455</fpage>â<lpage>66</lpage>.<pub-id pub-id-type="pmid">22716080</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schneider</surname><given-names>G</given-names></string-name>, <string-name><surname>Clark</surname><given-names>DE</given-names></string-name></person-group>. <article-title>Automated de novo drug design: are we nearly there yet?</article-title> Â <source>Angew Chem Int Ed</source> Â <year>2019</year>;<volume>58</volume>:<fpage>10792</fpage>â<lpage>803</lpage>.</mixed-citation>
    </ref>
    <ref id="ref12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schneider</surname><given-names>G</given-names></string-name>, <string-name><surname>Fechner</surname><given-names>U</given-names></string-name></person-group>. <article-title>Computer-based de novo design of drug-like molecules</article-title>. <source>Nat Rev Drug Discov</source> Â <year>2005</year>;<volume>4</volume>:<fpage>649</fpage>â<lpage>63</lpage>.<pub-id pub-id-type="pmid">16056391</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref13">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>XC</given-names></string-name>, <string-name><surname>Wu</surname><given-names>CK</given-names></string-name>, <string-name><surname>Yang</surname><given-names>ZJ</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>MG-BERT: leveraging unsupervised atomic representation learning for molecular property prediction</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>(<issue>6</issue>):bbab152. <pub-id pub-id-type="doi">10.1093/bib/bbab152</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref14">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>CK</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>XC</given-names></string-name>, <string-name><surname>Yang</surname><given-names>ZJ</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Learning to SMILES: BAN-based strategies to improve latent representation learning from molecules</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>(<issue>6</issue>):bbab327. <pub-id pub-id-type="doi">10.1093/bib/bbab327</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chuang</surname><given-names>KV</given-names></string-name>, <string-name><surname>Gunsalus</surname><given-names>LM</given-names></string-name>, <string-name><surname>Keiser</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>Learning molecular representations for medicinal chemistry: miniperspective</article-title>. <source>J Med Chem</source> Â <year>2020</year>;<volume>63</volume>:<fpage>8705</fpage>â<lpage>22</lpage>.<pub-id pub-id-type="pmid">32366098</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>GÃ³mez-Bombarelli</surname><given-names>R</given-names></string-name>, <string-name><surname>Wei</surname><given-names>JN</given-names></string-name>, <string-name><surname>Duvenaud</surname><given-names>D</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Automatic chemical design using a data-driven continuous representation of molecules</article-title>. <source>ACS Cent Sci</source> Â <year>2018</year>;<volume>4</volume>:<fpage>268</fpage>â<lpage>76</lpage>.<pub-id pub-id-type="pmid">29532027</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bjerrum</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Sattarov</surname><given-names>B</given-names></string-name></person-group>. <article-title>Improving chemical autoencoder latent space and molecular de novo generation diversity with heteroencoders</article-title>. <source>Biomolecules</source> Â <year>2018</year>;<volume>8</volume>:<fpage>131</fpage>.<pub-id pub-id-type="pmid">30380783</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Winter</surname><given-names>R</given-names></string-name>, <string-name><surname>Montanari</surname><given-names>F</given-names></string-name>, <string-name><surname>NoÃ©</surname><given-names>F</given-names></string-name>, <string-name><surname>Clevert</surname><given-names>DA</given-names></string-name></person-group>. <article-title>Learning continuous and data-driven molecular descriptors by translating equivalent chemical representations</article-title>. <source>Chem Sci</source> Â <year>2019</year>;<volume>10</volume>:<fpage>1692</fpage>â<lpage>701</lpage>.<pub-id pub-id-type="pmid">30842833</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>ArÃºs-Pous</surname><given-names>J</given-names></string-name>, <string-name><surname>Johansson</surname><given-names>SV</given-names></string-name>, <string-name><surname>Prykhodko</surname><given-names>O</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Randomized SMILES strings improve the quality of molecular generative models</article-title>. <source>J Chem</source> Â <year>2019</year>;<volume>11</volume>:<fpage>1</fpage>â<lpage>13</lpage>.</mixed-citation>
    </ref>
    <ref id="ref20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Winter</surname><given-names>R</given-names></string-name>, <string-name><surname>Montanari</surname><given-names>F</given-names></string-name>, <string-name><surname>Steffen</surname><given-names>A</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Efficient multi-objective molecular optimization in a continuous latent space</article-title>. <source>Chem Sci</source> Â <year>2019</year>;<volume>10</volume>:<fpage>8016</fpage>â<lpage>24</lpage>.<pub-id pub-id-type="pmid">31853357</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vijayakumar</surname><given-names>AK</given-names></string-name>, <string-name><surname>Cogswell</surname><given-names>M</given-names></string-name>, <string-name><surname>Selvaraju</surname><given-names>RR</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Diverse beam search: Decoding diverse solutions from neural sequence model</article-title>. <source>Proceedings of the AAAI Conference on Artificial Intelligence</source> Â <year>2016</year>;<volume>32</volume>(<issue>1</issue>). <pub-id pub-id-type="doi">10.1609/aaai.v32i1.12340</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiong</surname><given-names>G</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Yi</surname><given-names>J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties</article-title>. <source>Nucleic Acids Res</source> Â <year>2021</year>;<volume>49</volume>:<fpage>W5</fpage>â<lpage>14</lpage>.<pub-id pub-id-type="pmid">33893803</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dong</surname><given-names>J</given-names></string-name>, <string-name><surname>Wang</surname><given-names>N-N</given-names></string-name>, <string-name><surname>Yao</surname><given-names>Z-J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database</article-title>. <source>J Chem</source> Â <year>2018</year>;<volume>10</volume>:<fpage>1</fpage>â<lpage>11</lpage>.</mixed-citation>
    </ref>
    <ref id="ref24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gaulton</surname><given-names>A</given-names></string-name>, <string-name><surname>Hersey</surname><given-names>A</given-names></string-name>, <string-name><surname>Nowotka</surname><given-names>M</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>The ChEMBL database in 2017</article-title>. <source>Nucleic Acids Res</source> Â <year>2017</year>;<volume>45</volume>:<fpage>D945</fpage>â<lpage>54</lpage>.<pub-id pub-id-type="pmid">27899562</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>DS</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>YD</given-names></string-name>, <string-name><surname>Guo</surname><given-names>AC</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res</source> Â <year>2018</year>;<volume>46</volume>:<fpage>D1074</fpage>â<lpage>82</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Fu</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J-W</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Three-level hepatotoxicity prediction system based on adverse hepatic effects</article-title>. <source>Mol Pharm</source> Â <year>2018</year>;<volume>16</volume>:<fpage>393</fpage>â<lpage>408</lpage>.<pub-id pub-id-type="pmid">30475633</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname><given-names>L</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Systematic Modeling of log D 7.4 Based on Ensemble Machine Learning, Group Contribution, and Matched Molecular Pair Analysis</article-title>. <source>J Chem Inf Model</source> Â <year>2019</year>;<volume>60</volume>:<fpage>63</fpage>â<lpage>76</lpage>.</mixed-citation>
    </ref>
    <ref id="ref28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname><given-names>L</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>QSAR-assisted-MMPA to expand chemical transformation space for lead optimization</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>:<fpage>bbaa374</fpage>.<pub-id pub-id-type="pmid">33418563</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>N-N</given-names></string-name>, <string-name><surname>Deng</surname><given-names>Z-K</given-names></string-name>, <string-name><surname>Huang</surname><given-names>C</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ADME properties evaluation in drug discovery: Prediction of plasma protein binding using NSGA-II combining PLS and consensus modeling</article-title>. <source>Chemom Intel Lab Syst</source> Â <year>2017</year>;<volume>170</volume>:<fpage>84</fpage>â<lpage>95</lpage>.</mixed-citation>
    </ref>
    <ref id="ref30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ertl</surname><given-names>P</given-names></string-name>, <string-name><surname>Schuffenhauer</surname><given-names>A</given-names></string-name></person-group>. <article-title>Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions</article-title>. <source>J Chem</source> Â <year>2009</year>;<volume>1</volume>:<fpage>1</fpage>â<lpage>11</lpage>.</mixed-citation>
    </ref>
    <ref id="ref31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wildman</surname><given-names>SA</given-names></string-name>, <string-name><surname>Crippen</surname><given-names>GM</given-names></string-name></person-group>. <article-title>Prediction of physicochemical parameters by atomic contributions</article-title>. <source>J Chem Inf Comput Sci</source> Â <year>1999</year>;<volume>39</volume>:<fpage>868</fpage>â<lpage>73</lpage>.</mixed-citation>
    </ref>
    <ref id="ref32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bickerton</surname><given-names>GR</given-names></string-name>, <string-name><surname>Paolini</surname><given-names>GV</given-names></string-name>, <string-name><surname>Besnard</surname><given-names>J</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Quantifying the chemical beauty of drugs</article-title>. <source>Nat Chem</source> Â <year>2012</year>;<volume>4</volume>:<fpage>90</fpage>â<lpage>8</lpage>.<pub-id pub-id-type="pmid">22270643</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref33">
      <label>33.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Kennedy</surname><given-names>J</given-names></string-name>, <string-name><surname>Eberhart</surname><given-names>R</given-names></string-name></person-group>. <part-title>Particle swarm optimization</part-title>. In: <source>Proceedings of ICNN'95-international conference on neural networks</source>, <year>1995</year>, <year>IEEE</year>, <fpage>1942</fpage>â<lpage>8</lpage>.</mixed-citation>
    </ref>
    <ref id="ref34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Z-Z</given-names></string-name>, <string-name><surname>Huang</surname><given-names>J-W</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cao</surname><given-names>DS</given-names></string-name></person-group>. <article-title>ECoFFeS: a software using evolutionary computation for feature selection in drug discovery</article-title>. <source>IEEE Access</source> Â <year>2018</year>;<volume>6</volume>:<fpage>20950</fpage>â<lpage>63</lpage>.</mixed-citation>
    </ref>
    <ref id="ref35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Huang</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>N</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Incorporating PLS model information into particle swarm optimization for descriptor selection in QSAR/QSPR</article-title>. <source>J Chemometr</source> Â <year>2015</year>;<volume>29</volume>:<fpage>627</fpage>â<lpage>36</lpage>.</mixed-citation>
    </ref>
    <ref id="ref36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cao</surname><given-names>D-S</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name><surname>Fan</surname><given-names>L</given-names></string-name>, <string-name><surname>Liang</surname><given-names>YZ</given-names></string-name></person-group>. <article-title>QSAR analysis of the effects of OATP1B1 transporter by structurally diverse natural products using a particle swarm optimization-combined multiple linear regression approach</article-title>. <source>Chemom Intel Lab Syst</source> Â <year>2014</year>;<volume>130</volume>:<fpage>84</fpage>â<lpage>90</lpage>.</mixed-citation>
    </ref>
    <ref id="ref37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yun</surname><given-names>Y-H</given-names></string-name>, <string-name><surname>Cao</surname><given-names>D-S</given-names></string-name>, <string-name><surname>Tan</surname><given-names>M-L</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>A simple idea on applying large regression coefficient to improve the genetic algorithm-PLS for variable selection in multivariate calibration</article-title>. <source>Chemom Intel Lab Syst</source> Â <year>2014</year>;<volume>130</volume>:<fpage>76</fpage>â<lpage>83</lpage>.</mixed-citation>
    </ref>
    <ref id="ref38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eckert</surname><given-names>H</given-names></string-name>, <string-name><surname>Bajorath</surname><given-names>J</given-names></string-name></person-group>. <article-title>Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches</article-title>. <source>Drug Discov Today</source> Â <year>2007</year>;<volume>12</volume>:<fpage>225</fpage>â<lpage>33</lpage>.<pub-id pub-id-type="pmid">17331887</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dong</surname><given-names>J</given-names></string-name>, <string-name><surname>Yao</surname><given-names>Z-J</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>M-F</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ChemSAR: an online pipelining platform for molecular SAR modeling</article-title>. <source>J Chem</source> Â <year>2017</year>;<volume>9</volume>:<fpage>1</fpage>â<lpage>13</lpage>.</mixed-citation>
    </ref>
    <ref id="ref40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X-G</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Z-Y</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>:<fpage>bbab135</fpage>.<pub-id pub-id-type="pmid">33940596</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Y-Q</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P-Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y-T</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>An update on poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy</article-title>. <source>J Med Chem</source> Â <year>2016</year>;<volume>59</volume>:<fpage>9575</fpage>â<lpage>98</lpage>.<pub-id pub-id-type="pmid">27416328</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L-X</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>T</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>The ups and downs of Poly (ADP-ribose) Polymerase-1 inhibitors in cancer therapyâCurrent progress and future direction</article-title>. <source>Eur J Med Chem</source> Â <year>2020</year>;<volume>203</volume>:<elocation-id>112570</elocation-id>.<pub-id pub-id-type="pmid">32717529</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name><surname>Mathiowetz</surname><given-names>A</given-names></string-name>, <string-name><surname>Gao</surname><given-names>H</given-names></string-name></person-group>. <article-title>Deep understanding of structureâsolubility relationship for a diverse set of organic compounds using matched molecular pairs</article-title>. <source>Bioorg Med Chem</source> Â <year>2011</year>;<volume>19</volume>:<fpage>5763</fpage>â<lpage>70</lpage>.<pub-id pub-id-type="pmid">21906951</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Do</surname><given-names>P-C</given-names></string-name>, <string-name><surname>Lee</surname><given-names>EH</given-names></string-name>, <string-name><surname>Le</surname><given-names>L</given-names></string-name></person-group>. <article-title>Steered molecular dynamics simulation in rational drug design</article-title>. <source>J Chem Inf Model</source> Â <year>2018</year>;<volume>58</volume>:<fpage>1473</fpage>â<lpage>82</lpage>.<pub-id pub-id-type="pmid">29975531</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tian</surname><given-names>C</given-names></string-name>, <string-name><surname>Kasavajhala</surname><given-names>K</given-names></string-name>, <string-name><surname>Belfon</surname><given-names>KAA</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum Mechanics Energy Surfaces in Solution</article-title>. <source>J Chem Theory Comput</source> Â <year>2020</year>;<volume>16</volume>:<fpage>528</fpage>â<lpage>52</lpage>.<pub-id pub-id-type="pmid">31714766</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vassetti</surname><given-names>D</given-names></string-name>, <string-name><surname>Pagliai</surname><given-names>M</given-names></string-name>, <string-name><surname>Procacci</surname><given-names>P</given-names></string-name></person-group>. <article-title>Assessment of GAFF2 and OPLS-AA general force fields in combination with the water models TIP3P, SPCE, and OPC3 for the solvation free energy of druglike organic molecules</article-title>. <source>J Chem Theory Comput</source> Â <year>2019</year>;<volume>15</volume>:<fpage>1983</fpage>â<lpage>95</lpage>.<pub-id pub-id-type="pmid">30694667</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eberhardt</surname><given-names>J</given-names></string-name>, <string-name><surname>Santos-Martins</surname><given-names>D</given-names></string-name>, <string-name><surname>Tillack</surname><given-names>AF</given-names></string-name>, <string-name><surname>Forli</surname><given-names>S</given-names></string-name></person-group>. <article-title>AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings</article-title>. <source>J Chem Inf Model</source> Â <year>2021</year>;<volume>61</volume>:<fpage>3891</fpage>â<lpage>8</lpage>.<pub-id pub-id-type="pmid">34278794</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Case</surname><given-names>DA</given-names></string-name>, <string-name><surname>Aktulga</surname><given-names>HM</given-names></string-name>, <string-name><surname>Belfon</surname><given-names>K</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>AmberTools</article-title>. <source>J Chem Inf Model</source> Â <year>2023</year>;<volume>63</volume>:<fpage>6183</fpage>â<lpage>91</lpage>.<pub-id pub-id-type="pmid">37805934</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>Z-Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Z-J</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <etal>etÂ al.</etal></person-group> Â <article-title>PySmash: Python package and individual executable program for representative substructure generation and application</article-title>. <source>Brief Bioinform</source> Â <year>2021</year>;<volume>22</volume>:<fpage>bbab017</fpage>.<pub-id pub-id-type="pmid">33709154</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
